

# Index to Volume 55

The index to Volume 55 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *AJHP* as "index terms" after abstracts.) *IPA* covers all authored papers and editorials in *AJHP*, as well as selected letters and news reports. Items that were published in the ASHP Reports section, including official ASHP Statements and Guidelines, are indexed under "American Society of Health-System Pharmacists" as well as being covered by

*IPA* in many cases. The subject index also notes all regular *AJHP* columns and, under the respective column headings, the titles of items in the following: ASHP Foundation Reports, Book Reviews, Editorials, Frontline Pharmacist, How To, Letters, Managed Care Forum, Management Consultation, News, Questions and Answers, Self-study Materials, Software Reviews and World Wide Web Reviews. The page numbers of articles that appear in ASHP Affiliates are listed under that heading by the names of the societies. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages
January 1	1-96
January 15	97-196
February 1	197-310
February 15	311-406
March 1	407-512
March 15	513-624
April 1	625-748
April 15	749-864
May 1	865-970
May 15	971-1084
June 1	1085-1224
June 15	1225-1328
July 1	1329-1432
July 15	1433-1536

Issue	Pages
August 1	1537-1636
August 15	1637-1738
September 1	1739-1840
September 15	1841-1948
October 1	1949-2048
October 1 Supplement	S1-S31
October 15	2049-2210
November 1	2211-2316
November 1 Supplement	S1-S31
November 15	2317-2436
November 15 Supplement	S1-S23
December 1	2437-2582
December 15	2583-2680
December 15 Supplement	S1-S39

## Subject Index

### A

#### Abciximab

angioplasty; clinical studies, 2409  
cardiovascular diseases; review, 2363  
coronary disease; cost-benefit analysis, Dec 15 suppl S35  
vials; storage, 2026

**Abortifacients;** methotrexate; ectopic pregnancy, 171

**Absorption;** nicotine; transdermal patches, 1413

#### Accreditation

home health care; JCAHO standards, 2299  
hospital pharmacy; history, 1344  
hospitals; France, 173; sentinel-event policies, 1112  
Joint Commission on Accreditation of Healthcare Organizations; sentinel events, 764  
managed care systems; NCQA standards, 1351, 2221  
organizations; performance measurements, 1348  
pharmacy; pharmacist certification programs, 1856

#### Acetaminophen

overdose; cimetidine therapy, 1516  
prescribing; emergency room therapy, 1158

**Acetylcysteine;** antidotes; acetaminophen overdose, 1516

**Achlorhydria;** proton-pump inhibitors; toxicity, 2268

**Acquired immunodeficiency syndrome;** antiviral; cytomegalovirus retinitis, 392

**Acyclovir sodium;** stability; incompatibilities, 574

**Addicts;** narcotics; methadone therapy, 208

**Additives;** injections; acyclovir incompatibilities, 574; carboplatin, 602; cisatracurium incompatibilities, 1037; fentanyl incompatibilities, 1194; organ preservation solutions, 266; topotecan contamination, 1584; toremide stability, 1042

**Adenosine;** incompatibilities; diluents, containers,

466; sodium chloride, 1161

#### Administration

ambulatory care; alternative medicine, 435; clinical pharmacists, 1753; VA centers, 68

*American Journal of Health-System Pharmacy*; content selection, 1773

American Society of Health-System Pharmacists; public relations, 1570, 1975; services, 31; Task Force on Science, 2519

Board of Pharmaceutical Specialties; psychopharmacology examinations, 1594

clinical studies; ASHP guidelines, 369; outcomes research, 62

formulary system; Russia, 1308

health care; error prevention, 1968; interdisciplinary team, 1369

health maintenance organizations; decision-making, 56; enrollee benefits, 422; formulary decisions, 50; HMG-CoA reductase inhibitors, 995; physician prescribing, 2234

hospital pharmacy; abciximab storage, 2026; alternative medicine protocols, 1266; anti-infective prophylaxis, 993; ASHP meeting papers, 888; automated dispensing, 1924; clinical technicians, 1375; contract services, 2537; discharge medications consultation, Dec 15 suppl S32; drug information centers, 1146; formularies, Oct 1 suppl S28; globulin immune shortages, 1341, 2090; HIV infection clinics, 955; inpatient consultation, 1127; investigational drug services, 2611; latex allergies, 1462; liability, 1874; medication-error monitoring, 946; outpatient services, 1763; outsourcing guidelines, 1611; patient consultation, 1792; pharmaceutical care, 486; pharmacists' interventions, 1151; planning and design, 2505; residencies, 1826; residency funding, 1618; residency reimbursement, 1620; robotics, 1907; staff development, 1760; taxes, 772; technician certification, 1799; technicians' role, 1810; U.S., 229

hospitals; accreditation, 173; allergy documentation, 289; dispensing-automation guidelines, 1403; integrated health care, 669; medication errors, 1123; staff meetings participation, 2360

industry, pharmaceutical; consumers' influence, 876

integrated health care; pharmaceutical services, 35; statistics, 1450

leadership; ASHP, 1717; professional excellence, 782

managed care systems; health care delivery, 1490; NCQA standards, 1351

Medicare; prospective-pricing system, 1645

National Cancer Institute; compassionate-use protocols, 651

organizations; accreditation, 1348

pharmaceutical services; allergy documentation, 364; anticoagulation clinic, 1033; disease management, 471; military programs, 1656; patient satisfaction, 1025

pharmacy, community; patient confidentiality, 875, 895; pharmaceutical care, 635

pharmacy, institutional; layoffs, 2387; managed care systems, 27; nonprescription drug programs, 1357; pharmacokinetics services, 2027; poison prevention programs, 1971

policies and procedures; allergy documentation, 1524; APhA, 878; ASHP, 1044; assisted suicides, 1235; cleanrooms, 458; continuing education, 426, 2472; HIV prophylaxis, 1921; hospital pharmacy, 1164; JCAHO sentinel events, 1112; JCAHO Sentinel Event Alert, 764; latex-free products, 437; medication errors, 1092; telepharmacy, 1512; telephone services, 453; therapeutic substitution, 1382; U.S. health care, 17

#### Administrators

attitudes; consumers' influence, 876

health-benefit programs; managed care perspectives, 1482

hospital pharmacy; globulin immune shortages, 1341; integrated health care, 665; job satisfaction, 360; staff development, 1760; technician certification, 1799

hospitals; staff meetings participation, 2360

managed care systems; disease management, 1029

personnel; pharmacists' role, 1482

pharmacists, hospital; infant formulas, 84; liability, 1874

# Index to Volume 55

The index to Volume 55 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *AJHP* as "index terms" after abstracts.) *IPA* covers all authored papers and editorials in *AJHP*, as well as selected letters and news reports. Items that were published in the ASHP Reports section, including official ASHP Statements and Guidelines, are indexed under "American Society of Health-System Pharmacists" as well as being covered by

*IPA* in many cases. The subject index also notes all regular *AJHP* columns and, under the respective column headings, the titles of items in the following: ASHP Foundation Reports, Book Reviews, Editorials, Frontline Pharmacist, How To, Letters, Managed Care Forum, Management Consultation, News, Questions and Answers, Self-study Materials, Software Reviews and World Wide Web Reviews. The page numbers of articles that appear in ASHP Affiliates are listed under that heading by the names of the societies. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages
January 1	1-96
January 15	97-196
February 1	197-310
February 15	311-406
March 1	407-512
March 15	513-624
April 1	625-748
April 15	749-864
May 1	865-970
May 15	971-1084
June 1	1085-1224
June 15	1225-1328
July 1	1329-1432
July 15	1433-1536

Issue	Pages
August 1	1537-1636
August 15	1637-1738
September 1	1739-1840
September 15	1841-1948
October 1	1949-2048
October 1 Supplement	S1-S31
October 15	2049-2210
November 1	2211-2316
November 1 Supplement	S1-S31
November 15	2317-2436
November 15 Supplement	S1-S23
December 1	2437-2582
December 15	2583-2680
December 15 Supplement	S1-S39

## Subject Index

### A

#### Abciximab

angioplasty; clinical studies, 2409  
cardiovascular diseases; review, 2363  
coronary disease; cost-benefit analysis, Dec 15 suppl S35  
vials; storage, 2026

**Abortifacients;** methotrexate; ectopic pregnancy, 171

**Absorption;** nicotine; transdermal patches, 1413

#### Accreditation

home health care; JCAHO standards, 2299  
hospital pharmacy; history, 1344  
hospitals; France, 173; sentinel-event policies, 1112  
Joint Commission on Accreditation of Healthcare Organizations; sentinel events, 764  
managed care systems; NCQA standards, 1351, 2221  
organizations; performance measurements, 1348  
pharmacy; pharmacist certification programs, 1856

#### Acetaminophen

overdose; cimetidine therapy, 1516  
prescribing; emergency room therapy, 1158

**Acetylcysteine;** antidotes; acetaminophen overdose, 1516

**Achlorhydria;** proton-pump inhibitors; toxicity, 2268

**Acquired immunodeficiency syndrome;** antiviral; cytomegalovirus retinitis, 392

**Acyclovir sodium;** stability; incompatibilities, 574

**Addicts;** narcotics; methadone therapy, 208

**Additives;** injections; acyclovir incompatibilities, 574; carboplatin, 602; cisatracurium incompatibilities, 1037; fentanyl incompatibilities, 1194; organ preservation solutions, 266; topotecan contamination, 1584; toremide stability, 1042

**Adenosine;** incompatibilities; diluents, containers,

466; sodium chloride, 1161

#### Administration

ambulatory care; alternative medicine, 435; clinical pharmacists, 1753; VA centers, 68

*American Journal of Health-System Pharmacy*; content selection, 1773

American Society of Health-System Pharmacists; public relations, 1570, 1975; services, 31; Task Force on Science, 2519

Board of Pharmaceutical Specialties; psychopharmacology examinations, 1594

clinical studies; ASHP guidelines, 369; outcomes research, 62

formulary system; Russia, 1308

health care; error prevention, 1968; interdisciplinary team, 1369

health maintenance organizations; decision-making, 56; enrollee benefits, 422; formulary decisions, 50; HMG-CoA reductase inhibitors, 995; physician prescribing, 2234

hospital pharmacy; abciximab storage, 2026; alternative medicine protocols, 1266; anti-infective prophylaxis, 993; ASHP meeting papers, 888; automated dispensing, 1924; clinical technicians, 1375; contract services, 2537; discharge medications consultation, Dec 15 suppl S32; drug information centers, 1146; formularies, Oct 1 suppl S28; globulin immune shortages, 1341, 2090; HIV infection clinics, 955; inpatient consultation, 1127; investigational drug services, 2611; latex allergies, 1462; liability, 1874; medication-error monitoring, 946; outpatient services, 1763; outsourcing guidelines, 1611; patient consultation, 1792; pharmaceutical care, 486; pharmacists' interventions, 1151; planning and design, 2505; residencies, 1826; residency funding, 1618; residency reimbursement, 1620; robotics, 1907; staff development, 1760; taxes, 772; technician certification, 1799; technicians' role, 1810; U.S., 229

hospitals; accreditation, 173; allergy documentation, 289; dispensing-automation guidelines, 1403; integrated health care, 669; medication errors, 1123; staff meetings participation, 2360

industry, pharmaceutical; consumers' influence, 876

integrated health care; pharmaceutical services, 35; statistics, 1450

leadership; ASHP, 1717; professional excellence, 782

managed care systems; health care delivery, 1490; NCQA standards, 1351

Medicare; prospective-pricing system, 1645

National Cancer Institute; compassionate-use protocols, 651

organizations; accreditation, 1348

pharmaceutical services; allergy documentation, 364; anticoagulation clinic, 1033; disease management, 471; military programs, 1656; patient satisfaction, 1025

pharmacy, community; patient confidentiality, 875, 895; pharmaceutical care, 635

pharmacy, institutional; layoffs, 2387; managed care systems, 27; nonprescription drug programs, 1357; pharmacokinetics services, 2027; poison prevention programs, 1971

policies and procedures; allergy documentation, 1524; APhA, 878; ASHP, 1044; assisted suicides, 1235; cleanrooms, 458; continuing education, 426, 2472; HIV prophylaxis, 1921; hospital pharmacy, 1164; JCAHO sentinel events, 1112; JCAHO Sentinel Event Alert, 764; latex-free products, 437; medication errors, 1092; telepharmacy, 1512; telephone services, 453; therapeutic substitution, 1382; U.S. health care, 17

#### Administrators

attitudes; consumers' influence, 876

health-benefit programs; managed care perspectives, 1482

hospital pharmacy; globulin immune shortages, 1341; integrated health care, 665; job satisfaction, 360; staff development, 1760; technician certification, 1799

hospitals; staff meetings participation, 2360

managed care systems; disease management, 1029

personnel; pharmacists' role, 1482

pharmacists, hospital; infant formulas, 84; liability, 1874

- pharmacy, institutional; HMO formularies, 56; lay-offs, 2387
- Additives**, see **Additives**
- Adrenergic agents**, see **Sympathomimetic agents**
- Adsorption**; ranitidine hydrochloride; filters, 840
- Adverse reactions**, see **Drugs, adverse reactions**
- Advertising**  
pharmacy, community; television, 536  
prescription drugs; direct to consumer, 594, 880  
prescriptions; direct-to-consumer, 2344
- Advertising Index**, 96, 196, 310, 405, 512, 624, 748, 863, 970, 1084, 1224, 1327, 1432, 1536, 1636, 1738, 1840, 1948, 2048, 2210, 2316, 2436, 2582, 2649
- Aerosols**; propellants; metered-dose inhalers, 226, 276
- Africa**; pharmacy; practice standards, 1928
- Age**  
neonates; gentamicin pharmacokinetics, 2280  
patients; cardiovascular circadian rhythm, Nov 15 suppl S5; cyanocobalamin intake, 981; discharge prescriptions, 1389; drug-related injuries, 1158
- AIDS**, see **Acquired immunodeficiency syndrome**
- Air**; cleanrooms; particle counts, 458
- AJHP**, see **American Journal of Health-System Pharmacy**
- AJHP Continuing Education**, 953, 1312, 1932, 2302
- Albendazole**; cysticercosis; comparisons, 598
- Albumin**; errors; medication; dilutions, 2078
- Albumin human**; incompatibilities; interferon alfa-2b, 1602
- Alcohols, polyvinyl**; incompatibilities; anti-infective agents, 463
- Aldesleukin**; HIV infections; overview, 1520
- Alendronate sodium**; toxicity; esophagitis, 892
- Alkyldiaminoethyl glycine**; contamination; microbiological, 2534
- Allergies**  
drugs; documentation, 289, 364, 1524  
latex; hospital policies, 437; labeling, 2059; sterile preparations, 1462
- Alprazolam**; stability; oral liquids, 1915
- Alternative medicine**  
dispensing; hospital pharmacy, 1266  
education, pharmaceutical; pharmacists, 2525  
medicinal plants; hospital formularies, 435; pharmacists' role, 125
- Alzheimer's disease**  
cholinesterase inhibitors; overview, Nov 1 suppl S22  
overview, Nov 1 suppl S5  
patient care; institutional pharmacists, Nov 1 suppl S3; pharmaceutical services, Nov 1 suppl S26  
therapy; overview, Nov 1 suppl S11
- Ambulatory care**  
alternative medicine; herbal formularies, 435  
antibiotics; pseudomembranous enterocolitis, 1365  
anticoagulants; pharmacists' training, 1033  
clinical pharmacists; HIV infection clinics, 955; interventions, 1753; outcomes research, 62; VA centers, 68  
HIV infections; antiretroviral agents, 661  
hospital pharmacy; planning and design, 2505  
hypertension; blood pressure monitoring, Nov 15 suppl S12  
integrated health care; pharmaceutical services, 35  
intravenous therapy; home health care, 2019  
patient information; continuity of care, 1017  
pharmaceutical services; Alzheimer's disease, Nov 1 suppl S26; continuity of care, 2500; heart failure clinics, 1626; patient consultation, 2485, 2615, 2621; patients' attitudes, 1025; telepharmacy, 1512  
pharmacists; ASHP services, 31
- American Academy of Family Practice Physicians**; protocols; pediatric vaccines, 563
- American Academy of Pediatrics**; protocols; pediatric vaccines, 563
- American Association of Colleges of Pharmacy**; standards; pharmacist certification, 1856
- American College of Cardiology**; guidelines; sildenafil, 2080
- American Council on Pharmaceutical Education**; standards; pharmacist certification, 1856
- American Heart Association**; guidelines; sildenafil, 2080
- American Journal of Health-System Pharmacy**  
acknowledgment of drafters and reviewers of ASHP practice standards—September 1, 1997, to August 31, 1998, 2637
- acknowledgment of reviewers for *AJHP* manuscripts, November 1, 1997, to October 31, 1998, 2636
- administration; content selection, 1773
- information; articles, 31; pharmacy public relations, 1569
- instructions for submitting computer disks, 82
- pharmacoeconomics and outcomes research; call for papers for *AJHP*, 726
- procedure for submissions to, 80
- sections, 82
- American Medical Association**  
administration; performance measurement, 1348  
attitudes; physician-assisted suicide, 543
- American Pharmaceutical Association**  
Pharmacist Practice Activity Classification; development, 642  
policies and procedures; 1998 annual meeting, 878
- American Society of Health-System Pharmacists**  
administration; policy development, 1044  
affiliated state society officers, 1714  
Annual Meeting, call for papers, 1813; program, 791  
annual report, 1171  
attitudes; HCFA regulations, 1092; NCQA standards, 1351  
Board of Directors; actions, September 26, 1997, meeting, 73; actions, November 15–16, 1997, meeting, 722; actions, April 20–22, 1998, meeting, 1624; actions, May 31, 1998, meeting, 2018; actions, September 18, 1998, meeting, 2635  
clinical pharmacy; staff development, 1760  
Council on Administrative Affairs; report on, 690  
Council on Educational Affairs; report on, 695  
Council on Legal and Public Affairs; report on, 699  
Council on Organizational Affairs; report on, 703  
Council on Professional Affairs; report on, 706  
errors; medication; antineoplastic agents, 137  
Executive Vice President; report of, 1703  
guidelines; automated dispensing, 1403; clinical research, 369; drug abuse, 1721; infection control, 1724; medication misadventure nomenclature, 165; outsourcing, 1611; pharmacokinetic monitoring, 1726  
Harvey A. K. Whitney Lecture Award—1998, 1675  
Home Care '98 meeting; call for papers, 167; program, 1394  
House of Delegates; 49th annual session, members of, 1681; proceedings, 1680  
journals; WWW, 1773  
meetings; managed care systems, 1488, 1497; paper submission guidelines, 888; poster sessions, 2038  
membership; nonhospital pharmacists, 31  
Midyear Clinical Meeting; call for papers, 74; call for student posters, 478; program, 2095  
officers, directors, councils, committees, and headquarters staff; directory of, 1708  
Pharmacist Practice Activity Classification; development, 642  
Pharmacy Student Forum, report, 721  
policy recommendations—invitation to comment, 688  
Practitioner Recognition Program—1998 fellows, 936  
President and Chair of the Board; report of, 1692  
President-elect and Vice Chair of the Board; report of, 1697  
protocols; antidepressants, 2514; antithrombotic therapy, 376; metronidazole, 1407  
public relations; campaigns, 1570; pharmacists' role, 1959, 1975  
reports; managed care conference, 1492; Task Force on Science, 2519  
roster of residents completing ASHP-accredited programs in calendar year 1998, 1050  
Section of Clinical Specialists, report, 720  
Section of Home Care Practitioners, report, 718  
standards; Healthy People 2000, 477; ketorolac repackaging, 388; pharmacy practice, 1879  
strategic-planning report for 1998-99, 1717  
Student Leadership Awards; recipients, 1927  
Treasurer; report of, 1699
- Amifostine**; approvals; Spain, 1827
- Amino acids**  
injections; metal contamination, 150  
photodecomposition; hydrogen peroxide production, 1288
- Aminoglycosides**  
dosage; extended-interval dosage, 397  
gentamicin; pharmacokinetics, 2280  
tobramycin sulfate; incompatibilities, 463
- 5-Aminosalicylic acid**, see **Mesalamine**
- Amoxicillin**; combination, clavulanic acid; otitis media, 1881
- Amphotericin B**; errors; medication; lipid formulations, 2078
- Aminone lactate**; heart failure; home health care, 930
- Anagrelide hydrochloride**; thrombocytosis; review, 1979
- Analgesics and antipyretics**  
acetaminophen; emergency room prescribing, 1158; overdose, 1516  
bromfenac sodium; toxicity, 526  
morphine; toxicity, 480  
pain; palliative care, 640
- Anastrozole**; breast neoplasms; review, 445
- Anemia**  
epoetin alfa; costs, 1898  
iron dextran; cost-benefit analysis, Dec 15 suppl S12
- Anesthetics**; fentanyl citrate; incompatibilities, 1194
- Anesthetics, local**; interactions; heparins, 210
- Angina**  
heparin; comparisons, 2402; weight-based protocols, Dec 15 suppl S29  
heparins; low molecular weight, 2402  
heparin sodium; activated partial thromboplastin time, 2002  
thrombolytic agents; comparisons, 2402  
verapamil hydrochloride; circadian rhythm, Nov 15 suppl S17
- Angioplasty**  
abciximab; clinical studies, 2409  
platelet aggregation inhibitors; review, 2363
- Anorexics**; obesity; guidelines, 1663
- Anthelmintics**  
albendazole; neurocysticercosis, 598  
praziquantel; neurocysticercosis, 598
- Antiarrhythmic drugs**, see **Cardiac drugs**
- Antibiotics**  
pleural effusion; therapy failure, 2304  
pneumococcal infections; penicillin resistance, 1987  
toxicity; emergency room visits, 1158; pseudomembranous enterocolitis, 1365  
vancomycin; pseudomembranous enterocolitis, 1365; resistance, 1407  
vancomycin hydrochloride; incompatibilities, 463; ophthalmic solutions, 1386  
veterinary; NABP resolutions, 1445
- Antibodies**; monoclonal; basiliximab, 1444; daclizumab, 207; infliximab, 2225; infliximab approvals, 2073; palivizumab FDA approvals, 1654; rituximab, 110; trastuzumab, 2326
- Anticoagulants**  
ambulatory care; clinical pharmacists, 68  
atrial fibrillation; pharmacists' role, 348  
enoxaparin; interactions, 210  
enoxaparin sodium; stability, 1296  
heparin; coronary disease, 2402; pharmacists' monitoring, 396; protocols, 159; thrombophlebitis, 1995; toxicity, 1444; weight-based protocols, Dec 15 suppl S29  
heparin sodium; i.v. catheters, 570; laboratory tests, 2002  
lepirudin; FDA approvals, 1444  
monitoring; pharmacists' training, 1033  
pharmaceutical services; outpatient clinics, 1763  
warfarin; atrial fibrillation, 376  
warfarin sodium; generic equivalency, 727, 729; interactions, 1071
- Anticonvulsants**  
carbamazepine; loading dose, 1134  
phenytoin; blood levels, 2392  
topiramate; review, 554
- Antidepressants**  
bupropion; SSRI toxicity, 1167  
citalopram hydrobromide; FDA approvals, 1963  
depression; geriatrics, 2514, 2481  
imipramine; toxicity, 1552  
mirtazapine; review, 44  
serotonin reuptake inhibitors; astemizole interactions, 526; sexual dysfunction, 1167
- Antidiabetic agents**  
glyburide; diabetes mellitus, 2509  
metformin; cost-benefit analysis, Dec 15 suppl S24  
troglitazone; interactions, 1071; review, 905
- Antidiarrheal agents**; diarrhea; neoplasms, 1573
- Antidotes**  
acetylcysteine; acetaminophen overdose, 1516  
ipeca; pediatric poisoning, 1971  
fomepizole; ethylene glycol poisoning, 110

## Annual Index

### Antiemetics

dolasetron mesylate; FDA approvals, 18  
granisetron; antineoplastic toxicity, 1269  
nausea; outpatient survey, 1903  
ondansetron hydrochloride; incompatibilities, 2630  
vomiting; outpatient survey, 1903

**Antiestrogens;** raloxifene hydrochloride; FDA approvals, 104

### Antifungals

amphotericin B; medication errors, 2078  
fluconazole; resistance, 279  
interactions; cisapride, 2418  
itraconazole; suspensions, 261

### Antihistamines

astemizole; toxicity, 526  
cyproheptadine; SSRI toxicity, 1167  
diphenhydramine; emergency room prescribing, 1158

### Anti-infective agents

epidermal necrolysis; cimetidine toxicity, 163  
metronidazole; pseudomembranous enterocolitis, 1365, 1407  
rational therapy; infection control, 1724  
surgery; documentation, 993  
thalidomide; FDA approvals, 1746  
toxicity; emergency room visits, 1158

### Anti-inflammatory agents

bromfenac sodium; product withdrawal, 1548  
flurbiprofen; cataract surgery, Dec 15 suppl S23  
indomethacin sodium; incompatibilities, 154  
ketorolac tromethamine; DUE, 1274; repackaging, 388  
mesalamine; toxicity, 2304  
nonsteroidal; Alzheimer's disease, Nov 1 suppl S11; toxicity, 883, 2289

### Antilipemic agents

atorvastatin calcium; review, 2253  
HMG-CoA reductase inhibitors; costs, 995; mibe-  
fradil, 210

**Antimalarial agents;** chloroquine phosphate; stability, 1915

### Antineoplastic agents

anastrozole; review, 445  
capecitabine; breast neoplasms, 2326  
carboplatin; incompatibilities, 602  
compassionate-use protocols; investigational, 651  
daunorubicin citrate; medication errors, 2078  
dissolution; oral syringes, 735  
docetaxel; breast neoplasms, 1777, 2326  
doxorubicin hydrochloride; medication errors, 2078  
hydroxyurea; FDA approvals, 875  
interactions; amifostine, 1827  
interferon alfa-2b; stability, 1602  
paclitaxel; breast neoplasms, 2326  
protocols; medication orders, 137  
rituximab; FDA approvals, 110  
tacrolimus; mibefradil interactions, 210  
tamoxifen; breast neoplasms, 978, 2326  
topotecan hydrochloride; microbiological contamination, 1584  
toxicity; anemia, 1898; antiemetic prophylaxis, 1269; diarrhea, 1573; dolasetron therapy, 18; outpatient survey, 1903  
trastuzumab; breast neoplasms, 2326

### Antioxidants

Egb 761; Alzheimer's disease, Nov 1 suppl S11  
selegiline; Alzheimer's disease, Nov 1 suppl S11  
sodium metabisulfite; amino acid stability, 1288

**Antiparkinson agents;** tolcapone; FDA approvals, 524

### Antipsychotic agents

drug use; prescription cap, Dec 15 suppl S19  
fluphenazine decanoate; cost comparisons, Dec 15  
suppl S17  
haloperidol decanoate; cost comparisons, Dec 15  
suppl S17  
olanzapine; review, 1003  
risperidone; cost comparisons, Dec 15 suppl S17  
toxicity; emergency room visits, 1158

### Antiretroviral agents

efavirenz; FDA approvals, 2458  
HIV infections; occupational exposure, 1921; patient compliance, 1817; pharmaceutical services, 661; pharmacists' consultation, 955  
neftravir mesylate; nomenclature similarities, 1728  
nevirapine; nomenclature similarities, 1728  
protease inhibitors; astemizole interactions, 526; dosage, 2528  
reverse transcriptase inhibitors; dosage, 2528  
saquinavir; toxicity, 2016

### Antituberculars

pyrazinamide; suspensions, 1804  
rifampin; suspensions, 1804

### Antivirals

acyclovir sodium; stability, 574  
cidofovir; cytomegalovirus retinitis, 392  
delavirdine mesylate; HIV infections, 283  
foscarnet; cytomegalovirus retinitis, 392  
ganciclovir; cytomegalovirus retinitis, 392  
nevirapine; HIV infections, 283  
protease inhibitors; HIV infections, 233

### Anxiolytics, sedatives and hypnotics

alprazolam; stability, 1915  
droperidol; incompatibilities, 2630  
lorazepam; incompatibilities, 2013, 2305  
palliative care; NIH reports, 640

### Apparatus, see Equipment

**Arrhythmia;** imipramine; toxicity, 1552

**Arterial occlusive diseases;** urokinase; overview, 2414

### Arthritis

disease management; guidelines, 1943  
leflunomide; rheumatoid, 2225

### Artificial tears

alcohols, polyvinyl; incompatibilities, 463  
vehicles; vancomycin ophthalmic solutions, 1386  
**Aseptic areas;** cleanrooms; hospital pharmacy, 458;  
laminar-flow ceiling, 182

**ASHP, see American Society of Health-System Pharmacists**

**ASHP Affiliates,** 24, 218, 428, 647, 990, 1257, 1457, 1666, 1870, 2084, 2354, 2606

Alabama, 225, 992, 1872, 2356

Arizona, 1870

California, 25, 429, 992, 2610

Chapter Briefs, 224, 430, 650, 992, 1260, 2086, 2356, 2608

Colorado, 222, 992

Connecticut, 223, 648, 992, 1262, 1458, 1872, 2358

Delaware, 25

Educational Meetings, 25, 430, 648, 992, 1262, 1458, 1667, 1872, 2358, 2610

Florida, 224, 2086, 2356, 2608

Forty states represented at presidential officers' retreats, 24

Georgia, 1872, 2606

Hawaii, 430

Idaho, 2354

Illinois, 430, 2354

Indiana, 25, 224, 648, 1667, 2086, 2356

Iowa, 648, 1460

Kansas, 224, 1260

Kentucky, 2356

Louisiana, 1667

Maine, 25, 990

Maryland, 25, 224, 647, 992, 1262, 1872, 2358

Massachusetts, 1258

Michigan, 223, 2357

Minnesota, 25, 1457

Mississippi, 1666

Missouri, 1260

Montana, 26

National Health-System Pharmacy Week planned, 2610

Nebraska, 1458

Nevada, 26, 1668

New Hampshire, 430, 1458, 1872, 2358, 2608

New Jersey, 224, 2356

New Mexico, 992, 2608

New York, 25, 1260, 1460, 2084

North Carolina, 648

North Dakota, 1460

Ohio, 1870

Oklahoma, 25, 1258, 2086

Oregon, 25, 1260, 1666

Pennsylvania, 219, 430, 992, 1257, 2086

Rhode Island, 25, 430, 1262, 1458

South Carolina, 430, 1257

South Dakota, 1458

State societies on the Internet, 1258

State society events in Baltimore cover leadership, public relations, government affairs, meeting programming, 1457

State society executives meet at ASHP headquarters, visit Capitol Hill, 647

State society members, executives attend Midyear sessions on legislative and regulatory issues, public relations, membership matters, 218

Survey profiles state societies, 2084

Tennessee, 1260

Texas, 428, 2358

Upcoming Meetings, 26, 222, 430, 650, 992, 1262, 1461, 1668, 1872, 2357, 2608

Utah, 992, 2086

Vermont, 990, 1667, 2358

Virginia, 1262, 2606

Washington Metropolitan, 25, 648, 992, 1262, 1458, 1667, 1872, 2358

Washington State, 218, 2086

West Virginia, 991

Wisconsin, 24, 2088

Wyoming, 1260, 1872

### ASHP Foundation Reports, 1322, 2572

Anticoagulation program trains 16 more pharmacists, 2574

ASHP Student Leadership Award program to benefit from Jones fund, 2574

Asthma care traineeship begins, 1322

Cohen, others to be honored for contributions to literature, 2572

Disease management conference planned, 1322

New program aims to improve immunization rates, 2572

Odds Endowment receives large gifts from industry, 1323

Other Foundation activities, 1324

Program launched in stem-cell transplantation, 1322

Sixteen complete spring anticoagulation traineeships, 1323

Stem cell traineeship launched, 2574

**Aspergillus niger;** contamination; topotecan, 1584

### Aspirin

atrial fibrillation; protocols, 376

cerebrovascular disorders; overview, Oct 1 suppl S17

coronary disease; review, Oct 1 suppl S8

peripheral vascular diseases; overview, Oct 1 suppl S21

**Astemizole;** toxicity; liver diseases, 526

### Asthma

disease management; guidelines, 1943; Medicaid reimbursement, 1238; pharmacists' certification, 2452

montelukast sodium; FDA approvals, 759

### Atherosclerosis

clopidogrel bisulfate; FDA approvals, 207

overview, Oct 1 suppl S4

**Atorvastatin calcium;** hypercholesterolemia; review, 2253

### Atrial fibrillation

anticoagulants; cerebrovascular disorders, 348

aspirin; protocols, 376

ibutilide fumarate; review, 255

platelet aggregation inhibitors; cerebrovascular disorders, 348

warfarin; protocols, 376

**Authorship;** pharmacists; ASHP meeting papers, 888

### Automation

compounding; parenteral nutrition, 1503, 1606

dispensing; access discrepancies, 1924; ASHP guidelines, 1403; hospital pharmacy, 229; integrated health care, 669; pharmacists' role, 1302; robotics, 1907; telepharmacy, 1512

pharmacy practice, 782

**Autonomic drugs;** nicotine; toxicity, 1413

**Availability, drugs, see Drugs, availability**

**Azithromycin;** otitis media; review, 1881

## B

**Basiliximab;** approvals; FDA, 1444

### Benchmarking

health maintenance organizations; physician prescribing, 2234

managed care systems; pharmacists' interventions, 1141

**Benazalkonium chloride;** contamination; microbiological, 2534

**Ben zodiazepines;** prescriptions; New York laws, 2074

**Bethanechol chloride;** stability; suspensions, 1804

**Beverages;** grapefruit juice; astemizole interactions, 526

**Bid contracting, see Purchasing**

**Bioavailability, see Drugs, availability**

**Biologicals;** approvals; 1997, 336

**Blood;** transfusions; anemia, 1898; iron dextran, Dec 15 suppl S12

**Blood coagulation disorders;** disease management; Medicaid reimbursement, 1238

**Blood derivatives;** albumin; dilutions, 2078



**Blood levels**

- carbamazepine; loading dose, 1134
- carbamazepine-10,11-epoxide; carbamazepine toxicity, 1134
- ceftazidime; continuous infusion, 145
- cisapride; antifungals interaction, 2418
- cyclosporine; obesity, 1598
- dextrose; home tests, 2509; monitoring devices, 1877
- gentamicin; neonates, 2280
- heparin sodium; laboratory tests, 2002
- hydroxyitraconazole; itraconazole suspensions, 261
- itraconazole; suspensions, 261
- monitoring; pharmaceutical services, 2027; protocols, 1306
- phenytoin; methodology, 2392

**Blood pressure; monitoring; hypertension, Nov 15 suppl S12****Board of Pharmaceutical Specialties; certification; pharmacy specialties, 427; psychopharmacy, 1594****Book Reviews, 94, 191, 308, 404, 510, 619, 744, 858, 1430, 1534, 2044, 2314, 2578, 2648**  
*American College of Physicians Home Care Guide for HIV and AIDS for Family and Friends Giving Care at Home, 404**Approaching Death: Improving Care at the End of Life, 858**Bedside Diagnosis: An Annotated Bibliography of Literature on Physical Examination and Interviewing, Third Edition, 308**The Complete Care Plan Manual for Long-Term Care, 308**Creating You & Co.: Learning to Think Like the CEO of Your Own Career, 309**A Dictionary of Natural Products: Terms in the Field of Pharmacognosy Relating to Natural Medicinal and Pharmaceutical Materials and the Plants, Animals, and Minerals from Which They Are Derived, 1430*  
*Drugs of Natural Origin: Economic and Policy Aspects of Discovery, Development, and Marketing, 862**The Essentials of Contraceptive Technology: A Handbook for Clinical Staff, 744**Ethical Practices in Pharmacy: A Guidebook for Pharmacy Technicians, 191**A Guide to Performance Improvement for Pharmacies, 192**Handbook of Essential Psychopharmacology, 2044**How To Report Statistics in Medicine: Annotated Guidelines for Authors, Editors, and Reviewers, 94**Introduction to Health Care Delivery: A Primer for Pharmacists, 2314**Life in the Balance: Emergency Medicine and the Quest to Reverse Sudden Death, 1534**Literature reviews: clinical practice guidelines for the provision of pharmaceutical care, 1943; literature on cancer on the Internet, 2429**Lyne Disease, 2047**Medical Writing in Drug Development: A Practical Guide for Pharmaceutical Research, 2648**The Merck Manual of Medical Information—Home Edition, 510**Omega, 619**Pharmaceutical Economics and Policy, 744**Pharmacogenetics, 94**Prescription for Disaster: How Safe Are the Drugs You Take, 511**Systematic Reviews: Synthesis of Best Evidence for Health Care Decisions, 2578***Books Received, 95, 309, 623, 968, 1082, 1222, 1431, 1737, 1839, 2209, 2315****Bradycardia**  
clarithromycin; verapamil interactions, 2417**Breast neoplasms**  
verapamil; clarithromycin interactions, 2417**Cardiac drugs**  
anastrozole; review, 445**Cardiovascular diseases**  
antineoplastic agents; overview, 2326**Carcinoma**  
doxorubicin; review, 1777**Carcinoma**  
epoetin alfa; anemia, 1898**Carcinoma**  
tamoxifen; toxicity, 978**Carcinoma**  
product withdrawal, 1548**Carcinoma**  
gastrointestinal hydrochloride; FDA approvals, 20**Carcinoma**  
hospital pharmacy; Medicare reimbursement, 1620; residency funding, 1618**Carcinoma**  
hospitals; globulin immune shortage, 2090**Carcinoma**  
pharmacy; institutional; HMOs, 422**Carcinoma**  
buffers; citric acid; enalapril incompatibilities, 1155**Carcinoma**  
buprenorphine  
pain; pancreatitis, 480

therapy; narcotics dependence, 208  
**Bupropion**; sexual dysfunction; SSRI toxicity, 1167

**C**

**Cachexia**; palliative care; NIH, 640  
**Calcium**; concentration; automated TPN compounding, 1503

**Calcium gluconate**; injections; metal contamination, 150

**Calcium regulators**  
alendronate sodium; esophagitis, 892

risedronate sodium; FDA approvals, 984

**Calculations**; phenytoin; blood levels, 2392

**California**  
clinical pharmacists; ambulatory care, 1753

regulations; patient consultation, 2485

**Caloric agents**; dextrose; metal contamination, 150

**Canadian Pharmaceutical Association**; guidelines; infant formulas, 84

**Cancer**, see **Antineoplastic agents**

**Cancer drugs**, see **Antineoplastic agents**

**Candida albicans**  
contamination; toposcan, 1584

resistance; fluconazole, 279

**Candidiasis**; fluconazole; resistance, 279

**Capecitabine**; breast neoplasms; overview, 2326

**Capitation**; managed care systems; pharmacists' interventions, 1141

**Capsules**  
antineoplastic agents; oral liquid compounding, 735

compounding; suspensions, 1804

drugs; glaucoma, 272

folic acid; generic equivalency, 1415

itraconazole; availability, 261

mycophenolate mofetil; suspensions, compounding, 926

**Carbamazepine**; pharmacokinetics; loading dose, 1134

**Carbamazepine-10,11-epoxide**; blood levels; carbamazepine toxicity, 1134

**Carbohydrate metabolism**; sacrosidase; inborn errors, 1102

**Carbonic anhydrase inhibitors**; glaucoma; costs, 272

**Carboplatin**; incompatibilities; polyvinyl chloride, 602

**Cardiac drugs**  
adenosine; incompatibilities, 466, 1161

amrinone lactate; heart failure, 930

cardiovascular diseases; circadian rhythm, Nov 15 suppl S5

carvedilol; congestive heart failure, 676, 1626

dobutamine hydrochloride; heart failure, 930

dopamine hydrochloride; heart failure, 930

enalapril maleate; suspensions, stability, 1155

ibutilide fumarate; review, 255

mibefradil; interactions, 210

mibefradil dihydrochloride; product withdrawal, 1445

milrinone; heart failure, 930

nifedipine; powder content uniformity, 1299

quinidine sulfate; suspensions, 1804

verapamil; clarithromycin interactions, 2417

verapamil hydrochloride; circadian rhythm, Nov 15 suppl S17

**Cardiovascular diseases**  
astemizole; drug interactions, 526

cardiac drugs; circadian rhythm, Nov 15 suppl S5

platelet aggregation inhibitors; review, 2363

sildenafil citrate; toxicity, 2080

verapamil hydrochloride; circadian rhythm, Nov 15 suppl S17

**Cardiovascular drugs**; pleural effusion; therapy failure, 2304

**Career Opportunities**, 87, 184, 292, 399, 494, 606, 736, 848, 957, 1074, 1200, 1317, 1418, 1526, 1627, 1730, 1829, 1936, 2028, 2197, 2306, 2420, 2540, 2641

**Careers**  
pharmacists; nontraditional Pharm.D., 1281

pharmacy; professional excellence, 782

**Caregivers**  
Alzheimer's disease; indirect costs, Nov 15 suppl S17; pharmacists' role, Nov 15 suppl S26

antineoplastic agents; exposure, 735

patient information; confidentiality, 764

pharmaceutical services; disease management, 471

**Carvedilol**; heart failure; ambulatory care, 1626; congestive, 676

**Cataract**; flurbiprofen; cost-benefit analysis, Dec 15 suppl S23

**Catecholamines**; heart failure; hemodynamics, 676

**Catheters**; intravenous; pediatrics, 570

**CD-ROM**; drug information; managed care systems, 2007

**Cefazolin sodium**; incompatibilities; artificial tears, 463

**Cefepodoxime proxetil**; otitis media; review, 1881

**Cefprozil**; otitis media; review, 1881

**Ceftazidime**  
blood levels; continuous infusion, 145

incompatibilities; infusion pumps, 683

**Ceftriaxone**; otitis media; review, 1881

**Cefuroxime axetil**; otitis media; review, 1881

**Celecoxib**; arthritis; rheumatoid, 2225

**Centers for Disease Control and Prevention**; protocols; health professions' immunization, 760; pediatric vaccines, 563

**Central nervous system stimulants**; dextroamphetamine; SSRI toxicity, 1167

**Cephalosporins**  
cefazolin sodium; incompatibilities, 463

cefazidime; incompatibilities, 683; stability, 145

otitis media; review, 1881

**Cerebral ischemia**  
aspirin; transient, Oct 1 suppl S17

dipyridamole; transient, Oct 1 suppl S17

ticlopidine; transient, Oct 1 suppl S17

**Cerebrovascular disorders**  
anticoagulants; atrial fibrillation, 348

aspirin; atrial fibrillation, 376; overview, Oct 1 suppl S17

clopidogrel bisulfate; FDA approvals, 207

dipyridamole; overview, Oct 1 suppl S17

epidemiology; Healthy People 2000, 477

overview; atherosclerosis, Oct 1 suppl S4

platelet aggregation inhibitors; atrial fibrillation, 348

ticlopidine; overview, Oct 1 suppl S17

warfarin; atrial fibrillation, 376

**Certification**  
pharmacists; disease management, 1238, 2452;

pharmacy organizations, 2444; program accreditation, 1856; psychopharmacy, 1594

pharmacists, community; clinical services, 635

pharmacy; specialties, 427

technicians; administrators' attitudes, 1799

**Cervicitis**; grepafloxacin hydrochloride; FDA approvals, 20

**Charity**  
drugs; NABP resolutions, 1445

HIV infections; antiretroviral agents, 661

industry, pharmaceutical; indigent psychiatric patients, 1293

**Charts**; errors, medication; process control, 946

**Cherry syrup**  
incompatibilities; vehicles, 1804

vehicles; mycophenolate suspensions, 926; oral liquids, 1915

**Chlorhexidine gluconate**; contamination; microbiological, 2534

**Chlorofluorocarbons**; propellants; metered-dose inhalers, 226, 276

**Chloroquine phosphate**; stability; oral liquids, 1915

**Chromium**; contamination; parenteral nutrition, 150

**Chronopharmacology**  
cardiac drugs; cardiovascular diseases, Nov 15 suppl S5

verapamil hydrochloride; cardiovascular diseases, Nov 15 suppl S17

**Cidofovir**; cytomegalovirus retinitis; AIDS, 392

**Cigarettes**; smoking; Healthy People 2000, 477

**Cimetidine**  
adverse reactions; epidermal necrolysis, 163

interactions; sildenafil, 2080

liver diseases; acetaminophen overdose, 1516

substitution; therapeutic, 1382

ulcers; cost comparisons, Dec 15 suppl S8

**Circadian rhythm**  
cardiac drugs; cardiovascular diseases, Nov 15 suppl S5

verapamil hydrochloride; cardiovascular diseases, Nov 15 suppl S17

**Cisapride**  
interactions; triazole antifungals, 2418

stability; oral liquids, 1915

**Cisatracurium besylate**; incompatibilities; stability, 1037

**Citalopram hydrobromide**; approvals; FDA, 1963

**Citric acid**; buffers; enalapril suspensions, 1155

# **Clarithromycin**

interactions; verapamil, 2417  
otitis media; review, 1881

**Classification:** pharmacy; job description, 642

**Classified advertising:** see **Career Opportunities**

**Clavulanic acid:** combination, amoxicillin; otitis media, 1881

**Clearance:** see **Excretion**

## **Clinical pharmacists**

ambulatory care; anticoagulation clinics, 1033;  
heart failure clinics, 1626; interventions, 1753;  
VA centers, 68  
consultation; antiretroviral agents, 955; discharge  
medications, Dec 15 suppl 532  
hospitals; history, 229  
interventions; patient information, 1017  
pharmaceutical care; outcomes research, 62

## **Clinical pharmacy**

ambulatory care; ASHP services, 31  
hospitals; history, 229  
pharmacists, hospital; job satisfaction, 360  
pharmacists, institutional; layoffs, 2387  
services; ambulatory care, 68, 1753; community  
pharmacists, 635; heart failure clinics, 1626;  
home health care, 486; hospital technicians,  
1375; outcomes research, 62; planning and de-  
sign, 2505; staff development, 1760

## **Clinical studies**

Alzheimer's disease; overview, Nov 1 suppl 53, Nov  
1 suppl 511  
amifostine; neoplasms, 1827  
antineoplastic agents; breast neoplasms, 2326;  
compassionate-use protocols, 651  
atorvastatin calcium; hypercholesterolemia, 2253  
cholinesterase inhibitors; Alzheimer's disease, Nov  
1 suppl 522  
citalopram hydrobromide; overview, 1963  
clonidine; overview, 207  
daclizumab; overview, 207  
delavirdine mesylate; overview, 283  
drugs, investigational; ASHP guidelines, 369  
efavirenz; HIV infections, 2458  
gene therapy; review, 899  
geriatrics; medication misuse, 1654  
infliximab; Crohn's disease, 2073  
methotrexate; ectopic pregnancy, 171  
misoprostol; NSAIDs toxicity, 883  
montelukast sodium; asthma, 759  
natural products; need, 125  
nevirapine; overview, 283  
nicotine; transdermal patches, 1413  
omeprazole; NSAIDs toxicity, 883  
oprelvekin; thrombocytopenia, 107  
pharmaceutical care; methodology, 62  
pharmacists, hospital; outpatient clinics, 1763  
platelet aggregation inhibitors; cardiovascular dis-  
eases, 2363  
proton-pump inhibitors; gastric acid-related dis-  
eases, 2289  
raloxifene hydrochloride; osteoporosis, 104  
ranitidine; NSAIDs toxicity, 883  
regulations; conflict of interest, 642  
rituximab; non-Hodgkin's lymphoma, 110  
rizatriptan benzoate; migraine, 1656  
rotavirus vaccines; FDA approvals, 2226  
thrombophlebitis; drug comparisons, 1995  
warfarin sodium; pharmacokinetics, 727, 729

## **Clopidogrel**

coronary disease; review, Oct 1 suppl 58  
peripheral vascular diseases; overview, Oct 1 suppl  
521

**Clopidogrel bisulfate:** approvals; FDA, 207

**Clostridium difficile:** resistance; antibiotics, 1365  
**Clostridium infections:** metronidazole; protocols,  
1407

**Closures:** vials; latex free, 437

**Cognition disorders:** palliative care: NIH reports,  
640

## **Combined therapy**

drugs; glaucoma, 272  
insulins and troglitazone; diabetes mellitus, 905  
parasympathomimetic agents; Alzheimer's disease,  
Nov 1 suppl 511  
sulfonylureas and troglitazone; diabetes mellitus,  
905  
troglitazone and insulins or sulfonylureas; diabetes  
mellitus, 905  
vaccines; pediatrics, 563

**Commentaries:** 382, 480, 578, 727, 946, 1302,  
2289, 2402, 2525

# **Committees**

formularies; HMOs, 56  
hospitals; latex-free products, 437

## **Communication**

American Society of Health-System Pharmacists;  
public relations campaigns, 1570  
health care; direct-to-consumer advertising, 594  
health professions; institutional pharmacists, 1769;  
pharmacokinetic monitoring, 1726  
hospital pharmacy; globulin immune shortage,  
2090  
Joint Commission on Accreditation of Healthcare  
Organizations; Sentinel Event Alert, 764  
patient information; continuity of care, 1017  
patients; allergy documentation, 1524  
pharmacists; continuity of care, 2500; privacy tele-  
phone, 2245; public relations, 1569; risk manage-  
ment, 585  
pharmacists, hospital; health professions, 486; Na-  
tional Hospital Pharmacy Week, 843; patient  
consultation, 1792  
pharmacists, institutional; layoffs, 2387; poison  
control centers, 1971  
television; patient information, 536

**Community service:** pharmacists, institutional;  
poison prevention programs, 1971

**Compassion in Dying:** suicides; perspective, 547

## **Compliance**

patients; ambulatory care, 35, 1753; antiretroviral  
agents, 955, 1817; antiretrovirals, 661; discharge  
prescriptions, 1389; fluconazole, 279; pharma-  
cists' role, 441; protease inhibitors, 233; proton-  
pump inhibitors, 2249  
physicians; H<sub>2</sub> antagonists substitution, 1382  
standards; home health care, 2299

## **Compounding**

alprazolam; oral liquids, 1915  
anti-infective agents; ophthalmic solutions, 463  
antineoplastic agents; oral liquids, 735  
chloroquine phosphate; oral liquids, 1915  
cisapride; oral liquids, 1915  
enalapril maleate; oral liquids, 1915; suspensions,  
1155  
granisetron hydrochloride; suspensions, 2511  
hydralazine hydrochloride; oral liquids, 1915  
injections; cleanrooms, 458  
itraconazole; suspensions, 261  
mycophenolate mofetil; oral suspensions, 926  
nifedipine; powders, 1299  
parenteral nutrition; automated, 1503; automa-  
tion, 1606  
potassium chloride; injections, 1098  
regulations; Food and Drug Administration, 1859  
sterile products; laminar-flow ceiling, 182; latex al-  
lergies, 1462  
suspensions; stability, 1804  
vancomycin hydrochloride; ophthalmic solutions,  
1386

**Comprehension:** patients; discharge prescriptions,  
1389

## **Computers**

databases; drug information, 1164  
drug distribution systems; automation safety, 1403  
drug information; hospital pharmacy, 229  
equipment; wide-area networks, 1146  
hospital pharmacy; drug-food interactions, 122  
pharmaceutical care; telepharmacy, 1512  
pharmacy, institutional; drug information, 2007  
programs; phenytoin blood levels, 2392; wide-area  
networks, 1146  
records; patient confidentiality, 875, 895

## **Concentration**

acyclovir sodium; incompatibilities, 574  
adenosine; incompatibilities, 466  
albumin; toxicity, 2078  
carboplatin; incompatibilities, 602  
cefazidime; incompatibilities, 683  
chromium; parenteral nutrition, 150  
cisatracurium besylate; incompatibilities, 1037  
electrolytes; automated TPN compounding, 1503  
interferon alfa-2b; stability, 1602  
lorazepam; incompatibilities, 2013, 2305  
ondansetron hydrochloride; incompatibilities,  
2630  
polyethylene glycol 400; lorazepam solubility,  
2305  
potassium chloride; floor stock, 1098  
ranitidine hydrochloride; filter adsorption, 840  
riboflavin; amino acid stability, 1288  
sodium metabisulfite; amino acid stability, 1288  
somatropin; incompatibilities, 1508  
torsemide; stability, 1042  
zinc; parenteral nutrition, 150

# **Consumers**

advertising; prescription drugs, 594  
attitudes; direct-to-consumer advertising, 2344;  
health care industry, 876; health-benefit pro-  
grams, 878; pharmacists, 1482  
communication; ASHP public relations, 1570  
health-benefit programs; third party, 1663  
patient information; television, 536  
prescription drugs; direct advertising, 880  
satisfaction; managed care systems, 986

## **Containers**

glass; adenosine incompatibilities, 1161; lorazepam  
incompatibilities, 2013  
packaging; beyond-use vs. expiration dates, 433  
plastics; granisetron suspensions, 2511  
polyethylene terephthalate; oral liquid compound-  
ing, 1915; suspensions, stability, 1804  
polyethylene terephthalate glycol; mycophenolate  
incompatibilities, 926  
polyvinyl chloride; adenosine incompatibilities,  
466; carboplatin, 602; incompatibilities, 1037;  
organ preservation solutions, 266; torsemide sta-  
bility, 1042

## **Contamination**

chromium; parenteral nutrition, 150  
hydrogen peroxide; parenteral nutrition, 1288  
microbiological; abxiximab, 2026; disinfectants,  
2534; enoxaparin, 1296; syringes, 956; topotecan,  
1584  
particles; air, 458; organ preservation solutions, 266  
zinc; parenteral nutrition, 150

## **Content uniformity**

folic acid; capsules, 1415  
nifedipine; powders, 1299  
warfarin sodium; pharmaceutical industry, 727,  
729

**Contraceptives:** patient education; thalidomide  
prescribing, 1746

## **Contracts**

managed care systems; pharmaceutical services,  
523  
Owen Healthcare; University of Florida, 530

## **Contract services**

clinical studies; ASHP guidelines, 369  
home health care; hospitals, 2019  
hospital pharmacy; ASHP guidelines, 1611; inte-  
grated health care, 669; radiopharmaceuticals,  
2537  
integrated health care; statistics, 1450  
managed care systems; drug information centers,  
2007  
pharmacy, community; refill reminders, 875

## **Contraindications**

astemizole; drug interactions, 526  
naratriptan hydrochloride; overview, 638  
olanzapine; review, 1003  
sacrosidase; overview, 1102  
sildenafil citrate, 2080

## **Control**

costs; drugs, 2234; HMO drug use, 422; hospital  
pharmacy outsourcing, 1611; outpatient pre-  
scriptions, 1763; outpatient services, 669; phar-  
macists' role, 1123; radiopharmaceuticals, 2537  
drug abuse; pharmacists' role, 1721  
errors, medication; process control charts, 946

**Controlled substances:** prescriptions; New York  
laws, 2074

## **Control, quality**

benzalkonium chloride; microbiological contam-  
ination, 2534  
dietary supplements; manufacturing, 2341; USP  
standards, 2330  
medicinal plants; manufacturing, 2341; USP stan-  
dards, 2330  
parenteral nutrition; automated compounding,  
1606  
warfarin sodium; generic equivalency, 729

## **Coronary disease**

abxiximab; cost-benefit analysis, Dec 15 suppl 535  
aspirin; review, Oct 1 suppl 58  
atorvastatin calcium; hypercholesterolemia, 2253  
clopidogrel; review, Oct 1 suppl 58  
dipyridamide; review, Oct 1 suppl 58  
epidemiology; Healthy People 2000, 477  
eptifibatide; FDA approvals, 1440  
pathophysiology; overview, 2402  
patient information; drug histories, 1769  
sildenafil citrate; contraindications, 2080  
ticlopidine; review, Oct 1 suppl 58  
tirofiban hydrochloride; FDA approvals, 1440

**Correction Notices:** 84, 735, 847, 1416, 1729,  
2419, 2640

Appointments & Promotions (Oct 15, 1998, News),  
2419

- Compatibility of meropenem with commonly used injectable drugs (Dec 1, 1996, Notes), 735
- An ethicist's perspective (Mar 15, 1998, Special Features), 1416
- In nursing facilities, cost of drug-related problems tops cost of drugs (Dec 1, 1997, News), 84
- Participation and influence of individuals and committees that decide on drug availability in HMOs (Jan 1, 1998, Reports), 847
- Protease inhibitors for the treatment of human immunodeficiency virus infection (Feb 1, 1998, Clinical Review), 847
- Stability of mycophenolate mofetil in an extemporaneously compounded oral liquid (May 1, 1998, Report), 1729
- Etiology and pathogenesis of Alzheimer's disease (Nov 1, 1998, Suppl 2) 2640
- Cost-benefit, see Economics; cost-benefit analysis**
- Cost-effectiveness, see Economics; cost-benefit analysis**
- Costs**
- abacimab; clinical studies, 2409; coronary disease, Dec 15 suppl S35
- Alzheimer's disease; overview, Nov 1 suppl S17
- anagrelide hydrochloride; thrombocytosis, 1979
- anastrozole; review, 445
- antidepressants; geriatrics, 2514
- antipsychotic agents; prescription cap, Dec 15 suppl S19
- antiretroviral agents; HIV infections, 661
- cimetidine; comparisons, Dec 15 suppl S8
- cleanrooms; hospital pharmacy, 458
- computers; wide-area networks, 1146
- contract services; radiopharmaceuticals, 2537
- data collection; performance measurements, 1348
- disease management; managed care systems, 1029; pharmaceutical services, 471
- drugs; control, 2234; glaucoma, 272; HIV infections, 1151; hospital pharmacy, 229; integrated health care, 669; 1998 projections, 127; patient consultation, 2485; pharmacists' role, 347, 441; toxicity, 1588
- efavirenz; HIV infections, 2458
- epoetin alfa; anemia, 1898
- famotidine; comparisons, Dec 15 suppl S8
- flurbiprofen; cataract surgery, Dec 15 suppl S23
- health care; artherosclerosis, Oct 1 suppl S4; hospital pharmacy, 665; patient consultation, 2485; pharmacists' role, 441, 1123; pharmacy benefit, 767
- heparin; weight-based protocols, Dec 15 suppl S29
- histamine H<sub>2</sub> antagonists; therapeutic substitution, 1382
- HMG-CoA reductase inhibitors; HMOs, 995
- hospital pharmacy; outsourcing guidelines, 1611; residencies, 1620
- ibutilide fumarate; atrial fibrillation, 255
- iron dextran; hemodialysis, Dec 15 suppl S12
- itraconazole; suspensions, 261
- ketorolac tromethamine; pharmacists' interventions, 1274; repackaging, 388
- managed care systems; pharmaceutical services, 523
- metronidazole; pseudomembranous enterocolitis, 1407
- mirtazapine; review, 44
- olanzapine; review, 1003
- patient care; clinical studies, 62; diabetes mellitus, 10; managed care systems, 1488; professional priorities, 782; prospective-pricing system, 1645; telephone services, 453
- pharmaceutical services; military programs, 1656
- platelet aggregation inhibitors; formularies, Oct 1 suppl S28
- prescription drugs; HMOs, 422
- prescriptions; outpatients, 1763
- protease inhibitors; review, 233
- psychotherapeutic agents; indigent care program, 1293
- surgical wound infection; hospitals, 777
- trogilazine; review, 905
- urokinase; arterial occlusive diseases, 2414
- vancomycin; *Enterococcus* species, 1407
- varicella vaccines; institutional personnel, Dec 15 suppl S4
- warfarin sodium; generic, 727, 729
- Council on Credentialing in Pharmacy; certification; pharmacists, 2444**
- m-Cresol, see Metacresol**
- Crime**
- hospitals; sentinel-event policies, 1112
- suicides; physician assisted, 547
- Critical pathways; managed care systems; pharmacists' role, 441**
- Crohn's disease; infliximab; FDA approvals, 2073**
- Current Literature, 92, 190, 307, 403, 508, 618, 742, 854, 964, 1081, 1220, 1325, 1429, 1532, 1633, 1736, 1836, 1943, 2042, 2208, 2313, 2429, 2576, 2647**
- Curriculum; alternative medicine; pharmaceutical education, 2525**
- Cyanocobalamin; protocols; Institute of Medicine, 981**
- Cyclosporine**
- blood levels; obesity, 1598
- interactions; mibefradil, 210
- Cyproheptadine; sexual dysfunction; SSRI toxicity, 1167**
- Cysteine hydrochloride; injections; metal contamination, 150**
- Cysticercosis**
- albendazole; comparisons, 598
- praziquantel; comparisons, 598
- Cystic fibrosis; gene therapy; review, 899**
- Cytomegalovirus retinitis; antivirals; AIDS, 392**
- Cytoprotectants; amifostine; interactions, 1827**
- Cytotoxic agents, see Antineoplastic agents**
- D**
- Dacizumab; approvals; FDA, 207**
- Databases**
- drug information; hospital pharmacy, 1164
- hospital pharmacy; allergy documentation, 289
- managed care systems; coronary disease monitoring, 1769
- pharmaceutical services; military programs, 1656
- pharmacy, community; continuity of care, 2500
- Data collection**
- administration; health care organizations, 876
- administrators; disease management, 1029; technician certification, 1799
- ambulatory care; VA centers, 68
- clinical pharmacists; anticoagulation clinics, 1033
- consumers; direct-to-consumer advertising, 2344; health-benefit programs, 878; health care organizations, 876
- costs; performance measurement, 1348
- education, pharmaceutical; residency funding, 1618
- geriatrics; pharmacists' consultation, 768
- health-benefit programs; managed care systems, 1663
- health care; costs, 767
- health maintenance organizations; formulary decisions, 50, 56
- health professions; formulary system development, 1308
- hospital pharmacy; abacimab storage, 2026; drug information centers, 1164
- hospitals; drug-related injuries, 1158; potassium floor stock, 1098
- integrated health care; survey, 1450
- managed care systems; conference registrants, 1488; customer satisfaction, 986; drug information, 2007; participants' attitudes, 1490
- National Committee for Quality Assurance; managed care systems, 2351
- outpatients; antineoplastics, toxicity, 1903
- patients; discharge medications consultation, Dec 15 suppl S32; discharge prescriptions, 1389; pharmaceutical services, 1025, 2615, 2621; telephone services, 453
- personnel, pharmacy; robotics, 1907
- pharmaceutical services; integrated health care, 35
- pharmacists; nontraditional Pharm.D., 1281
- pharmacists, community; pharmaceutical care, 2009
- pharmacists, hospital; inpatient consultation, 1127; job satisfaction, 360; patient consultation, 1792
- pharmacists, institutional; layoffs, 2387
- physicians; consultant pharmacists, 1588
- Daurorubicin citrate; errors, medication; lipid formulations, 2078**
- Death; drugs; consultant pharmacists' interventions, 1588; sentinel-event policies, 1112**
- Death with Dignity Act; Oregon; implementation, 318, 1235**
- Decision-making**
- formularies; integrated health care, 35
- health care; consumers' influence, 876; interdisciplinary team, 1369
- health maintenance organizations; formularies, 50, 56
- hospital pharmacy; platelet aggregation inhibitors, Oct 1 suppl S28
- pharmacists, institutional; managed care systems, 441
- Degrees**
- Bachelor of Science; psychopharmacy certification, 1594
- Doctor of Pharmacy; clinical pharmacists, 68; non-traditional, 530, 1281; psychopharmacy certification, 1594
- external; nontraditional Pharm.D., 530, 1281
- Delavirdine mesylate; HIV infections; overview, 283**
- Demographics; patients; drug-related injuries, 1158**
- Department of Defense; health-benefit programs; pharmacy benefit, 1656**
- Department of Health and Human Services**
- drug distribution; globulin immune shortages, 1341
- nursing homes; DUR, 330
- standards; Healthy People 2000, 477
- Department of Veterans Affairs**
- ambulatory care; clinical pharmacists, 68, 1753
- pharmaceutical care; outcomes research, 62
- Dependence; narcotics; methadone therapy, 208**
- i-Deprenyl, see Selegiline**
- Depression**
- antidepressants; geriatrics, 2481; protocols, 2514
- citalopram hydrobromide; FDA approvals, 1963
- disease management; guidelines, 1943
- mirtazapine; review, 44
- palliative care; AMA and NHO, 543; ethics, 539
- Devices**
- catheters; heparin vs. sodium chloride, 570
- diabetes mellitus; blood glucose meters, 1877
- dosage schedules; antiretroviral agents, 1817
- drug administration systems; somatropin reconstitution, 734
- infusion pumps; ceftazidime incompatibilities, 683; elastomeric, 145
- inhalers; metered dose, 226, 276
- injections; flow restricting, 351
- medical; blood pressure monitoring, Nov 15 suppl S12; FDA regulations, 426, 2472; latex-free products, 437; latex labeling, 2059; unlabeled use, 1449
- Dexamethasone; concomitant therapy, 1269**
- Dexamethasone sodium phosphate; incompatibilities; organ preservation solutions, 266**
- Dextroamphetamine; sexual dysfunction; SSRI toxicity, 1167**
- Dextrose**
- concentration; automated TPN compounding, 1503
- diluents; acyclovir, 574; carboplatin injections, 602; lorazepam incompatibilities, 2013, 2305
- home tests; dextrose, 2509
- incompatibilities; adenine, 466; cisatracurium, 1037; torsemide, 1042
- injections; metal contamination, 150
- monitoring; pharmacists' consultation, 1877
- Diabetes mellitus**
- disease management; guidelines, 1943; Medicaid reimbursement, 1238; pharmacists' certification, 2452
- glyburide; dextrose test strips, 2509
- insulin; cost-benefit analysis, Dec 15 suppl S24
- metformin; cost-benefit analysis, Dec 15 suppl S24
- patient care; pharmacotherapy services, Dec 15 suppl S27
- patient information; blood glucose meters, 1877
- pharmaceutical care; community pharmacists, 10
- trogilazine; interactions, 1071; review, 905
- Diagnosis**
- Alzheimer's disease; overview, Nov 1 suppl S3, Nov 1 suppl S5
- depression; geriatrics, 2514
- diseases; clinical pharmacists, 1753
- hypertension; protocols, 382
- mental disorders; future, 83
- peripheral vascular diseases; overview, Oct 1 suppl S21
- Dialysis; hemo-; clarithromycin-verapamil interactions, 2417; iron dextran, Dec 15 suppl S12**
- Diarrhea; antidiarrheal agents; neoplasms, 1573**
- Dietary supplements**
- control, quality; manufacturing, 2341; USP standards, 2330
- labeling; beyond-use vs. expiration dates, 433; FDA regulations, 1239
- protocols; Institute of Medicine, 981

## Annual Index

**Dietitians;** role; drug-food interactions, 114, 122  
**Digoxin;** concomitant therapy, 2417

### Diluents

dextrose; acyclovir, 574; adenosine incompatibilities, 466; carboplatin injections, 602; cisatracurium incompatibilities, 1037; lorazepam incompatibilities, 2013, 2305; torsemide stability, 1042  
 lactated Ringer's injection; adenosine incompatibilities, 466  
 sodium chloride; acyclovir, 574; adenosine incompatibilities, 466, 1161; cisatracurium incompatibilities, 1037; lorazepam incompatibilities, 2013  
 water; lorazepam incompatibilities, 2305  
 water for injection; indomethacin incompatibilities, 154; interferon alfa-2b, 1602

**Dilutions;** albumin; toxicity, 2078

**Diphenhydramine;** prescribing; emergency room therapy, 1158

**Diphtheria and tetanus toxoids;** health professions; CDC protocols, 760

**Diphtheria and tetanus toxoids and pertussis vaccines;** protocols; pediatrics, 563

### Dipyridamole

cerebrovascular disorders; overview, Oct 1 suppl S17  
 coronary disease; review, Oct 1 suppl S8

### Disease management

guidelines; WWW, 1943  
 health maintenance organizations; physician prescribing, 2234  
 managed care systems; medical directors, 1029  
 pharmaceutical services; administration, 471; reimbursement, 523  
 pharmacists; certification, 2452; professional fees, 1238  
 pharmacy; community; services, 635

### Diseases

diagnosis; clinical pharmacists, 1753

prescription drugs; HMO costs, 422

### Disinfectants

alkylldiminoethyl glycine; microbiological contamination, 2534  
 benzalkonium chloride; microbiological contamination, 2534  
 chlorhexidine gluconate; microbiological contamination, 2534

**Disintegration;** folic acid; capsules, 1475

### Dispensing

alternative medicine; hospital pharmacy, 1266  
 automation; access discrepancies, 1924; ASHP guidelines, 1403; hospital pharmacy, 229; telepharmacy, 1512  
 drugs; allergies, 289; indigent patients, 1445  
 hospital pharmacy; robotics, 1907  
 managed care systems; pharmacists' role, 441  
 nevirapine; nomenclature similarities, 1728  
 nelfinavir mesylate; nomenclature similarities, 1728  
 patient information; Healthy People 2000, 477  
 pharmacists; thalidomide, 1746  
 prescriptions; hospital pharmacy taxes, 772  
 remote; integrated health care, 669  
 sterile products; latex allergies, 1462  
 unit dose; medication errors, 946

### Dissolution

antineoplastic agents; oral syringes, 735  
 folic acid; generic equivalency, 1415

### Diuretics

hypertension; protocols, 382  
 torsemide; stability, 1042

**Dobutamine hydrochloride;** heart failure; home health care, 930

**Docetaxel;** breast neoplasms; overview, 2326; review, 1777

### Documentation

allergies; hospitals, 289; medical records, 1524; pharmaceutical services, 364  
 anti-infective agents; surgical prophylaxis, 993  
 antineoplastic agents; compassionate-use protocols, 651  
 dispensing; alternative medicine, 1266  
 drugs; adverse reactions; hospitals, 289  
 patient care; telephone services, 453  
 pharmaceutical care; community pharmacists, 2009

**Dolasetron mesylate;** approvals; FDA, 18

**Donepezil;** Alzheimer's disease; overview, Nov 1 suppl S22

**Dopamine hydrochloride;** heart failure; home health care, 930

### Dosage

alendazole; neurocysticercosis, 598  
 anagrelide hydrochloride; thrombocytosis, 1979

anastrozole; review, 445

antidepressants; geriatrics, 2514

antifungals; candidiasis, 279

antineoplastic agents; toxicity, 1269

antiretroviral agents; HIV infections, 955

basiliximab; overview, 1444

carbamazepine; loading, 1134

cardiac drugs; home health care, 930

carvedilol; clinical pharmacy services, 1626

citalopram hydrobromide; depression, 1963

clopidogrel bisulfate; overview, 207

dacizumab; organ rejection, 207

delavirdine mesylate; HIV infections, 283

docetaxel; breast neoplasms, 1777

dolasetron mesylate; overview, 18

drugs; blood level monitoring, 1306; pharmacokinetic monitoring, 1726

efavirenz; HIV infections, 2458

epitoin alfa; hemodialysis, Dec 15 suppl S12

epitoin alfa; overview, 1440

folic acid; protocols, 981

fomepizole; overview, 110

grefaploxacillin hydrochloride; FDA approvals, 20

heparin; patients' weight, 159; pharmacists' training, 396; weight-based protocols, Dec 15 suppl S29

HMG-CoA reductase inhibitors; cost-benefit analysis, 995

hydroxyurea; sickle cell trait, 875

ibutilide fumarate; atrial fibrillation, 255

infliximab; overview, 2073

leflunomide; rheumatoid arthritis, 2225

lepinudin; overview, 1444

mesalamine; toxicity, 2304

metronidazole; pseudomembranous enterocolitis, 1407

mirtazapine; depression, 44

montelukast sodium; overview, 759

naratriptan hydrochloride; overview, 638

nelfinavir mesylate; nomenclature similarities, 1728

irapine; HIV infections, 283; nomenclature similarities, 1728

nicotine; transdermal patches, 1413

olanzapine; review, 1003

oprelvekin; overview, 107

overdose; acetaminophen, 1516; ethylene glycol, 110; imipramine, 1552; potassium chloride, 1098

palivizumab; pediatrics, 1654

praziquantel; neurocysticercosis, 598

prednisone; pleural effusion, 2304

protease inhibitors; review, 233

proton-pump inhibitors; gastric acid-related diseases, 2289

psychotherapeutic agents; Alzheimer's disease, Nov 1 suppl S26

raloxifene hydrochloride; overview, 104

risedronate sodium; overview, 984

rituximab; overview, 110

rizatriptan benzoate; overview, 1656

sacrosidase; carbohydrate metabolism, 1102

serotonin-reuptake inhibitors; sexual dysfunction, 1167

sildenafil citrate; overview, 981

somatropin; administration systems, 734

thalidomide; erythema nodosum, 1746

tirofiban hydrochloride; overview, 1440

tolcapone; overview, 524

topiramate; review, 554

troglitazone; diabetes mellitus, 905

verapamil; clarithromycin interactions, 2417

warfarin sodium; interactions, 1071

zolmitriptan; overview, 110

### Dosage forms

amphotericin B; lipid formulations, 2078  
 daunorubicin citrate; lipid formulations, 2078

doxorubicin hydrochloride; lipid formulations, 2078

drugs; asthma, 276; costs, 272

### Dosage schedules

alendronate sodium; toxicity, 892

aminoglycosides; extended interval, 397

antimetotics; antineoplastics toxicity, 1269

antifungals; candidiasis, 279

antineoplastic agents; protocols, 137

antiretroviral agents; HIV infections, 955; patient compliance, 1817

bromfenac sodium; long term, 526

carbamazepine; loading, 1134

carvedilol; clinical pharmacy services, 1626

efavirenz; HIV infections, 2458

gentamicin; neonates, 2280

heparin; clinical studies, 1995

methotrexate; ectopic pregnancy, 171

metronidazole; pseudomembranous enterocolitis, 1407

proton-pump inhibitors; gastric acid-related diseases, 2289; long term, 2268

risedronate sodium; overview, 984

rotavirus vaccines; overview, 2226

serotonin-reuptake inhibitors; sexual dysfunction, 1167

sildenafil citrate; overview, 981

streptokinase; clinical studies, 1995

vaccines; pediatrics, 563

**Doxorubicin hydrochloride;** errors; medication; lipid formulations, 2078

**Droperidol;** incompatibilities; injections, 2630

### Drug abuse

narcotics; methadone therapy, 208

pharmacists; ASHP guidelines, 1721

### Drug administration

alternative medicine; protocols, 1266

antidiarrheal agents; neoplasms, 1573

antineoplastic agents; oral liquids, 735

cardiac drugs; home health care, 930

carvedilol; clinical pharmacy services, 1626

delavirdine mesylate; HIV infections, 283

docetaxel; breast neoplasms, 1777

gene therapy; review, 899

metronidazole; pseudomembranous enterocolitis, 1407

naratriptan hydrochloride, 638

nevirapine; HIV infections, 283

pharmacists; APa policies, 878

posture; alendronate toxicity, 892

protease inhibitors; review, 233

sacrosidase; carbohydrate metabolism, 1102

self-medication; HMO programs, 1357

### Drug administration rate

cefazidime; continuous i.v., 145

heparin; dosage protocols, 159

injections; flow-restricting devices, 351

### Drug administration routes

epidural; low-molecular-weight heparins, 210

intramuscular; polio vaccines, 563

intravenous; cardiac drugs, 930

oral; polio vaccines, 563; sildenafil, 981

subcutaneous; aldesleukin, 1520

**Drug administration systems;** somatropin; wastage, 734

### Drug comparisons

alendazole and praziquantel; neurocysticercosis, 598

Alzheimer's disease; overview, Nov 1 suppl S11

cholinesterase inhibitors; Alzheimer's disease, Nov 1 suppl S22

clometidine and famotidine; cost-benefit analysis, Dec 15 suppl S8

famotidine and clometidine; cost-benefit analysis, Dec 15 suppl S8

fluphenazine decanoate, haloperidol decanoate and risperidone; costs, Dec 15 suppl S17

haloperidol decanoate, fluphenazine decanoate and risperidone; costs, Dec 15 suppl S17

heparin and streptokinase; thrombophlebitis, 1995

heparins and thrombolytic agents; coronary disease, 2402

heparin sodium and sodium chloride; i.v. catheters, 570

histamine H<sub>2</sub> antagonists and proton-pump inhibitors; gastric acid-related diseases, 2289

HMG-CoA reductase inhibitors; hypercholesterolemia, 2253

insulin and metformin; cost-benefit analysis, Dec 15 suppl S24

metformin and insulin; cost-benefit analysis, Dec 15 suppl S24

misoprostol, omeprazole and ranitidine; NSAIDs toxicity, 883

omeprazole, misoprostol and ranitidine; NSAIDs toxicity, 883

praziquantel and alendazole; neurocysticercosis, 598

proton-pump inhibitors and histamine H<sub>2</sub> antagonists; gastric acid-related diseases, 2289

ranitidine, misoprostol and omeprazole; NSAIDs toxicity, 883

risperidone, fluphenazine decanoate and haloperidol decanoate; costs, Dec 15 suppl S17

sodium chloride and heparin sodium; i.v. catheters, 570

streptokinase and heparin; thrombophlebitis, 1995

thrombolytic agents and heparins; coronary disease, 2402

### Drug distribution

globulin immune; U.S. shortages, 1341, 2090, 2228



pharmacy, institutional; cost projections, 127  
prescription drugs; USP standards, 1554

# Drug distribution systems

automation; ASHP guidelines, 1403  
hospital pharmacy; access discrepancies, 1924; robotics, 1907  
managed care systems; pharmacists' role, 441  
psychotherapeutic agents; indigent care program, 1293  
unit dose; medication errors, 946; radiopharmaceuticals, 2537

# Drug histories, see Patient information; drug histories

# Drug information

anti-infective agents; pharmacists' role, 1724  
computers; professional priorities, 782  
drug abuse; pharmacists' role, 1721  
education, pharmaceutical; clerkships, 1146  
health maintenance organizations; formulary decisions, 50; physician prescribing, 2234  
hospital pharmacy; history, 229; Hong Kong, 1164  
managed care systems; survey, 2007  
medicinal plants; USP monographs, 527  
mifepradil dihydrochloride; product withdrawal, 1445  
natural products; pharmacists' role, 125  
patients; direct-to-consumer advertising, 594  
pharmacists, hospital; patient consultation, 1792  
pharmacists, institutional; formulary decisions, 56  
radiopharmaceuticals; contract services, 2537  
unlabeled use; FDA regulations, 1449

# Drug information centers

contract services; managed care systems, 2007  
hospital pharmacy; Hong Kong, 1164  
hospitals; wide-area networks, 1146

# Drug Information Handbook; monographs; cisapride-antifungal interactions, 2418

# Drug interactions

albendazole; overview, 598  
alternative medicine; protocols, 1266  
amifostine and antineoplastic agents; clinical studies, 1827  
anagrelide hydrochloride; review, 1979  
anesthetics, local and heparin; hematoma, 210  
antidepressants; geriatrics, 2514  
antifungals and cisapride; blood levels, 2418  
antineoplastic agents and amifostine; clinical studies, 1827  
antiretroviral agents; patient compliance, 1817; patient consultation, 955  
astemizole; metabolism, 526  
atorvastatin calcium; review, 2253  
 $\beta$ -blockers and mifepradil; mechanism of action, 210  
carvedilol; clinical pharmacy services, 1626  
cisapride and antifungals; blood levels, 2418  
cimetidine and sildenafil citrate; half-life, 2080  
clarithromycin and verapamil; bradycardia, hypotension, 2417  
cyclosporine and mifepradil; mechanism of action, 210  
efavirenz; HIV infections, 2458  
erythromycin and sildenafil citrate; half-life, 2080  
food; patient information, 114, 122  
grapefruit juice and astemizole; metabolism, 526  
heparin and anesthetics, local; hematoma, 210  
HMG-CoA reductase inhibitors and mifepradil; mechanism of action, 210  
hypotensive agents and sildenafil citrate; toxicity, 2080  
ibutilide fumarate; review, 255  
juices and warfarin; grapefruit, 1581  
macrolides and astemizole; metabolism, 526  
mifepradil; mechanism of action, 210  
mifepradil dihydrochloride; product withdrawal, 1445  
mirtazapine; review, 44  
olanzapine; review, 1003  
praziquantel; overview, 598  
protease inhibitors; review, 233  
protease inhibitors and astemizole; metabolism, 526  
proton-pump inhibitors; overview, 2289; review, 2268  
psychotherapeutic agents; Alzheimer's patients, Nov 1 suppl 526  
serotonin reuptake inhibitors and astemizole; metabolism, 526  
sildenafil citrate, toxicity, 2080  
tacrolimus and mifepradil; mechanism of action, 210  
topiramate; review, 554  
troglitazone; review, 905

troglitazone and warfarin sodium; blood levels, 1071  
verapamil and clarithromycin; bradycardia, hypotension, 2417  
warfarin and juices; grapefruit, 1581  
warfarin sodium and troglitazone; blood levels, 1071

# Drugs

approvals; 1997, 336; basiliximab, 1444; citalopram, 1963; clopidogrel, 207; dactizumab, 207; dolasetron, 18; efavirenz, 2458; eptifibatide, tirofiban, 1440; fomepizole, 110; grepafloxacin, 20; hydroxyurea, 875; infliximab, 2073; leflunomide, 2225; lepirudin, 1444; montelukast, 759; naratriptan, 638; orelvekin, 107; palivizumab, 1654; raloxifene, 104; risedronate, 984; rituximab, 110; rizatriptan, 1656; rotavirus vaccines, 2226; sacrosidase, 1102; sildenafil, 981; thalidomide, 1746; tolcapone, 524; zolmitriptan, 110  
generic; narrow therapeutic index, 686; nomenclature similarities, 1728; warfarin, 727, 729  
new; 1997 approvals, 336; 1997 sales, 880; propellants, 226, 276  
reconstitution; indomethacin, 154; somatropin wastage, 734  
selection; Alzheimer's disease, Nov 1 suppl 53; antibiotics, 1987; antidepressants, 2481, 2514; anti-diarrheal agents, 1573; antifungals, 279; formulary decisions, 50; formulary system, 1308; glaucoma, 272; HMOs, 56; L.v. cardiac drugs, 930; medicinal plants, 435; NABP resolutions, 1445; opiates, 480; pharmacists' interventions, 1141; platelet aggregation inhibitors, Oct 1 suppl 517; pseudomembranous enterocolitis, 1365  
unlabeled use; FDA regulations, 1449, 2472

# Drugs, adverse reactions

see also Toxicity  
allergies; documentation, 1524  
cimetidine; toxic epidermal necrolysis, 163  
clarithromycin; verapamil interactions, 2417  
documentation; allergies, 364; hospitals, 289  
hospitals; visits, 1158  
latex; hospital policies, 437; labeling, 2059; sterile preparations, 1462  
managed care systems; pharmacists' role, 441  
monitoring; ambulatory care, 35  
nomenclature; ASHP draft, 165  
reports; hospital pharmacy, 1164; pharmacists' job satisfaction, 360  
verapamil; clarithromycin interactions, 2417

# Drugs, availability; itraconazole; suspensions, 261

# Drugs, body distribution; gentamicin; neonates, 2280

# Drugs, clinical effectiveness

abacimab; clinical studies, 2409  
cholinesterase inhibitors; Alzheimer's disease, Nov 1 suppl 522  
heparin; meta-analysis, 1995  
palivizumab; respiratory syncytial virus infections, 1654  
streptokinase; meta-analysis, 1995

# Drugs, investigational

Alzheimer's disease; clinical studies, Nov 1 suppl 511  
antineoplastic agents; compassionate-use protocols, 651  
clinical studies; ASHP guidelines, 369  
education, pharmaceutical; hospital pharmacy rotations, 2611

# Drugs, nonprescription

cimetidine; adverse reactions, 163  
labeling; geriatrics, 1654  
self-medication; HMO programs, 1357

# Drug use

antipsychotic agents; prescription cap, Dec 15 suppl 519  
evaluation; hospital pharmacists, 360; ketorolac, 1274  
geriatrics; misuse, 1654  
health maintenance organizations; control, 422  
HIV infections; pharmacists' interventions, 1151  
review; consultant pharmacists, 1588; HMOs, 50; nursing homes, 330  
self-medication; HMO programs, 1357  
Dyspnea; palliative care; NIH reports, 640

# E

# Economics

contract services; hospital pharmacy guidelines, 1611

cost-benefit analysis; consultant pharmacists' interventions, 1588; diabetes pharmacotherapy services, Dec 15 suppl 527; discharge medications consultation, Dec 15 suppl 532; epoetin alfa vs. transfusions, 1898; flurbiprofen, Dec 15 suppl 523; histamine H<sub>2</sub> antagonists, 1382; HMG-CoA reductase inhibitors, 995; indigent care program, 1293; ketorolac interventions, 1274; ketorolac repackaging, 388; pharmaceutical care, 62; pharmaceutical services, 1302; pharmacists' interventions, 1141, 1151; proton-pump inhibitors, 2289; residency reimbursement, 1620; telepharmacy, 1512

education, pharmaceutical; residency funding, 1618

health-benefit programs; pharmacy benefit, 767  
home health care; U.S., 2019

integrated health care; hospital pharmacy, 665  
managed care systems; institutional pharmacy, 27; pharmacists' role, 441

patient care; managed care systems, 1488  
pharmacy; drug cost projections, 127

Editorials, 31, 125, 229, 347, 441, 539, 665, 895, 1123, 1365, 1471, 1569, 1669, 1773, 1879, 1975, 2249, 2481

AJHP's content: making some tough decisions, 1773

ASHP: no longer hospitals only, 31  
Assisted suicide: an issue for pharmacists, 539

Celebrating ASHP's golden anniversary in best practices, 1879

Change of perspective, 665  
Confidentiality of patient records, 895

Depression in older adults, 2481  
HCFA's challenge to improve the medication-use process, 1123

Managing C. difficile-associated diarrhea, 1365  
National Pharmacy Week—all year long, 1975

Natural products: show me the data, 125  
Pharmacy's vision of its future in managed care, 1471

Proton-pump inhibitors in managed care, 2249  
The quest for quality measurement, 1669

Showing pharmacy's best side to the world, 1570  
Toward optimal provision of antithrombotic therapy, 348

Transition to managed care, part 1, 229; part 2, 347; part 3, 441

Truth in advertising, 1569

# Education

American Society of Health-System Pharmacists; Healthy People 2000, 477

continuing; alternative medicine, 2525; FDA regulations, 426

health professions; depression, 2514; formulary system, 1308; hospital pharmacy services, 1164; ISMP guidelines, 2078; therapeutic substitution, 1382; warfarin, 729

personnel; hospitals, 1092; nonprescription, 1357; pharmacist-managed protocols, 1826

physicians; formulary prescribing, 1763

# Education, pharmaceutical

Africa, 1928  
clerkships; drug information, 1146

clinical pharmacists; ambulatory care, 1753; anticoagulation clinics, 1033

continuing; diabetes mellitus, 10; television, 536  
continuing education; FDA regulations, 2472

degrees; psychopharmacy certification, 1594  
examinations; writing, 2397

health professions; infection control, 1724; pharmacokinetic monitoring, 1726

history; P. Parker, 1344  
nontraditional; Pharm.D., 530, 1281

pharmacists; certification, 1856, 2444; Healthy People 2000, 477; new roles, 585

pharmacists, community; pharmaceutical care, 635  
pharmacists, hospital; ASHP Clinical Skills Program, 1760; heparin monitoring, 396; history, 229; integrated health care, 665; patient consultation, 1792

pharmacists, institutional; layoffs, 2387; nonprescription drugs, 1357

residencies; hospital pharmacy, 1618; investigational drug services, 2611; pharmacist-managed protocols, 1826; reimbursement, 1620

Educators; pharmacy; writing test questions, 2397

Efavirenz; approvals; HIV infections, 2458

Egb 761; Alzheimer's disease; overview, Nov 1 suppl 511

# Electrolytes

concentration; automated TPN compounding, 1503

## Annual Index

potassium chloride; floor stock, 1098  
**Elements**; trace; metal contamination, 150  
**Elimination**, see **Metabolism**  
**Emetics**; ipecac; poisoning antidotes, 1971  
**Employers**; health-benefit programs; third party, 1663  
**Employment**  
 personnel; health-benefit programs, 878; health care costs, 767  
 pharmacists; nontraditional Pharm.D., 1281  
 pharmacists, institutional; layoffs, 2387  
**Enalapril maleate**; stability; oral liquids, 1915; suspensions, 1155  
**Endocarditis**; disease management; guidelines, 1943  
**Endometrial neoplasms**; tamoxifen; toxicity, 978  
**Enoxaparin**; interactions; local anesthetics, 210  
**Enoxaparin sodium**; stability; syringes, 1296  
**Enterococcus species**; resistance; vancomycin, 1407  
**Enterocolitis**  
 metronidazole; pseudomembranous, 1365, 1407  
 vancomycin; pseudomembranous, 1365  
**Enzyme inhibitors**  
 celecoxib; rheumatoid arthritis, 2225  
 fomepizole; FDA approvals, 110  
 MK-966; rheumatoid arthritis, 2225  
**Enzymes**; sacrosidase; FDA approvals, 1102  
**Epidemiology**  
 atherosclerosis; overview, Oct 1 suppl S4  
 cerebrovascular disorders; Healthy People 2000, 477  
 coronary disease; Healthy People 2000, 477  
 peripheral vascular diseases; overview, Oct 1 suppl S21  
 pneumococcal infections; penicillin resistance, 1987  
**Epidermal necrolysis**; cimetidine; toxic, 163  
**Epilepsy**; topiramate; review, 554  
**Epoetin alfa**  
 anemia; costs, 1898  
 dosage; hemodialysis, Dec 15 suppl S12  
**Eptifibatide**  
 approvals; FDA, 1440  
 cardiovascular diseases; review, 2363  
**Equipment**  
 blood pressure; monitoring, Nov 15 suppl S12  
 carts; medication errors, 946  
 compounding; automation, 1606; parenteral nutrition, 1503  
 drug distribution systems; automation guidelines, 1403  
 laminar flow; cleanrooms, 182  
**Equivalency**  
 carbamazepine; suspensions, tablets, 1134  
 drugs; glaucoma, 272  
 itraconazole; suspensions, capsules, 261  
**Equivalency, generic**  
 drugs; narrow therapeutic index, 686  
 folic acid; oral capsules, 1415  
 warfarin sodium; overview, 729; standards, 727  
**Equivalency, therapeutic**; histamine H<sub>1</sub> antagonists; hospital pharmacy policies, 1382  
**Errors**; hospitals; JCAHO sentinel-event policies, 1112  
**Errors, medication**  
 albumin; dilutions, 2078  
 allergies; pharmacists' interventions, 289  
 amphotericin B; dosage, 2078  
 antineoplastic agents; ASHP protocols, 137; liquid compounding, 735  
 cisapride; antifungal interactions, 2418  
 clinical studies; outcomes research, 62  
 daunorubicin citrate; dosage, 2078  
 dispensing; automation, 1924  
 doxorubicin hydrochloride; dosage, 2078  
 drug distribution systems; automated dispensing, 1403  
 hospital pharmacy; process control charts, 946  
 hospitals; guidelines, 1092; HCFA regulations, 1123; sentinel-event policies, 1112  
 nelfinavir mesylate; nomenclature similarities, 1728  
 nevirapine; nomenclature similarities, 1728  
 nomenclature; ASHP draft, 165  
 packaging; prevention, 1968  
 pharmaceutical services; clinical technicians, 1375  
 pharmacists, hospital; role, 229  
 pharmacists, institutional; ASHP public relations, 1959  
 potassium chloride; floor stock, 1098  
 prescriptions; pharmacists' interventions, 1141  
 quality assurance; pharmacists' role, 347

reports; JCAHO Sentinel Event Alert, 764  
**Erythema nodosum**; thalidomide; FDA approvals, 1746  
**Erythromycin**  
 interactions; sildenafil, 2080  
 resistance; otitis media, 1881  
**Escherichia coli**; contamination; topotecan, 1584  
**Esophagitis**; alendronate sodium; toxicity, 892  
**Estrogens**; Alzheimer's disease; overview, Nov 1 suppl S11  
**Etanercept**; arthritis; rheumatoid, 2225  
**Ethics**  
 clinical studies; conflict of interest, 642  
 pharmacists; assisted suicides, 318, 539, 578; conscience clause, 878; patient confidentiality, 895; prescribing issues, 585; professional excellence, 782  
 pharmacists, hospital; infant formulas, 84; ketorolac repackaging, 388  
 pharmacy; pharmaceutical care, 1477; public relations, 1569  
 pharmacy, community; patient confidentiality, 875  
 physicians; assisted suicides, 1235  
 suicides; physician assisted, 543, 547, 551  
**Ethylene glycol**; poisoning; fomepizole antidotes, 110  
**Examinations**  
 certification; psychopharmacy, 1594  
 education, pharmaceutical; writing, 2397  
 pharmacists; certification, 2444; disease management, 2452; specialties, 427  
**Excipients**; lactose; nifedipine powders, 1299  
**Excretion**  
 antiretroviral agents; kidney, liver failure, 2528  
 carbamazepine; loading dose, 1134  
 gentamicin; neonates, 2280  
 phenytoin; blood levels, 2392  
**Exercise**; obesity; guidelines, 1663  
**Expiration dates**; labeling; regulations, 433

## F

**Famotidine**  
 substitution; therapeutic, 1382  
 ulcers; cost comparisons, Dec 15 suppl S8  
**Fax**; patient information; continuity of care, 1017  
**FDA Medical Products Reporting Form and Instructions**, 85, 1425  
**Fellowships**; primary care; health care policies, 17  
**Fentanyl citrate**; incompatibilities; parenteral nutrition, 1194  
**Filters**  
 HEPA; cleanrooms, 182  
 inline; organ preservation solutions, 266  
 polysulfones; ranitidine adsorption, 840  
**Floor stock**; potassium chloride; injections, 1098  
**Flow**; rates; infusion devices, 351  
**Flow rates**; equipment; automated compounding, 1606  
**Fluconazole**  
 interactions; cisapride, 2418  
 resistance; *C. albicans*, 279  
**Fluoxetine**; toxicity; sexual dysfunction, 1167  
**Fluphenazine decanoate**; schizophrenia; cost comparisons, Dec 15 suppl S17  
**Flurbiprofen**; cataract; cost-benefit analysis, Dec 15 suppl S23  
**Folic acid**  
 equivalency, generic; oral capsules, 1415  
 protocols; Institute of Medicine, 981  
**Fomepizole**; approvals; FDA, 110  
**Food**; interactions; antiretroviral agents, 955, 1817; patient information, 114, 122; protease inhibitors, 233  
**Food and Drug Administration (U.S.)**  
 approvals; basiliximab, 1444; citalopram, 1963; clopidogrel, 207; dactinib, 207; dolasetron, 18; efavirenz, 2458; eptifibatide, 1440; fomepizole, 110; gempoxacin, 20; hydroxyurea marketing, 875; infliximab, 2073; leflunomide, 2225; lepridin, 1444; montelukast, 759; natriptan, 638; new drugs, 336; orelvekin, 107; palivizumab, 1654; raloxifene, 104; risedronate, 984; rituximab, 110; rizatriptan, 1656; rotavirus vaccines, 2226; sacrosidase, 1102; sildenafil, 981; thalidomide marketing, 1746; tolcapone, 524; zolmitriptan, 110  
 attitudes; generic equivalency, 686  
 drugs; adverse reactions; reports, 477  
 guidelines; direct-to-consumer advertising, 594

inspections; immune globulin manufacturers, 2228  
 labeling; astemizole, bromfenac, 526; beyond-use vs. expiration dates, 433; low-molecular-weight heparins, 210  
 mifepristide; interactions warnings, 210  
 regulations; clinical studies, 642; compounding, 1859; dietary supplements labeling, 1239; drugs, unlabeled use, 1449; educational programs, 2472; latex labeling, 2059; patient information, 1552; pharmaceutical industry programs, 426  
**Food and Drug Administration Modernization Act of 1997**; pharmacists; compounding, 1859

## Forms

allergies; documentation, 364  
 documentation; allergies, 1524  
 medication orders; antineoplastic agents, 137  
 pharmacy; continuity of care, 2500  
 prescriptions; controlled substances, 2074

## Formularies

alternative medicine; hospital pharmacy, 1266  
 atorvastatin calcium; hypercholesterolemia, 2253  
 health maintenance organizations; decision-making, 50, 56; physician prescribing, 2234  
 histamine H<sub>1</sub> antagonists; cost-benefit analysis, Dec 15 suppl S8; therapeutic substitution, 1382  
 hospital pharmacy; military, 1658; platelet aggregation inhibitors, Oct 1 suppl S28  
 integrated health care; pharmacoeconomics, 35  
 managed care systems; pharmaceutical services, 523; pharmacists' role, 2221; proton-pump inhibitors, 2249  
 medicinal plants; hospital pharmacy, 435  
 military; pharmacy programs, 1656  
 pharmacy, institutional; cost projections, 127  
 prescribing; physician education, 1763  
 standards; NCQA, 1351  
 telepharmacy; implementation, 1512

**Formulary system**; Russia; development, 1308

**Formulary systems**; hospitals; quality assurance, 1092

## Formulations

lipids; toxicity, 2078  
 ophthalmic preparations; costs, 272  
 parenteral nutrition; automated compounding, 1503

**Foscarnet**; cytomegalovirus retinitis; AIDS, 392

**France**; health care reform; hospital accreditation, 173

**Frontline Pharmacist**, 114, 226, 437, 661, 892, 1877, 1971, 2245

Counseling about chlorofluorocarbon-free inhalers, 226

Giving patients privacy in the pharmacy, 2245

Helping HIV-infected patients at the clinic, 661

Lowering the risk of esophagitis from alendronate therapy, 892

Protecting children in the community from poisons, 1971

Refining a food-drug interaction program, 114

Teaching patients about blood glucose meters, 1877

Working in a latex-safe environment, 437

## G

**Ganciclovir**; cytomegalovirus retinitis; AIDS, 392

### Gastroesophageal reflux

disease management; guidelines, 1943  
 gastrointestinal drugs; comparisons, 2289  
 proton-pump inhibitors; managed care systems, 2249; review, 2268

### Gastrointestinal drugs

cimetidine; adverse reactions, 163; acetaminophen overdose, 1516; cost-benefit analysis, Dec 15 suppl S8; sildenafil interactions, 2080  
 cisapride; antifungal interaction, 2418; stability, 1915

famotidine; cost-benefit analysis, Dec 15 suppl S8  
 ranitidine hydrochloride; suspension stability, 2511

histamine H<sub>1</sub> antagonists; comparisons, 2289; therapeutic substitution, 1382

misoprostol; NSAIDs toxicity, 883

omeprazole; NSAIDs toxicity, 883

proton-pump inhibitors; managed care systems, 2249; overview, 2289; review, 2268

ranitidine; NSAIDs toxicity, 883  
 ranitidine hydrochloride; filter adsorption, 840

**Gastrointestinal hemorrhage**; gastrointestinal drugs; comparisons, 2289

**Gene therapy:** clinical studies; review, 899**Genetics**

Alzheimer's disease; overview, Nov 1 suppl S5  
hereditary diseases; gene therapy, 899

**Gentamicin**

dosage schedules; extended interval, 397  
pharmacokinetics; neonates, 2280

**Geography:** pharmaceutical care; telepharmacy, 1512**Geriatrics**

Alzheimer's disease; overview, Nov 1 suppl S3, Nov 1 suppl S5  
antidepressants; depression, 2481; protocols, 2514  
attitudes; pharmacists' consultation, 768  
diabetes mellitus; pharmacotherapy services, Dec 15 suppl S27  
drug use; misuse, 1654  
nursing homes; consultant pharmacists' interventions, 1588

**Gilgobila**

EGB 761; Alzheimer's disease, Nov 1 suppl S11  
sexual dysfunction; SSRI toxicity, 1167

**Glass**

containers; adenosine incompatibilities, 1161  
incompatibilities; lorazepam, 2013  
vials; indomethacin incompatibilities, 154; ondansetron, 2630

**Glaucoma:** drugs; costs, 272**Globulin immune**

distribution; U.S. shortages, 1341, 2228  
shortage; administration, 2090

**Gloves:** latex; labeling, 2059**Glucose, see Dextrose**

**Glyburide:** diabetes mellitus; dextrose test strips, 2509

**Glycoprotein antagonists:** coronary disease; review, Oct 1 suppl S8

**Gonorrhea:** girepafloxacin hydrochloride; FDA approvals, 20

**Government:** information; propellants, 276

**Graft rejection:** basiliximab; FDA approvals, 1444

**Graft-versus-host disease:** antidiarrheal agents; neoplasms, 1573

**Granisetron:** nausea; antineoplastics toxicity, 1269

**Granisetron hydrochloride:** stability; suspensions, 2511

**Grepafloxacin hydrochloride:** approvals; FDA, 20

**Group purchasing, see Purchasing**

**Guidelines**

American College of Cardiology; sildenafil, 2080  
American Heart Association; sildenafil, 2080  
American Society of Health-System Pharmacists; clinical research, 369; drug abuse, 1721; infection control, 1724; medication errors, 1092; medication misadventure nomenclature, 165; outsourcing, 1611; paper submission, 888; pharmacokinetic monitoring, 1726; poster sessions, 2038  
automation; drug distribution systems, 1403  
disease management; WWW, 1943  
education, pharmaceutical; test questions, 2397  
Food and Drug Administration; direct-to-consumer advertising, 594  
health care; assisted suicides, 1235  
Institute for Safe Medication Practices; lipid-based products, 2078  
National Coordinating Council for Medication Error Reporting and Prevention; error prevention, 1968  
nutrition; infant formulas, 84  
obesity; lifestyle changes, 1663  
organizations; propellants, 276  
Presidential Advisory Commission on Consumer Protection and Quality in the Health Care Industry; health care quality, 1669

**Guidelines, treatment, see Protocols**

**Guidelines Update, 191, 510, 858, 1222, 1535, 1838, 2209, 2578**

**H**

**Haemophilus influenzae:** resistance; anti-infective agents, 1881

**Half-life**

carbamazepine; loading dose, 1134  
gentamicin; neonates, 2280  
sildenafil citrate; interactions, 2080

**Haloperidol decanoate:** schizophrenia; cost comparisons, Dec 15 suppl S17

**Harvey A. K. Whitney Lecture Award:** pharmacy; pharmaceutical care, 1675

**Health-benefit programs**

administrators; pharmacists' role, 1482  
costs; pharmacy benefit, 767  
managed care systems; quality assurance, 2351  
Medicaid; disease management, 1238; HCFA regulations, 1092, 1123; home health care, 2019; ketorolac DUE, 1274; pharmacists' reimbursement, 2452; prescription cap, Dec 15 suppl S19  
Medicare; antiretroviral agents, 661; consumer surveys, 878; HCFA regulations, 1092, 1123; home health care, 2019; prospective-pricing system, 1645; reform, 1850; residencies reimbursement, 1620  
membership; customer satisfaction, 986  
military; pharmacy benefit, 1656  
pharmacy, institutional; enrollee benefits, 422  
profits; managed care principles, 1490  
third party; Alzheimer's disease costs, Nov 1 suppl S17; consumers' influence, 876; disease management, 471; managed care systems, 1663

**Health care**

administration; consumers' influence, 876  
atherosclerosis; costs, Oct 1 suppl S4  
costs; hospital pharmacy, 229; patient consultation, 2485; pharmacy benefit, 767  
guidelines; assisted suicides, 1235  
home; ASHP services, 31; dextrose test strips, 2509; disease management services, 471; i.v. cardiac drugs, 930; performance measurement, 2299; pharmaceutical care, 486; prospective pricing, 1850; U.S. economics, 2019  
managed care systems; customer satisfaction, 986; future trends, 1490; pharmacists' role, 347, 1488; pharmacy practice, 1497  
patient care; collaborative drug therapy management, 1859  
performance; measurement systems, 1348  
pharmaceutical services; patient consultation, 2615, 2621  
pharmacists, hospital; pharmaceutical education, 665  
pharmacists, institutional; strategic planning, 441  
pharmacy; role, 1302  
profits; pharmacist layoffs, 2387  
quality assurance; measurement, 1669  
reform; France, 173  
team; interdisciplinary, 1369  
United States; policies, 17

**Health Care Financing Administration**

regulations; hospitals, 1092; medication errors, 1123

reimbursement; residency funding, 1618

**Health maintenance organizations**

see also **Managed care systems**  
drugs, nonprescription; self-medication programs, 1357  
formularies; decision-making, 50, 56  
health-benefit programs; third party, 1663  
HMG-CoA reductase inhibitors; costs, 995  
pharmaceutical services; patient consultation, 2615, 2621  
pharmacists, institutional; ASHP services, 31; enrollee benefits, 422  
physicians; prescribing, 2234

**Healthplan Employer Data and Information Set;** quality assurance; NCQA standards, 2221; standards, 1351**Health professions**

antineoplastic agents; exposure, 735  
attitudes; institutional pharmacists, 1959  
communication; hospital pharmacists, 486; institutional pharmacists, 1769; pharmacokinetic monitoring, 1726  
data collection; formulary system development, 1308  
documentation; allergies, 1524  
education; depression, 2514; hospital pharmacy services, 1164; infection control, 1724; ISMP guidelines, 2078; warfarin, 729  
health maintenance organizations; disease management, 2234  
managed care systems; role, 1471  
professional competence; interdisciplinary health care, 1369; Pew Health Professions Commission, 2454  
role; clinical research, 369  
vaccines; CDC protocols, 760

**Heart failure**

cardiac drugs; home health care, 930  
carvedilol; congestive, 676, 1626  
disease management; guidelines, 1943

**Helicobacter infections:** gastrointestinal drugs; comparisons, 2289

**Hematoma;** heparins; interactions, 210

**Hematopoietic agents**

epoetin alfa; anemia, 1898; hemodialysis, Dec 15 suppl S12  
oprelvekin; FDA approvals, 107

**Hemorrhage**

heparin; toxicity, Dec 15 suppl S29  
streptokinase; toxicity, 1995

**Heparin**

coronary disease; comparisons, 2402  
dosage; patients' weight, 159; weight-based protocols, Dec 15 suppl S29  
monitoring; pharmacists' training, 396  
thrombophlebitis; comparisons, 1995  
toxicity; lepirudin therapy, 1444

**Heparinoids;** interactions; local anesthetics, 210

**Heparins;** low molecular weight; coronary disease, 2402; interactions, 210

**Heparin sodium**

catheters; comparisons, 570  
monitoring; activated partial thromboplastin time, 2002

**Hepatitis B vaccines;** health professions; CDC protocols, 760

**Hereditary diseases;** gene therapy; review, 899

**History**

American Society of Health-System Pharmacists; practice standards, 1879  
hospital pharmacy; U.S., 229  
mental disorders; future diagnosis, 83  
pharmacists, hospital; P. Parker, 1344  
pharmacy, institutional; managed care systems, 27

**HIV infections**

aldesleukin; overview, 1520  
antiretroviral agents; ambulatory care, 661; occupational exposure, 1921; patient compliance, 1817; pharmacists' consultation, 955  
delavirdine mesylate; overview, 283  
disease management; guidelines, 1943  
efavirenz; FDA approvals, 2458  
fluconazole; candidiasis resistance, 279  
nevirapine; overview, 283  
pharmacoeconomics; pharmacists' interventions, 1151  
protease inhibitors; review, 233  
saquinavir; toxicity, 2016

**HIV Update, 279, 392, 1520, 1817, 2528**

**HMOs, see Health maintenance organizations**

**Home Care Exchange, 2299**

**Home health care, see Health care; home**

**Homeopathy**

education, pharmaceutical; pharmacists, 2525  
hospital pharmacy; protocols, 1266

**Home tests**

dextrose; quantity restrictions, 2509  
diabetes mellitus; blood glucose meters, 1877

**Hong Kong;** hospital pharmacy; drug information centers, 1164

**Hormones**

somatropin; administration systems, 734; incompatibilities, 1508  
toxicity; emergency room visits, 1158

**Hospices**

pharmaceutical services; disease management, 471  
pharmacists, hospital; integrated health care, 669

**Hospital pharmacy, see Pharmacy, institutional, hospital**

**Hospitals**

accreditation; France, 173  
administration; pharmacy technicians, 1810  
admissions; antipsychotics, Dec 15 suppl S17; discharge medications consultation, Dec 15 suppl S32; patient consultation, 2485  
discharge; inpatient consultation, 1127; patient information, 114  
documentation; allergies, 289, 1524  
emergency rooms; automation guidelines, 1403; drug-related injuries, 1158  
errors; sentinel-event policies, 1112  
formularies; medicinal plants, 435  
health-benefit programs; HCFA regulations, 1123  
home health care; i.v. therapy, 2019; performance measurement, 2299  
integrated health care; transition, 669  
length of stay; HIV infections, 1151; surgical wound infection, 777; weight-based heparin protocols, Dec 15 suppl S29  
outpatients; pharmacists' role, 1763; prospective pricing, 1850  
patient information; continuity of care, 1017  
personnel; meetings participation, 2360; protocol education, 1826

- pharmaceutical services; outsourcing, 1611; pharmaceutical education, 665; radiopharmaceuticals, 2537; staff development, 1792
- policies and procedures; HIV prophylaxis, 1921; latex-free products, 437; therapeutic substitution, 1382
- regulations; HCFA, 1092
- How To:** How to get the most out of poster sessions at ASHP meetings, 2038
- Human immunodeficiency virus;** resistance; antiretroviral agents, 1817; non-nucleoside reverse transcriptase inhibitors, 283; protease inhibitors, 233, 1728
- Hydralazine hydrochloride;** stability; oral liquids, 1915
- Hydrogen ion concentration**  
lorazepam; glass containers, 2013  
topotecan hydrochloride; stability, 1584
- Hydrogen peroxide;** contamination; parenteral nutrition, 1288
- Hydroxyitraconazole;** metabolites; itraconazole, 261
- Hydroxyurea;** approvals; FDA, 875
- Hyperalimentation;** see **Nutrition; parenteral**
- Hypercholesterolemia**  
atorvastatin calcium; review, 2253  
gene therapy; review, 899  
patient information; drug histories, 1769
- Hyperlipidemia**  
ambulatory care; clinical pharmacists, 68  
disease management; guidelines, 1943; Medicaid reimbursement, 1238; pharmacists' certification, 2452  
HMG-CoA reductase inhibitors; costs, 995
- Hypertension**  
disease management; guidelines, 1943  
tests; ambulatory blood pressure, Nov 15 suppl S12  
therapy; protocols, 382  
verapamil hydrochloride; circadian rhythm, Nov 15 suppl S17
- Hypotension**  
clarithromycin; verapamil interactions, 2417  
verapamil; clarithromycin interactions, 2417
- Hypotensive agents**  
drug interactions; sildenafil, 2080  
enalapril maleate; stability, 1915  
hydralazine hydrochloride; stability, 1915  
hypertension; protocols, 382
- I**
- Iatrogenic diseases;** see **Drugs, adverse reactions**
- Ibutilide fumarate;** atrial fibrillation; review, 255
- Illinois;** education, pharmaceutical; nontraditional Pharm.D., 530
- Imipramine;** toxicity; pediatrics, 1552
- Immunization**  
chickenpox; cost-benefit analysis, Dec 15 suppl S4  
diseases; health professions, 760; pediatrics, 563  
otitis media; review, 1881  
pneumococcal infections; resistance, 1987  
rotavirus infections; clinical studies, 2226
- Immunosuppressive agents**  
basiliximab; FDA approvals, 1444  
cyclosporine; blood levels, 1598; mibefradil interactions, 210  
etanercept; rheumatoid arthritis, 2225  
mycophenolate mofetil; oral suspensions, 926
- Immunotherapy**  
aldesleukin; overview, 1520  
leflunomide; FDA approvals, 2225
- Implants;** ganciclovir; cytomegalovirus retinitis, 392
- Imports;** globulin immune; U.S. shortages, 2228
- Impotence;** sildenafil citrate; FDA approvals, 981
- Incompatibilities**  
acyclovir sodium and dextrose or sodium chloride; stability, 574  
additives and organ preservation solutions, 266  
adenosine and containers or diluents; injections, 466  
adenosine and sodium chloride; dilutions, 1161  
albumin human and interferon alfa-2b; syringes, 1602  
alprazolam and syrups or polyethylene terephthalate; stability, 1915  
anti-infective agents and artificial tears; ophthalmic solutions, 463  
artificial tears and anti-infective agents; ophthalmic solutions, 463
- bethanechol chloride; suspensions, 1804  
carboplatin and polyvinyl chloride; stability, 602  
ceftazidime and infusion pumps; decomposition products, 683; elastomeric, 145  
chloroquine phosphate; stability, 1915  
cisapride; stability, 1915  
cisatracurium besylate; stability, 1037  
containers and adenosine; injections, 466  
dextrose and acyclovir sodium; stability, 574  
dextrose and cisatracurium besylate; stability, 1037  
dextrose and lorazepam; stability, 2013  
dextrose and torsemide; stability, 1042  
diluent and adenosine; injections, 466  
droperidol and ondansetron hydrochloride; injections, 2630  
drugs; *American Journal of Health-System Pharmacy*, 1773  
enalapril maleate; stability, 1915; suspensions, 1155  
fentanyl citrate and parenteral nutrition; injections, 1194  
filters and ranitidine hydrochloride; adsorption, 840  
glass and lorazepam; stability, 2013  
granisetron hydrochloride; suspensions, 2511  
hydralazine hydrochloride and syrups or polyethylene terephthalate; stability, 1915  
indomethacin sodium and syringes or vials; stability, 154  
infusion pumps and ceftazidime; decomposition products, 683; elastomeric, 145  
interferon alfa-2b and albumin human or water for injection; syringes, 1602  
lactose and nifedipine; powder content uniformity, 1299  
lorazepam and dextrose or sodium chloride; stability, 2013  
lorazepam and glass or polyethylene; stability, 2013  
lorazepam and water; precipitation, 2305  
mycophenolate mofetil; oral suspensions, 926  
nifedipine and lactose; powder content uniformity, 1299  
ondansetron hydrochloride; injections, 2630  
organ preservation solutions and additives or polyvinyl chloride, 266  
parenteral nutrition and fentanyl citrate; injections, 1194  
plastics and cisatracurium besylate; stability, 1037  
plastics and somatropin; syringes, 1508  
polyethylene and lorazepam; stability, 2013  
polyvinyl chloride and carboplatin; stability, 602  
polyvinyl chloride and cisatracurium besylate; stability, 1037  
polyvinyl chloride and organ preservation solutions, 266  
pyrazinamide; suspensions, 1804  
quinidine sulfate; suspensions, 1804  
ranitidine hydrochloride and filters; adsorption, 840  
rifampin; suspensions, 1804  
sodium chloride and acyclovir sodium; stability, 574  
sodium chloride and adenosine; dilutions, 1161  
sodium chloride and cisatracurium besylate; stability, 1037  
sodium chloride and lorazepam; stability, 2013  
somatropin and plastics; syringes, 1508  
syringes and indomethacin sodium; stability, 154  
tetracycline hydrochloride; suspensions, 1804  
torsemide and dextrose; stability, 1042  
vials and indomethacin sodium; stability, 154  
water and lorazepam; precipitation, 2305  
water for injection and interferon alfa-2b; syringes, 1602
- Indinavir sulfate;** HIV infections; review, 233
- Indomethacin sodium;** incompatibilities; vials, syringes, 154
- Industry;** medical devices; unlabeled use, 1449
- Industry, pharmaceutical**  
administration; consumers' influence, 876  
advertising; direct to consumer, 594  
charity; antiretroviral agents, 661; indigent psychiatric patients, 1293  
clinical studies; conflict of interest, 642; medication misuse, 1654  
contract services; hospital pharmacy guidelines, 1611; patient confidentiality, 895  
dietary supplements; labeling regulations, 1239  
drugs; cost projections, 127; unlabeled use, 1449  
education; pharmaceutical; workshop, 1792  
errors, medication; prevention, 1698  
imports; immune globulin, 2228  
labeling; beyond-use vs. expiration dates, 433
- marketing; brand-name drugs, 1445  
medicinal plants; formularies, 435  
quality assurance; warfarin, 727  
regulations; educational programs, 426, 2472  
sales; 1997, 880  
warfarin sodium; generic equivalency, 729
- Infection control**  
enterocolitis; pharmacists' role, 1407  
pharmacists; institutional; ASHP guidelines, 1724  
protocols; health professions, 760
- Infections;** transplantation; antidiarrheal agents, 1573
- Infliximab**  
approvals; FDA, 2073  
arthritis; rheumatoid, 2225
- Influenza vaccines;** health professions; CDC protocols, 760
- Information**  
confidentiality; sentinel-event policies, 1112  
disease management; WWW, 1943  
labeling; dietary supplements, 1239  
managed care systems; pharmacists' role, 441  
pharmacists; ASHP services, 31  
posters; ASHP meetings, 2038  
propellants; organizations, 276  
technology; uniformity, 1850
- Infusion devices;** see **Devices; infusion pumps**
- Inhalers**  
see also **Aerosols**  
metered dose; propellants, 226; propellants, 276
- Injections**  
acyclovir sodium; incompatibilities, 574  
adenosine; incompatibilities, 466, 1161  
carboplatin; stability, 602  
catheters; heparin vs. sodium chloride, 570  
ceftazidime; decomposition products, 683; infusion pumps, 145  
cisatracurium besylate; stability, 1037  
compounding; cleanrooms, 458; latex allergies, 1462  
devices; flow rates, 351  
fentanyl citrate; incompatibilities, 1194  
heparin; dosage protocols, 159  
interferon alfa-2b; stability, 1602  
intravenous; cardiac drugs, 930  
ketorolac tromethamine; repackaging, 388  
lorazepam; incompatibilities, 2013, 2305  
ondansetron hydrochloride; incompatibilities, 2630  
parenteral nutrition; automated compounding, 1606; metal contamination, 150  
potassium chloride; floor stock, 1098  
ranitidine hydrochloride; filter adsorption, 840  
somatropin; administration systems, 734  
syringes; microbiological contamination, 956  
topotecan hydrochloride; microbiological contamination, 1584  
torsemide; stability, 1042  
urokinase; arterial occlusive diseases, 2414  
vials; latex-free closures, 437
- Inspections;** Food and Drug Administration; immune globulin manufacturers, 2228
- Institute for Safe Medication Practices;** guidelines; lipid-based products, 2078
- Institute of Medicine;** protocols; vitamins, 981
- Insulin;** diabetes mellitus; cost-benefit analysis, Dec 15 suppl S24
- Insulin human;** incompatibilities; organ preservation solutions, 266
- Insulins**  
diabetes mellitus; combined therapy, 905  
insulin; cost-benefit analysis, Dec 15 suppl S24  
insulin human; incompatibilities, 266
- Integrated health care**  
hospital pharmacy; economics, 665  
hospitals; transition, 669  
pharmaceutical services; ambulatory care, 35  
pharmacists, institutional; ASHP services, 31  
statistics; survey, 1450
- Interferon alfa-2b;** stability; syringes, 1602
- Internal Revenue Service;** hospital pharmacy; taxes, 772
- International Pharmaceutical Abstracts;** drug information; managed care systems, 2007
- Interventions**  
antipsychotic agents; prescription cap, Dec 15 suppl S19  
clinical pharmacists; ambulatory care, 1753; discharge medications consultation, Dec 15 suppl S32; outcomes research, 62; patient information, 1017  
pharmacists; ketorolac DUE, 1274; pseudomembranous enterocolitis, 1365



- pharmacists, community; managed care systems, 1141; pharmaceutical care, 635, 2009
- pharmacists, consultant; cost-benefit analysis, 1588
- pharmacists, hospital; allergies, 289; diabetes pharmacotherapy services, Dec 15 suppl S27; HIV infections, 1151; inpatient consultation, 1127; outpatient clinics, 1763; patient care programs, 453
- pharmacists, institutional; Alzheimer's disease, Nov 1 suppl S26; coronary disease, 1769; proton-pump inhibitors, 2249
- Intravenous therapy**  
heart failure; home health care, 930  
home health care; hospitals, 2019
- Investigational drugs**, see **Drugs, investigational**
- Ipecac**; antidotes; pediatric poisoning, 1971
- Iron dextran**; anemia; cost-benefit analysis, Dec 15 suppl S12
- Iron preparations**; iron dextran; cost-benefit analysis, Dec 15 suppl S12
- Itraconazole**  
availability; dosage forms, 261  
interactions; cisapride, 2418
- IVIG**, see **Globulin immune**
- J**
- Japan**; pharmacists, hospital; job satisfaction, 360
- Job description**  
pharmacists; classification, 642  
pharmacists, hospital; history, 229; pharmacy design, 2505  
pharmacists, institutional; managed care systems, 27  
technicians; pharmacy design, 2505
- Job satisfaction**  
pharmacists; nontraditional Pharm.D., 1281; professionalism, 782  
pharmacists, hospital; clinical services, 360  
pharmacists, institutional; pharmacist layoffs, 2387
- Joint Commission of Pharmacy Practitioners**; attitudes; HCFA regulations, 1092
- Joint Commission on Accreditation of Health-care Organizations**  
administration; performance measurement, 1348  
home health care; performance measurement, 2299  
policies and procedures; sentinel events, 1112  
publications; Sentinel Event Alert, 764
- Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure**; protocols; hypertension, 382
- Journal References**, 92, 190, 307, 403, 508, 618, 742, 854, 964, 1081, 1220, 1325, 1429, 1532, 1633, 1736, 1836, 2042, 2208, 2313, 2431, 2576, 2647
- Journals**  
*American Journal of Health-System Pharmacy*; articles, 31; content selection, 1773; pharmacy public relations, 1569  
drug information; formulary decisions, 50
- Juices**; interactions; astemizole, 526; warfarin, 1581
- K**
- Ketoconazole**; interactions; cisapride, 2418
- Ketorolac tromethamine**  
injections; repackaging, 388  
use; pharmacists' interventions, 1274
- Kidney failure**  
antiretroviral agents; dosage, 2528  
sildenafil citrate; contraindications, 2080
- L**
- Labeling**  
antineoplastic agents; new indications, 2326; standards, 137  
antiretroviral agents; patient compliance, 1817  
astemizole; warnings, 526  
bromfenac sodium; warnings, 526  
dietary supplements; beyond-use vs. expiration dates, 433; FDA regulations, 1239; USP standards, 2330  
drugs; beyond-use vs. expiration dates, 433; FDA regulations, 1552; error prevention, 1968  
nonprescription drugs, geriatrics, 1654  
heparins; interactions, 210  
drugs, latex; FDA regulations, 2059  
medicinal plants; USP standards, 2330
- Lactation**; nutrition; pediatrics, 84
- Lactose**; incompatibilities; nifedipine powders, 1299
- Lamifiban**; cardiovascular diseases; review, 2363
- Laminar flow**; hoods; cleanrooms, 182
- Latex**  
allergies; hospital policies, 437; sterile preparations, 1462  
labeling; FDA regulations, 2059
- Law Note**, 686
- Laws**  
Africa; pharmacy practice, 1928  
cases; assisted suicides, 539; physician-assisted suicide, 543, 551, 578; taxes, 772  
certification; pharmacists, 2444  
controlled substances; pain, 2074  
Death with Dignity Act; implementation, 318, 1235  
FDA Modernization Act of 1997; compounding, 1859  
hospital pharmacy; outsourcing guidelines, 1611  
liability; pharmacy administrators, 1874  
states; pharmacists' prescribing, 585  
suicides; physician assisted, 547
- Leftunomide**; approvals; FDA, 2225
- Lefradafiban**; cardiovascular diseases; review, 2363
- Legislation**  
home health care; U.S. economics, 2019  
hospital pharmacy; residency reimbursement, 1620  
nursing homes; pharmacists' monitoring, 330  
patient information; confidentiality, 895  
professional competence; health professions, 2454
- Lepirudin**; approvals; FDA, 1444
- Letters**, 83, 182, 289, 396, 491, 602, 734, 840, 955, 1057, 1194, 1313, 1413, 1524, 1626, 1728, 1826, 1934, 2026, 2195, 2304, 2417, 2534, 2639
- Abciximab vials as multidose containers, 2026
- Aluminum contamination of neonatal parenteral nutrient solutions and additives, 1071
- Assay reliability, 491
- Comparison of electronic drug information resources, 1197
- Differences in warfarin products are not the issue, 1935
- Drawing on university resources to train hospital pharmacists in anticoagulant drug monitoring, 396
- Drug allergy communication, 1524
- Drug interaction inconsistency in *Drug Information Handbook*, 2418
- Ethics of supplying starter kits of infant formula, 84
- Filtration recommendations for I.V. medications, 1313
- Fluorouracil precipitate, 1314
- Hemolysis and renal failure associated with use of sterile water for injection to dilute 25% human albumin solution, 1057
- HIV pharmacotherapy clinic, 955
- Inconsistent documentation of drug-related allergies and adverse effects in patient charts, 289
- Indications for use of amifostine, 1827
- Inline filtration of ranitidine hydrochloride solutions, 840
- Lack of sexual adverse effects with mirtazapine, 2195
- Laminar-airflow ceiling in a hospital pharmacy cleanroom, 182
- Mesalamine-associated pleural effusion with pulmonary infiltration, 2304
- Microbial contamination of benzalkonium chloride products, 2534
- Mibefradil and an effective formulary system, 1934
- National Hospital Pharmacy Week, 1997, 843
- Nicotine patch needs to breathe, 1413
- Noticeable difference in admixtures prepared from lorazepam 2 and 4 mg/mL, 2305
- Oral syringe for extemporaneously preparing doses, 735
- Outsourcing radiopharmaceutical services, 2537
- Pearls in therapeutic drug monitoring, 2027
- Pharmacist-managed carvedilol heart failure clinic, 1626
- Pharmacy-managed extended-interval aminoglycoside program in a community hospital, 397
- Possible troglitazone-warfarin interaction, 1071
- Potential confusion with antiretroviral drugs, 2639
- Replacement of divalproex sodium with valproic acid not clear-cut, 1073
- Resident's perspective on pharmacist-managed drug therapy protocols, 1826
- Severe hypotension and bradycardia associated with verapamil and clarithromycin, 2417
- Sheath for disposable syringes, 956
- Somatropin administration by three drug-delivery systems, 734
- Stability of carboplatin in polyvinyl chloride bags, 602
- Testing commercially available folic acid capsules, 1415
- Two antiretroviral drugs likely to be confused, 1728
- A vision for psychopharmacology, 83
- Visual compatibility of fentanyl citrate with parenteral nutrient solutions, 1194
- Leukotriene antagonists**; montelukast sodium; FDA approvals, 759
- Levomethadyl acetate**; therapy; narcotics dependence, 208
- Liability**  
hospitals; sentinel-event policies, 1112  
pharmacists; prescribing, 585  
pharmacists, hospital; administrators, 1874
- Liquids**  
alprazolam; compounding, 1915  
chloroquine phosphate; compounding, 1915  
cisapride; compounding, 1915  
enalapril maleate; compounding, 1915  
hydralazine hydrochloride; compounding, 1915  
oral; antineoplastic agents, 735
- Liver diseases**  
acetaminophen; toxicity, 1516  
bromfenac sodium; toxicity, 526
- Liver failure**  
antiretroviral agents; dosage, 2528  
bromfenac sodium; product withdrawal, 1548
- Long-term care facilities**  
equipment; automation guidelines, 1403  
patient information; continuity of care, 1017  
pharmaceutical services; Alzheimer's disease, Nov 1 suppl S26  
reimbursement; prospective-pricing system, 1645
- Loracarbef**; otitis media; review, 1881
- Lorazepam**; incompatibilities; diluents, containers, 2013; water, 2305
- Lung diseases**; mesalamine; toxicity, 2304
- Lymphoma**; rituximab; non-Hodgkin's, 1110
- M**
- Macrolides**  
clarithromycin; verapamil interactions, 2417  
erythromycin; sildenafil interactions, 2080  
interactions; astemizole, 526  
otitis media; review, 1881
- Magnesium**; concentration; automated TPN compounding, 1503
- Malpractice**; pharmacists; prescribing issues, 585
- Managed Care Forum**, 27, 435, 995, 1357, 1769, 2234  
Identifying ambulatory care patients with coronary heart disease who need cholesterol management, 1769  
Increasing the use of nonprescription drugs in a group-model HMO, 1357  
Influencing physician prescribing through academic detailing with benchmarks, 2234  
Forecasting the issues for managed care pharmacy, 27  
Reducing expenditures for statin-type lipid-lowering agents, 995  
Setting up the herbal formulary system for an alternative medicine clinic, 435
- Managed care systems**  
see also **Health maintenance organizations**  
administration; consumers' influence, 876; health care delivery, 1490  
contracts; pharmaceutical services, 523  
data collection; conference registrants, 1488; Medicare surveys, 878  
disease management; medical directors' survey, 1700  
for: studies; proton-pump inhibitors, 2249  
her: benefit programs; third party, 1663  
her: care; pharmacists' role, 347  
history; U.S., 229  
HMG-CoA reductase inhibitors; costs, 995  
home health care; U.S. economics, 2019  
membership; customer satisfaction, 986  
patient information; databases, 1769  
pharmaceutical care; transition, 1477  
pharmaceutical services; drug information, 2007; future, 27; pharmacists' role, 1471  
pharmacists, community; interventions, 1141  
pharmacy; challenges, 1492, 1497; role, 1482

- pharmacy, institutional; layoffs, 2387; role, 441  
standards; NQA accreditation, 2221  
quality assurance; data collection, 2351; standards, 1351
- Management, see Administration**
- Management Case Studies**, 364, 1512
- Management Consultation**, 772, 993, 1266, 1462, 1763, 1874, 2090, 2360, 2611  
Administrative liability of pharmacy managers, 1874  
Educational rotations in pharmacy-based investigational drug services, 2611  
Federal tax consequences of institutional pharmacy dispensing to outpatients, 772  
Herbals and homeopathic remedies as formulary items? 1266  
Holding more fruitful staff meetings, 2360  
Improving documentation of preoperative antimicrobial prophylaxis, 993  
Managing the shortage of intravenous immune globulin, 2090  
Realizing pharmacists' potential in the outpatient clinic arena, 1763  
Preparation of latex-safe sterile products, 1462
- Manpower**  
hospital pharmacy; inpatient consultation, 1127; outsourcing guidelines, 1611  
layoffs; institutional pharmacists, 2387  
pharmacists, hospital; drug information centers, 1164
- Manufacturers**  
medical devices; latex labeling, 2059  
nutrition; pediatrics, 84
- Manufacturing**  
benzalkonium chloride; quality control, 2534  
dietary supplements; quality control, 2341  
globulin immune; U.S. shortages, 1341, 2228  
medicinal plants; quality control, 2341
- Marketing**  
basiliximab; FDA approvals, 1444  
citalopram hydrobromide; FDA approvals, 1963  
clopidogrel bisulfate; FDA approvals, 207  
contract services; chain stores, 875  
daclizumab; FDA approvals, 207  
dolasetron mesylate; FDA approvals, 18  
efavirenz; FDA approvals, 2458  
epitibatide; FDA approvals, 1440  
fomepizole; FDA approvals, 110  
grefloxacin hydrochloride; FDA approvals, 20  
home health care; U.S. economics, 2019  
hydroxyurea; FDA approvals, 875  
industry, pharmaceutical; brand-name drugs, 1445; medicinal plants, 2341; patient confidentiality, 895  
infliximab; FDA approvals, 2073  
leflunomide; FDA approvals, 2225  
lepirudin; FDA approvals, 1444  
montelukast sodium; FDA approvals, 759  
naratriptan hydrochloride; FDA approvals, 638  
nutrition; infant formulas, 84  
oprelvekin; FDA approvals, 107  
palivizumab; FDA approvals, 1654  
prescriptions; direct-to-consumer, 2344  
raloxifene hydrochloride; FDA approvals, 104  
risdonate sodium; FDA approvals, 984  
rituximab; FDA approvals, 110  
rizatriptan benzoate; FDA approvals, 1656  
sacrosidase; FDA approvals, 1102  
sildenafil citrate; FDA approvals, 981  
thalidomide; FDA approvals, 1746  
trofiban hydrochloride; FDA approvals, 1440  
tolcapone; FDA approvals, 524  
zolmitriptan; FDA approvals, 110
- Measles, mumps, and rubella vaccines**; health professions; CDC protocols, 760
- Mechanism of action**  
aldesleukin; overview, 1520  
anagrelide hydrochloride; thrombocytosis, 1979  
antidiarrheal agents; review, 1573  
aspirin; overview, Oct 1 suppl S17  
atorvastatin calcium; review, 2253  
basiliximab; overview, 1444  
cimetidine; acetaminophen overdose, 1516  
clopidogrel bisulfate; overview, 207  
daclizumab; overview, 207  
dipyridamol; overview, Oct 1 suppl S17  
docetaxel; review, 1777  
epitibatide; overview, 1440  
fomepizole; ethylene glycol poisoning, 110  
hydroxyurea; overview, 875  
ibutilide fumarate; review, 255  
lepirudin; overview, 1444  
mifepradil; interactions, 210  
mirtazapine; review, 44  
morphine; pancreatitis pain, 480  
parasympathomimetic agents; Alzheimer's disease, Nov 1 suppl S11  
platelet aggregation inhibitors; review, Oct 1 suppl S8  
protease inhibitors; HIV infections, 233  
psychotherapeutic agents; mental disorders, 83  
rotavirus vaccines; FDA approvals, 2226  
serotonin-reuptake inhibitors; sexual dysfunction, 1167  
sildenafil citrate; overview, 981  
ticlopidine; overview, Oct 1 suppl S17  
trofiban hydrochloride; overview, 1440  
tolcapone; overview, 524  
troglitazone; review, 905
- Medication errors, see Errors, medication**
- Medication orders**  
antineoplastic agents; standards, 137  
automation; remote dispensing, 669  
interventions; HIV infections, 1151
- MEDLINE**; drug information; managed care systems, 2007
- Meetings**  
American Pharmaceutical Association; 1998 annual, 878  
American Society of Health-System Pharmacists; managed care systems, 1488, 1497; paper submission guidelines, 888; poster sessions, 2038  
Food and Drug Administration; compounding regulations, 1859  
National Association of Boards of Pharmacy; 1998 resolutions, 1445  
United States Pharmacopeia; dietary supplements, 2330
- Membership**  
American Society of Health-System Pharmacists; nonhospital pharmacists, 31  
managed care systems; customer satisfaction, 986
- Men**  
contraceptives; thalidomide, 1746  
patients; drug-related injuries, 1158
- Mental disorders**; psychotherapeutic agents; future, 83
- Meperidine**; pain; pancreatitis, 480
- Mergers**  
industry, pharmaceutical; cost purchasing, 127  
pharmacy, institutional; layoffs, 2387
- Mesalamine**; toxicity; pleural effusion, 2304
- Metabolism**  
antiretroviral agents; kidney, liver failure, 2528  
astemizole; interactions, 526  
carbamazepine; loading dose, 1134  
cisapride; antifungals interaction, 2418  
efavirenz; HIV infections, 2458  
itraconazole; metabolites, 261  
phenytoin; blood levels, 2392  
sildenafil citrate; overview, 981
- Metacresol**; preservatives; somatropin injections, 1508
- Metals**  
chromium; nutrition contamination, 150  
zinc; nutrition contamination, 150
- Metformin**; diabetes mellitus; cost-benefit analysis, Dec 15 suppl S24
- Methadone**; therapy; narcotics dependence, 208
- Methodology**  
blood levels; phenytoin, 2392  
blood pressure; monitoring, Nov 15 suppl S12  
clinical studies; abacimab, 2409  
cost-benefit analysis; histamine H<sub>2</sub> antagonists, Dec 15 suppl S8  
data collection; health-benefit programs, 878  
decision-making; formularies, Oct 1 suppl S28; HMO formularies, 50  
errors, medication; process control charts, 946  
heparin sodium; laboratory tests, 2002  
pharmaceutical care; outcomes research, 62  
pharmaceutical services; patient consultation, 2485  
protocols; patients' weight, 159
- Methotrexate**; pregnancy; ectopic, 171
- Methylcellulose**; incompatibilities; granisetron suspensions, 2511
- Metronidazole**; enterocolitis; pseudomembranous, 1365, 1407
- Mifepradil**; interactions; FDA warnings, 210
- Mibefradil dihydrochloride**; product withdrawal; interactions, 1445
- Miconazole**; interactions; cisapride, 2418
- Migraine**  
naratriptan hydrochloride; FDA approvals, 638  
rizatriptan benzoate; FDA approvals, 1656  
zolmitriptan; FDA approvals, 110
- Military**  
hospital pharmacy; formularies, 1658  
pharmaceutical services; costs, 1656
- Milrinone**; heart failure; home health care, 930
- Minerals**; injections; metal contamination, 150
- Minimum inhibitory concentration**; ceftazidime; *P. aeruginosa*, 145
- Mirtazapine**; depression; review, 44
- Misoprostol**; ulcers; NSAIDs toxicity, 883
- Mississippi**; Medicaid; disease management, 1238; pharmacists' reimbursement, 2452
- MK-966**; arthritis; rheumatoid, 2225
- Models**  
cost-benefit analysis; varicella vaccines, Dec 15 suppl S4  
errors, medication; process control charts, 946  
pharmaceutical services; patient consultation, 2485, 2615, 2621  
pharmacy; practice, 782
- Moisture**  
absorption; nicotine patches, 1413  
prescription drugs; USP standards, 1554
- Monographs**  
cisapride; antifungals interaction, 2418  
*Symphylum* species; USP, 527  
*Valeriana* species; USP, 527
- Montelukast sodium**; approvals; FDA, 759
- Moraxella catarrhalis**; resistance; anti-infective agents, 1881
- Morphine**; toxicity; pancreatitis pain, 480
- Mortality**  
cardiovascular diseases; platelet aggregation inhibitors, 2363  
surgical wound infection; hospitals, 777  
vascular disease; clopidogrel approvals, 207
- Mycophenolate mofetil**; stability; oral suspensions, 926
- Myocardial infarction**  
clopidogrel bisulfate; FDA approvals, 207  
heparin; comparisons, 2402  
heparins; low molecular weight, 2402  
heparin sodium; activated partial thromboplastin time, 2002  
overview; atherosclerosis, Oct 1 suppl S4  
platelet aggregation inhibitors; review, 2363  
thrombolytic agents; comparisons, 2402
- N**
- Naloxone**; pain; pancreatitis, 480
- Naltrexone**; therapy; narcotics dependence, 208
- Naratriptan hydrochloride**; approvals; FDA, 638
- Narcotics**; dependence; methadone therapy, 208
- National Association of Boards of Pharmacy**; meetings; 1998 resolutions, 1445
- National Asthma Education and Prevention Program**; patient information; propellants, 276
- National Cancer Institute**; antineoplastic agents; compassionate-use protocols, 651
- National Committee for Quality Assurance**  
administration; performance measurement, 1348  
managed care systems; data collection, 2351  
standards; managed care accreditation, 2221; managed care systems, 1351
- National Community Pharmacists Association**; television; patient information, 536
- National Coordinating Council for Medication Error Reporting and Prevention**; errors, medication; prevention, 1968
- National Hospice Organization**; attitudes; physician-assisted suicide, 543
- National Institute for Standards in Pharmacy**; certification; pharmacists, 2444
- National Institutes of Health**  
palliative care; reports, 640  
protocols; methadone therapy, 208
- National Pharmacy Week**; public relations; institutional pharmacists, 1975
- Natural products**; pharmacists; role, 125
- Nausea**  
antineoplastic agents; outpatient survey, 1903  
dolasetron mesylate; FDA approvals, 18  
granisetron; antineoplastic toxicity, 1269
- Negligence**; pharmacists; prescribing issues, 585
- Nelfinavir mesylate**  
HIV infections; review, 233  
nomenclature; similarities, 1728
- Neoplasms**  
amifostine; clinical studies, 1827  
antidiarrheal agents; diarrhea, 1573

- antiemetics; outpatient survey, 1903  
 antineoplastic agents; nomenclature protocols, 137
- Nevirapine**  
 HIV infections; overview, 283  
 nomenclature similarities, 1728
- News**, 10, 104, 207, 318, 421, 520, 635, 759, 875, 978, 1092, 1235, 1341, 1440, 1544, 1645, 1746, 1850, 1959, 2059, 2221, 2326, 2444, 2593  
 Accrediting bodies will mesh performance standards, 1348  
 Adults over 60 depend heavily on pharmacists for guidance in medication use, 768  
 AHCPR guidelines on smoking cessation found cost-effective, 211  
*AJHP's* editorial board; varied practice interests, many goals for *Journal*, 1249  
 Anti-TNF antibody approved for Crohn's disease, 2073  
 APHA adopts conscience clause, policies on pharmacists' role in care, 878  
 Appointments and Promotions, 325, 527, 764, 984, 1449, 1856, 2074, 2352, 2596  
 Approval of dolasetron expands antiemetic choices, 18  
 Basiliximab approved for use in renal transplant patients, 1444  
 Benefits of intensive antiretroviral therapy documented, 1102  
 Book Correction Notice, 1551  
 BPS exam results announced, 427  
 CDC identifies immunizations needed by health care workers, 760  
 Change in New York law is step toward better pain management, 2074  
 Citalopram approved for treatment of depression, 1963  
 Classification system for pharmacy practice activities released, 642  
 Clindamycin formulary restriction lowers costs, antimicrobial resistance, 1552  
 Clopidogrel approved on basis of CAPRIE study, 207  
 Community pharmacy strives for continuity of care, 635  
 Compliance interventions make a difference, but focus should shift to patient outcomes, 2231  
 Computer-assisted decision program for antimicrobial therapy raises quality of care, lowers costs, 421  
 Computerized decision support systems effectively defend against adverse drug events, 2594  
 Congress viewed with a scientist's critical eye, 1850  
 Consensus panel proposes sweeping changes to improve access to methadone maintenance treatment, 208  
 Consumer ads build awareness but not understanding of advertised medications, surveys reveal, 2344  
 Consumer group spotlights need for better patient drug information, urges FDA regulation, 1552  
 Consumers uninformed about nonprescription pain relievers, 2597  
 Core formulary issued for military treatment facilities, 1658  
 Customer service key to satisfaction with managed care plans, 986  
 Drug-approval pace remains brisk in 1997, 336  
 Drug information reaching more patients, FDA data show, 107  
 Educational Meetings, 641, 884, 1348  
 Education level, values influence pursuit of alternative therapies, 1352  
 Elderly may consume more health resources when formularies are more restricted, 2231  
 Endotoxin-like reactions reported with once-daily gentamicin, 2593  
 Enzyme therapy approved for sucrase deficiency, 1102  
 Error prevention group zeroes in on labeling, 1968  
 Etanercept marketed for moderate, severe rheumatoid arthritis, 2593  
 Ethylene glycol antidote cleared for marketing, 110  
 Experts weigh in on performance measurement, 1962  
 FDA announces financial disclosure policy affecting clinical investigators, 642  
 FDA approves oral therapy for erectile dysfunction, 981  
 FDA compounding committee to meet in October, 1859  
 FDA licenses rotavirus vaccine for infants, 2226  
 FDA proposes mechanism for disseminating information about off-label uses, 1449
- FDA proposes rules for health claims on dietary supplements, 1239  
 FDA sets policy on industry-sponsored educational programs, 426  
 Federal program, higher administration fees boost vaccination rates, study shows, 424  
 First COMT inhibitor approved for Parkinson's disease, 524  
 Five days' therapy adequate for uncomplicated otitis, meta-analysis shows, 1548  
 Glen Sperandio dies, 340  
 Government investigates ongoing shortage of i.v. immune globulin, 1341  
 Group begins work on indicators of quality medication use, 1854  
 Groups advise on managing sildenafil's cardiovascular risks, 2080  
 HCFA analysts say slow growth in health care spending is over; prescription drug costs will rise rapidly, 2230  
 HCFA to tighten oversight of nursing home care; says drug use improved under OBRA '87 guidelines, 1852  
 Half of drug donations to Bosnia unusable, 212  
 Health care industry feels the power of consumerism, 876  
 Health care personnel alerted to problems with lipid-based products, albumin, 2078  
 Health care spending growth at record low in 1996; prescription drugs break pattern with 9% increase, 768  
 Health plans should include patient perspective in cost-effectiveness decisions, 2080  
 Herbal quality seems to be growing, 2341  
 HMO enrollment continues to climb in 1996, 20  
 Hydroxyurea marketed for sickle cell anemia, 875  
 Immediate use of anticoagulants may not improve stroke outcomes, 1240  
 Improvement needed in nursing home medication review, say government reports, 330  
 Incorrect dosage calculations by pediatric residents common, study shows, 1866  
 In patients with chronic diseases, unrelated disorders may go untreated, 1755  
*Institutional Digest* reports changes in hospitals, nursing homes, home care, 1558  
 Integrated health systems increase ownership of components, 1450  
 Integrated systems may have economic incentive for using alteplase in stroke patients, 1248  
 Interleukin-11 product approved for chemotherapy support, 107  
 International pharmacists adopt statement on pharmaceutical care, 2598  
 IVIG shortage continues, 2228  
 JAMA authors tout benefits of computerized prescribing, 1100  
 JCAHO extends time, options for root cause analysis of sentinel events, 1856  
 JCAHO initiates *Sentinel Event Alert*, 764  
 Journal series examines potential for harm from unregulated dietary supplements, 2344  
 Leflunomide approved for rheumatoid arthritis; other drugs nearing approval, 2225  
 Managed care shows moderate gains, reluctance to share performance data in 1998, says NCQA, 2351  
 Marketing could be primary objective of managed care health promotion programs, 1756  
 Medicaid to pay Mississippi pharmacists for disease management, 1238  
 Medical devices with latex become easier to identify, 2059  
 Medicare HMO promotions paint rosy picture, lack details, 1968  
 Medicare managed care enrollees first in line for consumer survey, 878  
 Mississippi moves forward with disease-specific credentialing, 2452  
 Monoclonal antibody approved for renal transplants, 207  
 Monoclonal antibody approved for RSV disease prevention, 1654  
 Montelukast approved for asthma management, 759  
 More than half of employers report steeper rise in pharmacy benefit costs than in overall medical costs, 767  
 Most hospitals removing KCl concentrate from patient units, ISMP reports, 1098  
 NABP opposes anti-generic campaigns, overuse of antibiotics in animals, 1445
- NCQA's TV network primes consumers, pharmacists for pharmaceutical care, 536  
 NCQA to count performance measures in accreditation score, 1351  
 New guidelines target sexually transmitted diseases, 879  
 New monoclonal antibody approved as lymphoma therapy, 110  
 New oral fluoroquinolone marketed, 20  
 New products spurred 11% growth in pharmaceutical sales in 1997, 880  
 News Briefs, 23, 108, 211, 344, 424, 536, 645, 767, 884, 1100, 1256, 1354, 1450, 1562, 1664, 1749, 1866, 1969, 2083, 2232, 2337, 2468, 2598  
 New warnings issued for bromfenac, astemizole, 526  
 1999 accreditation standards address public concerns, says NCQA, 2221  
 Not enough physicians identify smokers, advise cessation, 988  
 Obesity guidelines prescribe limited role for weight-loss drugs, 1663  
 Once-daily nonnucleoside reverse-transcriptase inhibitor approved, 2458  
 One fourth of PBM pharmacists' phone calls lead to therapy changes, 2464  
 Oral migraine drug approved for marketing, 1656  
 Oral naratriptan approved for migraine attacks, 638  
 Oregon board of pharmacy gains physicians' support for collaborative practice, 1859  
 Oregon groups devise rules, policies on assisted suicide, 1235  
 Oregon voters confirm support for physician-assisted suicide; pharmacists and physicians struggle over implementation, 318  
 Organizations agree on tenets of palliative care, 2232  
 Overhaul of military pharmacy system recommended, 1656  
 Pain in nursing-home cancer patients often goes untreated, 1544  
 Panel cites policies for preventing medication misuse in the elderly, 1654  
 Panic-disorder treatment guidelines published, 1352  
 Patients, more than physicians, frown on drug company freebies, 1759  
 Patients who pay out-of-pocket receive lower-cost drugs, 1556  
 Patterns of antibiotic overuse in childhood respiratory infections explored, 883  
 Paul Parker, a pioneer in twentieth-century pharmacy, dies, 1344  
 Pediatric safety information added to corticosteroid labeling, 2597  
 Pew Commission calls for ongoing competency assessment of health professionals, greater say for public on regulatory boards, 2454  
 Pharmacist named to Joint Commission post, 989  
 Pharmacist-run anticoagulation clinic improves patient outcomes, lowers health care costs, 2078  
 Pharmacists in Asheville, North Carolina, pick up city paychecks for diabetes services, 10  
 Pharmacists must seek recognition on primary care team, 17  
 Pharmacy organizations form credentialing council to integrate efforts, 2444  
 PHS report addresses antiretroviral drug use during pregnancy, 1108  
 Prescription requests and patient satisfaction, 2347  
 Press coverage of pharmacy letters fans confidentiality concerns, 875  
 Progress in breast cancer treatment: prevention, new therapies come to forefront, 2326  
 Prospective pricing system for nursing facilities begins, 1645  
 Raloxifene approval ushers in new drug class for osteoporosis, 104  
 Recommendations for CMV treatment released, 1354  
 Recommendations issued for patients who took fenfluramine, dexfenfluramine, 18  
 Report identifies research priorities for improving end-of-life care, 640  
 Report recognizes greater role for vitamin supplements, fortified foods, 981  
 Reports prompt new warnings on LMW heparins, heparinoids, 210  
 Report tracks HMO pharmacy cost, benefit trends, 422  
 Report updates recommendations for health workers exposed to HIV, 1755

- Researchers report sustained suppression of HIV with nevirapine-didanosine-zidovudine, 1106  
 Risedronate released for Paget's disease, 984  
 Roche cites drug interactions in mifepradil withdrawal, 1445  
 Roche, FDA announce new drug-interaction warnings for mifepradil, 210  
 Rule revision puts patients at risk, ASHP and others tell HCFA, 1092  
 San Diego VA pharmacists find room in ambulatory care clinics, 1753  
 Seattle pilot project makes emergency contraception available directly from pharmacists, 520  
 Simple reminder can boost pneumococcal vaccination rates, say researchers, 1859  
 Spike in managed care enrollment curbed employer health costs in 1997, survey shows, 638  
 Standards to be set for pharmacy certificate programs, 1856  
 Studies highlight low use of  $\beta$ -blockers, 1967  
 Studies support use of omeprazole for NSAID-induced ulcers, 883  
 Study finds ADRs in 1 in 15 hospital patients, 1097  
 Study of estrogen-progestin for secondary prevention yields unexpected results, 1966  
 Study poses new questions about calcium-channel blockers, 762  
 Study raises question: are we harming patients with albumin? 2073  
 Study raises questions about corticosteroid use for lung maturation in premature infants, 1110  
 Study shows poor persistence with lipid-lowering therapy, even when cost not a factor, 1556  
 Study strengthens case against using aspirin to prevent preeclampsia, 986  
 Survey of pharmacy benefit trends released, 1663  
 Tamoxifen reduces risk of breast cancer in high-risk women, 978  
 Teen smoking up one third, 1248  
 Thalidomide approval brings tight restrictions on access, 1746  
 Therapy for patients with heparin-induced thrombocytopenia marketed, 1444  
 Two i.v. antiplatelet agents marketed for coronary disease, 1440  
 University of Florida signs up Pharm.D. students for Texas, Illinois sites, 530  
 Upcoming Meetings, 427, 526, 762, 1106, 1560, 1754, 2228  
 U.S. health system short on quality, consensus panel says, 2458  
 USP moves forward in providing information on botanical products, 527  
 USP to decide soon on storage and shipping requirements, 1554  
 USP to reevaluate its position on botanicals, 2330  
 We're here—use us, pharmacists tell consumers, 1959  
 Wisconsin health plan rolls out comprehensive pharmacy provider contract, 523  
 Wyeth-Ayerst pulls bromfenac off market, 1548  
 Yale-New Haven Hospital top contender in Abbott quality awards, 344  
 Zolmitriptan receives migraine indication, 110  
**Newsletters**; drug information; hospital pharmacy, 1164  
**News media**  
 pharmacy, community; patient confidentiality, 875  
 public relations; ASHP, 1959  
**New York**; laws; controlled substances, 2074  
**Nicotine**; patches; transdermal; toxicity, 1413  
**Nifedipine**; stability; powders, 1299  
**Nitrates**; drug interactions; sildenafil, 2080  
**Nizatidine**; substitution; therapeutic, 1382  
**Nomenclature**  
 antineoplastic agents; medication errors, 137  
 brand names; similarities, 1728  
 clinical studies; ASHP guidelines, 369  
 drugs, adverse reactions; ASHP draft, 165  
 errors, medication; ASHP draft, 165  
 expiration dates; vs. beyond-use, 433  
 similarities; neflavinir, nevirapine, 1728  
**Northern Ireland**; pharmacists, community; pharmaceutical care, 2009  
**Nuclear pharmacy**, see **Radiopharmacy**  
**Nurses**  
 alendronate sodium; esophagitis prophylaxis, 892  
 attitudes; pharmacy technicians, 1810  
 dispensing; automation, 1924  
 education; nonprescription, 1357; therapeutic substitution, 1382  
 errors, medication; monitoring, 946  
 health maintenance organizations; formulary decisions, 56  
 patient information; telephone, 453  
**Nursing**; hospitals; allergy documentation, 289  
**Nursing homes**  
 costs; Alzheimer's disease, Nov 1 suppl S17  
 drug use; review, 330  
 pharmaceutical services; Alzheimer's disease, Nov 1 suppl S26; consultant pharmacists, 1588  
**Nutrition**  
 diet; drug interactions, 114, 122; obesity, 1663; vitamin supplements, 981  
 dietary supplements; labeling, 1239  
 parenteral; amino acid stability, 1288; automated compounding, 1503, 1606; fentanyl incompatibilities, 1194; metal contamination, 150  
 pediatrics; infant formulas, 84  
 specialties; pharmacist certification, 427  
**Nutrition disorders**; proton-pump inhibitors; toxicity, 2268  
**O**  
**Obesity**  
 anorexics; guidelines, 1663  
 cyclosporine; blood levels, 1598  
 disease management; guidelines, 1943  
 heparin; dosage, 159  
**Ohio**; administrators; technician certification, 1799  
**Olanzapine**; schizophrenia; review, 1003  
**Omeprazole**; ulcers; NSAIDs toxicity, 883  
**Omnibus Budget Reconciliation Act of 1987**; psychotherapeutic agents; regulations, Nov 1 suppl S26  
**Ondansetron hydrochloride**; incompatibilities; injections, 2630  
**Ophthalmic preparations**  
 flurbiprofen; cataract surgery, Dec 15 suppl S23  
 glaucoma; costs, 272  
**Opiate antagonists**; naltrexone; narcotics dependence, 208  
**Opiates**  
 buprenorphine; narcotics dependence, 208  
 levomethadyl acetate; narcotics dependence, 208  
 methadone; narcotics dependence, 208  
 pain; pancreatitis, 480  
**Oprelvekin**; approvals; FDA, 107  
**Oregon**  
 Death with Dignity Act; implementation, 318, 1235  
 pharmacists; collaborative drug therapy management, 1859  
**Organizations**  
 American Pharmaceutical Association; policies, 878  
 American Society of Health-System Pharmacists; antidepressant protocols, 2514; antithrombotic protocols, 376; automation guidelines, 1403; drug abuse, 1721; formulary standards, 1351; HCFA regulations, 1092; Healthy People 2000, 477; infection control guidelines, 1724; medication errors, 137; meetings, 2038; outsourcing guidelines, 1611; paper submission guidelines, 888; pharmacokinetic monitoring, 1726; policy development, 1044; practice standards, 1879; pseudomembranous enterocolitis protocols, 1407; public relations, 1570, 1959, 1975; research guidelines, 369; services, 31; staff development, 1760; strategic planning, 1717; Task Force on Science, 2519; WWW, 1773  
 Board of Pharmaceutical Specialties; psychopharmacy examinations, 1594  
 Canadian Pharmaceutical Association; infant formulas, 84  
 Compassion in Dying; physician-assisted suicides, 547  
 guidelines; propellants, 276  
 health care; consumers' influence, 876; error prevention, 1968  
 Joint Commission of Pharmacy Practitioners; HCFA regulations, 1092  
 medical; pediatric vaccines, 563; performance measurement, 1348; pharmacy contract services, 875  
 National Committee for Quality Assurance; standards, 1351  
 National Coordinating Council for Medication Error Reporting and Prevention; labeling recommendations, 1968  
 pharmacy; certification, 2444; contract services, 875; Pharmacist Practice Activity Classification, 642  
 Public Citizen Health Research Group; FDA petitions, 1552  
**Organ preservation solutions**; incompatibilities; filters, 266  
**Osteoporosis**; raloxifene hydrochloride; FDA approvals, 104  
**Otitis media**; review, 1881  
**Outcomes**  
 clinical; abciximab, Dec 15 suppl S35; consultant pharmacists' interventions, 1588; hospital technicians, 1375; managed care systems, 441; metformin vs. insulin, Dec 15 suppl S24; telepharmacy, 1512; weight-based heparin protocols, Dec 15 suppl S29  
 economics; managed care systems, 441  
 pharmaceutical care; diabetes mellitus, 10; research, 62  
 pharmacoeconomics; abciximab clinical studies, 2409  
 therapeutic; antiemetics, 1269; disease management, 1029; varicella vaccines, Dec 15 suppl S4  
**Outpatients**, see **Patients**; **outpatients**  
**Owen Healthcare**; contracts; University of Florida, 530  
**P**  
**Packaging**  
 antiretroviral agents; patient compliance, 1817  
 drugs; error prevention, 1968; latex free, 437  
 ketorolac tromethamine; repackaging, 388  
 labeling; drug stability, 433  
 unit dose; enoxaparin repackaging, 1296  
**Paclitaxel**; breast neoplasms; overview, 2326  
**Paget's disease**; risedronate sodium; FDA approvals, 984  
**Pain**  
 benzodiazepines; New York laws, 2074  
 buprenorphine; pancreatitis, 480  
 controlled substances; New York laws, 2074  
 meperidine; pancreatitis, 480  
 morphine; pancreatitis, 480  
 nalbuphine; pancreatitis, 480  
 palliative care; AMA and NHO, 543; ethics, 539; NIH reports, 640  
**Pallivizumab**; approvals; FDA, 1654  
**Palliative care**  
 depression; ethics, 539  
 pain; controlled substances laws, 2074; ethics, 539; symptom management, 543  
 pharmaceutical care; pharmacists' role, 578  
 research; NIH reports, 640  
**Pancreatitis**  
 buprenorphine; pain, 480  
 meperidine; pain, 480  
 morphine; pain, 480  
 nalbuphine; pain, 480  
**Paranoid disorders**; saquinavir; toxicity, 2016  
**Parasympatholytic agents**; glaucoma; costs, 272  
**Parasympathomimetic agents**  
 bethanechol chloride; suspensions, 1804  
 cholinesterase inhibitors; Alzheimer's disease, Nov 1 suppl S22  
 tacrine; Alzheimer's disease, Nov 1 suppl S17  
**Parenterals**, see **Injections**  
**Parker, P.**; pharmacists, hospital; history, 1344  
**Parkinson's disease**; tolcapone; FDA approvals, 524  
**Particles**  
 air; cleanrooms, 458  
 organ preservation solutions; inline filters, 266  
**Patches, transdermal**; nicotine; toxicity, 1413  
**Patient care**  
 Alzheimer's disease; institutional pharmacists, Nov 1 suppl S3; pharmacists' role, Nov 1 suppl S26  
 ambulatory care; pharmaceutical services, 35  
 continuity; community pharmacy services, 635; integrated health care, 669; pharmacists' communication, 1017; referral forms, 2500  
 costs; outcomes research, 62; professional priorities, 782; prospective-pricing system, 1645  
 diabetes mellitus; costs, 10; pharmacotherapy services, Dec 15 suppl S27  
 disease management; pharmaceutical services, 471  
 health care; collaborative drug therapy management, 1859  
 managed care systems; pharmacists' role, 1471  
 military; formularies, 1658  
 pharmaceutical services; telephone, 453  
 pharmacists; Harvey A. K. Whitney Lecture Award, 1675; liability, 585; managed care systems, 347; role, 1850  
 pharmacists, community; interventions, 2009



pharmacists, hospital; heparin monitoring, 396; monitoring, 1826; outpatient clinics, 1763; role, 1092, 1123; telephone services, 453  
 pharmacists, institutional; ASHP public relations, 1959; managed care systems, 1488; public relations campaigns, 1570  
 technicians; role, 1810

#### Patient education

cerebrovascular disorders; pharmacists' role, 376  
 drug abuse; pharmacists' role, 1721  
 drugs, nonprescription; HMO programs, 1357  
 heart failure; ambulatory care, 1626  
 pharmacists, community; services, 635  
 pharmacists, hospital; job satisfaction, 360  
 pharmacists, institutional; infection control, 1724; poison prevention programs, 1971  
 thalidomide; regulations, 1746

#### Patient-focused care; health professions; interdisciplinary team, 1369

#### Patient information

clinical pharmacists; continuity of care, 1017  
 confidentiality; contract services, 875; JCAHO Sentinel Event Alert, 764; managed care systems, 2221; pharmacists' ethics, 895; pharmacists' role, 1850; pharmacy design, 2245  
 consultation; alternative medicine, 2525; antiretrovirals, compliance, 661; blood glucose meters, 1877; clinical pharmacists, 955, 1753; continuity of care, 2500; diabetes mellitus, 10; discharge, 114; discharge medications, Dec 15 suppl S32; discharge prescriptions, 1389; drug abuse, 1721; food interactions, 122; geriatrics, 768; hospital pharmacists, 1127, 1792; i.v. cardiac drugs, 930; infection control, 1724; institutional pharmacists, 2485, 2615, 2621; integrated health care, 35; managed care systems, 441; metered-dose inhalers, 226; natural products, 125; patient satisfaction, 1025; pediatric poisoning, 1971; pharmaceutical care, 2009; pharmacists' interventions, 1141; pharmacy design, 2245; protease inhibitors, 233; proton-pump inhibitors, 2249; thalidomide, 1746  
 dietary supplements; labeling regulations, 1239  
 drug histories; hypercholesterolemia, 1769  
 leaflets; botanical products, 527; drug-food interactions, 114, 122; FDA regulations, 1552; inhaler propellants, 276  
 medical histories; allergy documentation, 1524  
 pamphlets; pharmacists' role, 1975  
 pharmacists; Healthy People 2000, 477  
 prescription drugs; direct-to-consumer advertising, 594  
 telephone; patient care programs, 453  
 television; community pharmacy, 536  
 warfarin sodium; pharmaceutical industry, 729

#### Patients

attitudes; discharge medications consultation, Dec 15 suppl S32; managed care systems, 2351; pharmaceutical services, 1025, 2621; pharmacy contract services, 875; pharmacy technicians, 1810; telepharmacy, 1512  
 communication; health professions, 1524; pharmacists, 2245  
 discharge; prescription information, 1389; surgical wound infection, 777  
 drugs, personal; alternative medicine, 1266  
 inpatients; HIV infections, interventions, 1151; pharmacists' consultation, 1127  
 outpatients; antineoplasia, toxicity, 1903; pharmaceutical services, 669, 1763; pharmaceutical services, attitudes, 1025; prescription dispensing, 772  
 rights; assisted suicides, 318  
 thalidomide; regulations, 1746

#### Pediatrics

antibiotics; pseudomembranous enterocolitis, 1365  
 efavirenz; HIV infections, 2458  
 heparin sodium; i.v. catheters, 570  
 imipramine; overdose, 1552  
 metronidazole; pseudomembranous enterocolitis, 1407  
 montelukast sodium; dosage, 759  
 neonates; gentamicin pharmacokinetics, 2280  
 nutrition; infant formulas, 84  
 otitis media; review, 1881  
 palivizumab; respiratory syncytial virus infections, 1654  
 parenteral nutrition; amino acid stability, 1288; compounding automation, 1606; metal contamination, 150  
 poison prevention; programs, 1971  
 rotavirus vaccines; FDA approvals, 2226  
 sodium chloride; i.v. catheters, 570  
 vaccines; U.S. protocols, 563

#### Penicillin

allergies; documentation, 289  
 resistance; *S. pneumoniae*, 1987

#### Penicillin G potassium; incompatibilities; organ preservation solutions, 266

#### Penicillins

otitis media; review, 1881  
 penicillin; allergies documentation, 289; *S. pneumoniae* resistance, 1987  
 penicillin G potassium; incompatibilities, 266

#### Pennsylvania; hospital pharmacy; National Hospital Pharmacy Week, 843

#### Peptic ulcer;

gastrointestinal drugs; comparisons, 2289  
 proton-pump inhibitors; review, 2268

#### Pericardial effusion; mesalamine; toxicity, 2304

#### Peripheral vascular diseases

aspirin; overview, Oct 1 suppl S21  
 clopidogrel; overview, Oct 1 suppl S21  
 overview; atherosclerosis, Oct 1 suppl S4  
 ticlopidine; overview, Oct 1 suppl S21  
 troglitazone; interactions, 1071

#### Personnel

administrators; pharmacists' role, 1482  
 attitudes; health-benefit programs, 878  
 benefits; health care costs, 767  
 health care; immunization, 760; ISMP guidelines, 2078  
 hospitals; HIV prophylaxis, 1921; latex-free products, 437; medication error education, 1092; meetings participation, 2360; protocol education, 1826  
 immunization; varicella vaccines, Dec 15 suppl S4

#### Personnel, pharmacy

hospitals; cleanrooms, 458; staff development, 669  
 managed care systems; drug information, 2007  
 supportive; hospital pharmacy, 1799; indigent-patient services, 1293; patient care, 1810; robotics, 1907; technicians, 1375; workload, 2505

#### PETG, see Polyethylene terephthalate glycol

#### Pew Health Professions Commission; reports; health profession competence, 2454

#### Pharmaceutical care

Alzheimer's disease; pharmacists' role, Nov 1 suppl S26  
 ambulatory care; telepharmacy, 1512  
 clinical studies; methodology, 62  
 diabetes mellitus; community pharmacists, 10  
 home health care; hospital pharmacists, 486  
 managed care systems; implementation, 1497; reimbursement, 523; transition, 1477  
 pharmacists; Alpha policies, 878; assisted suicides, 578; certification, 2444; collaborative drug therapy management, 1859; television, 536  
 pharmacists, community; Northern Ireland, 2009; services, 635  
 pharmacists, hospital; outpatient clinics, 1763  
 pharmacists, institutional; public relations campaigns, 1570  
 pharmacokinetics; monitoring, 1726  
 pharmacy; Harvey A. K. Whitney Lecture Award, 1675; reprofessionalization, 1302  
 pharmacy, institutional; patient consultation, 2485, 2615, 2621  
 taxonomy; practice activity classification, 642

#### Pharmaceutical education, see Education, pharmaceutical

#### Pharmaceutical services

administration; poison prevention programs, 1971  
 allergies; documentation, 364  
 alternative medicine; dispensing, 1266  
 ambulatory; telepharmacy, 1512  
 ambulatory care; clinical pharmacists, 1753; heart failure clinics, 1626; outpatient clinics, 1763  
 aminoglycosides; extended-interval dosage, 397  
 anticoagulants; pharmacists' training, 1033  
 clinical; hospitals, 360; outcomes research, 62; staff development, 1760  
 clinical studies; ASHP guidelines, 369  
 community; continuity of care, 635, 2500; home health care, 2019; pharmaceutical care, 2009  
 compounding; potassium injections, 1098  
 consultation; inpatient, 1127; models, 2485, 2615, 2621; privacy telephone, 2245  
 contracts; managed care systems, 523  
 diabetes mellitus; community pharmacists, 10; cost-benefit analysis, Dec 15 suppl S27  
 disease management; alternate sites, 471; Medicaid reimbursement, 1238; pharmacists' certification, 2452  
 health maintenance organizations; nonprescription drug programs, 1357  
 heparin; monitoring, 396  
 HIV infections; pharmacists' interventions, 1151

home health care; hospital pharmacists, 486  
 hospitals; abxibimab storage, 2026; clinical technicians, 1375; continuity of care, 2500; drug information, 1164; HCFA regulations, 1092; history, 229; HIV infection clinics, 955; HIV infections, 661; HIV prophylaxis, 1921; integrated health care, 665; latex allergies, 1462; latex-free products, 437; medication error monitoring, 1123; outsourcing guidelines, 1611; patient care programs, 453; patient consultation, 1792; radio-pharmaceuticals, 2537; sterile products, 458; technicians' role, 1810; therapeutic substitution, 1382  
 institutional; pharmacokinetics monitoring, 2027  
 integrated health care; ambulatory care, 35  
 long-term-care facilities; Alzheimer's disease, Nov 1 suppl S26  
 mail order; HMOs, 422  
 managed care systems; coronary disease monitoring, 1769; disease management, 1029; drug information, 2007; future, 27; pharmacists' role, 347, 1471  
 military; costs, 1656  
 nursing homes; consultant pharmacists, 1588  
 outpatients; integrated health care, 669; patients' attitudes, 1025  
 patient information; drug-food interactions, 114, 122  
 pharmaceutical care; pharmacist certification, 2444; reprofessionalization, 1302  
 pharmacists; classification, 642; public relations, 1569  
 pharmacokinetics; monitoring, 1726  
 primary care; Public Health Service, 17  
 reimbursement; prospective-pricing system, 1645  
 technicians; administrators' attitudes, 1799; indigent care program, 1293

#### Pharmacist Practice Activity Classification; pharmacists; job description, 642

#### Pharmacists

attitudes; nontraditional Pharm.D., 1281  
 certification; program accreditation, 1856; specialties, 427  
 compounding; laws, 1859  
 consultation; antiemetic therapy, 1903; blood glucose meters, 1877; geriatrics, 768; metered-dose inhalers, 226; privacy telephone, 2245; protease inhibitors, 233; telepharmacy, 1512  
 disease management; certification, 2452; professional fees, 1238  
 dispensing; thalidomide, 1746  
 education, pharmaceutical; alternative medicine, 2525; Healthy People 2000, 477; nontraditional Pharm.D., 530  
 ethics; assisted suicides, 318; conscience clause, 878; patient confidentiality, 895  
 guidelines; ASHP meeting papers, 888  
 home health care; cardiac drugs, 930  
 interventions; ketorolac DUE, 1274; pseudomembranous enterocolitis, 1365  
 labeling; expiration dates, 433  
 managed care systems; challenges, 1492  
 patient care; challenges, 1675  
 pharmaceutical care; assisted suicides, 578; collaborative drug therapy management, 1859  
 prescribing; legal issues, 585  
 professional competence; interdisciplinary team, 1369; reports, 2454  
 professionalism; excellence, 782  
 psychopharmacy; certification examinations, 1594  
 public relations; ethics, 1569  
 reimbursement; prospective-pricing system, 1645  
 role; antithrombotic therapy, 348, 376; assisted suicides, 539; clinical research, 369; drug abuse, 1721; geriatric depression, 2481, 2514; health care, Africa, 1928; hypertension, 382; infection control, 1407; managed care systems, 347, 1471; natural products, 125; patient care, 1850; patient information, 594; pharmacokinetic monitoring, 1726; primary care, 17  
 specialties; reprofessionalization, 1302  
**Pharmacists, clinical, see Clinical pharmacists**  
**Pharmacists, community**  
 consultation; diabetes mellitus, 10  
 interventions; managed care systems, 1141  
 patient care; continuity, 2500  
 pharmaceutical care; Northern Ireland, 2009; services, 635  
 television; pharmaceutical care, 536  
**Pharmacists, consultant; interventions; drug toxicity, 1588**  
**Pharmacists, hospital**  
 administration; globulin immune shortages, 1341

- attitudes; pharmacy technicians, 1810; robotics, 1907
- clinical pharmacy; pharmaceutical care, 486
- communication; National Hospital Pharmacy Week, 843
- consultation; antiretroviral agents, 661; discharge prescriptions, 1389; drug-food interactions, 114, 122; inpatients, 1127
- data collection; robotics, 1907
- drug information; Hong Kong, 1164
- education, pharmaceutical; heparin monitoring, 396; patient consultation, 1792
- errors, medication; monitoring, 946
- ethics; infant formulas, 84; ketorolac repackaging, 388
- guidelines; automated dispensing, 1403
- history; P. Parker, 1344
- information; ASHP services, 31
- integrated health care; economics, 665; hospices, 669
- interventions; allergies, 289; HIV infections, 1151; patient care programs, 453
- job satisfaction; clinical services, 360
- liability; administrators, 1874
- patient care; continuity, 2500; diabetes mellitus, Dec 15 suppl S27
- prescribing; protocols, 1826
- psychopharmacy; certification, 1594
- reports; medication errors, 1123
- role; allergy documentation, 1524; history, 229; HIV prophylaxis, 1921; outpatient clinics, 1763; patient care, 1092
- services; aminoglycoside dosage, 397
- staff development; ASHP Clinical Skills Program, 1760
- substitution; therapeutic, 1382
- workload; clinical technicians, 1375; pharmacy design, 2505
- Pharmacists, institutional**
- administration; layoffs, 2387
- alendronate sodium; esophagitis prophylaxis, 892
- ambulatory care; integrated health care, 35
- antineoplastic agents; nomenclature protocols, 137
- consultation; models, 2485, 2615, 2621
- education, pharmaceutical; nonprescription, 1357
- formularies; managed care systems, 2221
- health maintenance organizations; formulary decisions, 56
- information; ASHP services, 31
- integrated health care; pharmaceutical education, 665
- interventions; Alzheimer's disease, Nov 1 suppl S26; coronary disease, 1769; proton-pump inhibitors, 2249
- managed care systems; changes, 27; role, 441
- nursing homes; DUR, 330
- patient care; Alzheimer's disease, Nov 1 suppl S3
- poison prevention; patient education, 1971
- public relations; ASHP campaigns, 1570
- role; ASHP public relations, 1959; infection control, 1724; managed care systems, 1488, 1492; patient care, 1497; public relations campaign, 1975
- Pharmacoeconomics**
- cost-benefit analysis; abacimab, 2409, Dec 15 suppl S35; antipsychotics, Dec 15 suppl S17; histamine H<sub>2</sub> antagonists, Dec 15 suppl S8; iron dextran, Dec 15 suppl S12; metformin vs. insulin, Dec 15 suppl S24; platelet aggregation inhibitors, Oct 1 suppl S28; rotavirus vaccines, 2226; tacrine, Nov 1 suppl S17; varicella vaccines, Dec 15 suppl S4; weight-based heparin protocols, Dec 15 suppl S29
- formularies; integrated health care, 35
- purchasing; 1998 projections, 127
- Pharmacokinetics**
- albendazole; neurocysticercosis, 598
- anagrelide hydrochloride; review, 1979
- anastrozole; review, 445
- antiretroviral agents; kidney, liver failure, 2528
- atorvastatin calcium; review, 2253
- basiliximab; overview, 1444
- carbamazepine; loading dose, 1134
- cholinesterase inhibitors; Alzheimer's disease, Nov 1 suppl S22
- citalopram hydrobromide; overview, 1963
- daclizumab; overview, 207
- doxetaxel; review, 1777
- dolasetron mesylate; overview, 18
- epitibatide; overview, 1440
- gentamicin; neonates, 2280
- grepafloxacin hydrochloride; overview, 20
- ibutilide fumarate; review, 255
- leflunomide; overview, 2225
- lepirudin; overview, 1444
- mirtazapine; review, 44
- monitoring; blood levels, 1306; pharmaceutical services, 2027; pharmacists' role, 1726
- montelukast sodium; overview, 759
- naratriptan hydrochloride; overview, 638
- olanzapine; review, 1003
- praziquantel; neurocysticercosis, 598
- protease inhibitors; HIV infections, 233
- risedronate sodium; overview, 984
- tirofiban hydrochloride; overview, 1440
- tolcapone; overview, 524
- topiramate; review, 554
- trogilazone; review, 905
- verapamil hydrochloride; circadian rhythm, Nov 15 suppl S17
- warfarin sodium; generic equivalency, 727, 729
- Pharmacopoeial standards**; United States Pharmacopeia; ketorolac repackaging, 388; warfarin, 727
- Pharmacotheapy**; specialties; pharmacist certification, 427
- Pharmacy**
- managed care systems; challenges, 1492
- planning and design; patient consultation, 2245
- practice; Africa, 1928; ASHP standards, 1879; classification, 642; drug abuse, 1721; managed care systems, 347, 1477; nontraditional Pharm.D., 1281; pharmaceutical care, 1675; public relations, 1569; reprofessionalization, 1302
- professions; excellence, 782
- regulations; thalidomide, 1746
- role; managed care, 1482, 1497
- specialties; psychopharmacy, 1594
- state boards; collaborative drug therapy management, 1859; Death with Dignity Act, 318; narrow therapeutic index drugs, 686; telepharmacy, 1512
- students; investigational drug services, 2611
- Pharmacy Abroad**, 173, 1308, 1928
- Pharmacy and therapeutics committees**
- health maintenance organizations; formulary decisions, 56
- hospital pharmacy; drug information centers, 1164
- Pharmacy benefit management companies**
- health-benefit programs; third party, 1663
- pharmacists, institutional; formularies, 2249
- Pharmacy, clinical**, see **Clinical pharmacy**
- Pharmacy, community**
- chain stores; patient confidentiality, 875, 895
- home health care; i.v. injections, 2019
- managed care systems; pharmacists' interventions, 1141
- patient information; continuity of care, 1017
- services; continuity of care, 635, 2500; diabetes mellitus, 10; disease management, 471; pharmaceutical care, 2009
- television; patient information, 536
- Pharmacy, education**, see **Education, pharmaceutical**
- Pharmacy, institutional**
- administration; layoffs, 2387
- costs; 1998 projections, 127
- errors, medication; prevention, 1968
- health maintenance organizations; enrollee benefits, 422; formulary decisions, 56
- integrated health care; ambulatory care, 35
- managed care systems; future, 27; impact, 1490
- nursing homes; DUR, 330
- patient information; continuity of care, 1017
- public relations; ASHP campaigns, 1570
- services; Alzheimer's disease, Nov 1 suppl S26; consultant pharmacists, 1588; coronary disease monitoring, 1769; drug information, 2007; nonprescription drug use, 1357; patient consultation, 2485, 2615, 2621; poison prevention programs, 1971; proton-pump inhibitors, 2249
- Pharmacy, institutional, hospital**
- administration; abacimab storage, 2026; anti-infective prophylaxis, 993; ASHP meeting papers, 888; globulin immune shortages, 1341, 2090; investigational drug services, 2611; latex allergies, 1462; latex-free products, 437; liability, 1874; staff development, 1792; technician certification, 1799
- alternative medicine; protocols, 1266
- aseptic areas; laminar-flow ceiling, 182
- automation; access discrepancies, 1924
- clinical pharmacists; ambulatory care, 68, 1753; outcomes research, 62
- compounding; TPN, 1503
- contract services; ASHP guidelines, 1611; radio-pharmaceuticals, 2537
- decentralized; technicians' role, 1810
- documentation; allergies, 289
- drug distribution systems; personnel survey, 1907
- drug information centers; Hong Kong, 1164; wide-area networks, 1146
- errors, medication; process control charts, 946
- formularies; medicinal plants, 435; platelet aggregation inhibitors, Oct 1 suppl S28
- guidelines; automated dispensing, 1403
- histamine H<sub>2</sub> antagonists; therapeutic substitution, 1382
- history; P. Parker, 1344; U.S., 229
- HIV infections; ambulatory care, 661
- information; ASHP services, 31
- injections; potassium chloride, 1098
- integrated health care; economics, 665; transition, 669
- military; formularies, 1658
- patient information; continuity of care, 1017
- pharmaceutical care; home health care, 486
- planning and design; workload, 2505
- practice; Africa, 1928
- public relations; National Hospital Pharmacy Week, 843
- reimbursement; residencies, 1620
- residencies; funding, 1618; pharmacist-managed protocols, 1826
- services; allergy documentation, 364; aminoglycoside dosage, 397; clinical, 360; continuity of care, 2500; discharge medications consultation, Dec 15 suppl S32; drug-food interactions, 114, 122; heparin monitoring, 396; HIV infection clinics, 955; HIV infections, 1151; HIV prophylaxis, 1921; indigent care program, 1293; inpatient consultation, 1127; medication error monitoring, 1092, 1123; outpatient clinics, 1763; patient care programs, 453; patient satisfaction, 1025; pharmacokinetics monitoring, 2027
- staff development; ASHP Clinical Skills Program, 1760
- sterile products; cleanrooms, 458
- taxes; outpatient prescription dispensing, 772
- technicians; clinical services, 1375
- Pharmacy personnel**, see **Personnel, pharmacy**
- Pharmacy services**, see **Pharmaceutical services**
- Phenytin**; blood levels; methodology, 2392
- Phosphates**; injections; metal contamination, 150
- Photodecomposition**
- amino acids; hydrogen peroxide production, 1288
- cisatracurium besylate; stability, 1037
- nifedipine; powders, 1299
- Physicians**
- alendronate sodium; esophagitis prophylaxis, 892
- attitudes; collaborative drug therapy management, 1859; consultant pharmacists, 1588; pharmacists, 1482; pharmacists' diabetes services, 10
- documentation; allergies, 1524
- education; managed care systems, 523; nonprescription, 1357; therapeutic substitution, 1382
- prescribing; formularies, 1763; HMOs, 2234; patient information, 477; proton-pump inhibitors, 2249; thalidomide, 1746
- role; drug-food interactions, 114
- suicides; assisted, 318, 543, 547, 551, 1235
- Physostigmine**; Alzheimer's disease; overview, Nov 1 suppl S22
- Piactal transfer**; thalidomide; pregnancy, 1746
- Planning and design**
- hospital pharmacy; cleanrooms, 458; workload, 2505
- laminar flow; cleanrooms, 182
- pharmacy; patient consultation, 2245
- Plants**
- herbs; pharmacists' role, 125
- medicinal; formularies, 435; hospital pharmacy protocols, 1266; labeling regulations, 1239; pharmaceutical education, 2525; pharmacists' role, 125; quality control, 2341; USP monographs, 527; USP standards, 2330
- Plastics**
- incompatibilities; granisetron suspensions, 2511
- polyethylene terephthalate glycol; mycophenolate incompatibilities, 926
- polypropylene; adenosine incompatibilities, 466; indomethacin incompatibilities, 154; somatropin incompatibilities, 1508
- polyvinyl chloride; adenosine incompatibilities, 466; solution incompatibilities, 266
- propylene ethylene copolymer; somatropin incompatibilities, 1508
- syringes; ondansetron incompatibilities, 2630
- Platelet aggregation inhibitors**
- abacimab; clinical studies, 2409; cost-benefit analysis, Dec 15 suppl S35; vials, 2026
- aspirin; atrial fibrillation, 376; cerebrovascular disorders, Oct 1 suppl S17; coronary disease, Oct 1

- suppl 58; peripheral vascular diseases, Oct 1 suppl S21
- atherosclerosis; overview, Oct 1 suppl S4
- atrial fibrillation; pharmacists' role, 348
- cardiovascular diseases; review, 2363
- clopidogrel; coronary disease, Oct 1 suppl 58; peripheral vascular diseases, Oct 1 suppl S21
- clopidogrel bisulfate; FDA approvals, 207
- dipyridamole; cerebrovascular disorders, Oct 1 suppl S17; coronary disease, Oct 1 suppl 58
- epifibatide; FDA approvals, 1440
- pharmacoeconomics; formularies, Oct 1 suppl S28
- ticlopidine; cerebrovascular disorders, Oct 1 suppl S17; coronary disease, Oct 1 suppl 58; peripheral vascular diseases, Oct 1 suppl S21
- tirofiban hydrochloride; overview, 1440
- Pleural effusion;** mesalamine; toxicity, 2304
- Pneumococcal infections;** antibiotics; penicillin resistance, 1987
- Pneumococcal vaccines**  
health professions; CDC protocols, 760  
prophylaxis; penicillin resistance, 1987
- Pneumonia;** grepafloxacin hydrochloride; FDA approvals, 20
- Poison control centers;** patient information; pediatric poisoning, 1971
- Poisoning**  
ethylene glycol; antidotes, 110  
pediatrics; prevention programs, 1971
- Poison prevention;** patient education; institutional pharmacy, 1971
- Policies and procedures;** see **Administration**
- Polio vaccines;** protocols; pediatrics, 563
- Polyethylene;** incompatibilities; lorazepam, 2013
- Polyethylene glycol 400;** solubilizing agents; lorazepam injections, 2305
- Polyethylene terephthalate;** containers; oral liquids, 1915; suspensions; stability, 1804
- Polyethylene terephthalate glycol;** incompatibilities; mycophenolate, 926
- Polypropylene**  
incompatibilities; adenosine, 466; indomethacin, 154; somatropin, 1508  
syringes; interferon alfa-2b, 1602
- Polysulfones;** filters; ranitidine adsorption, 840
- Polyvinyl chloride**  
containers; toremide stability, 1042  
incompatibilities; adenosine, 466; carboplatin, 602; cisplatin, 1037; organ preservation solutions, 266
- Postmenopausal;** raloxifene hydrochloride; osteoporosis, 104
- Potassium;** concentration; automated TPN compounding, 1503
- Potassium chloride;** injections; floor stock, 1098; metal contamination, 150
- Powders;** nifedipine; content uniformity, 1299
- Praziquantel;** cysticercosis; comparisons, 598
- Precipitates**  
acyclovir sodium; incompatibilities, 574  
somatropin; incompatibilities, 1508
- Precipitation;** lorazepam; incompatibilities, 2305
- Prenatal**  
concomitant therapy, 163  
pleural effusion; mesalamine toxicity, 2304  
prescribing; emergency room therapy, 1158
- Pregnancy**  
methotrexate; ectopic, 171  
thalidomide; laboratory tests, 1746
- Prescribing**  
clinical pharmacists; ambulatory care, 1753; VA centers, 68  
pharmacists; legal issues, 585  
pharmacists; hospital; protocols, 1826; telephone services, 453  
physicians; HMOs, 2234; formularies, 1763; H, antagonist substitution, 1382; nonprescription, 1357; proton-pump inhibitors, 2249; thalidomide, 1746
- Prescriptions**  
advertising; direct to consumer, 880, 2344  
antipsychotic agents, Dec 15 suppl S19  
benzodiazepines; New York laws, 2074  
controlled substances; New York laws, 2074  
databases; coronary disease monitoring, 1769  
discharge; continuity of care, 2500; patients' comprehension, 1389; pharmacists' consultation, Dec 15 suppl S32  
dispensing; hospital pharmacy taxes, 772; pharmacy design, 2505  
drugs; direct-to-consumer advertising, 594; HMO costs, 422; nursing homes, 330  
drug use; HMO nonprescription programs, 1357
- ketorolac tromethamine; pharmacists' interventions, 1274  
mail order; stability, 1554  
managed care systems; pharmacists' interventions, 1141  
patient information; leaflets, 1552  
pharmacy, community; pharmaceutical care, 2009  
psychotherapeutic agents; indigent care program, 1293  
quantity; dextrose test strips, 2509  
records; patient confidentiality, 895  
refills; ambulatory care, 62, 68; HIV infections clinics, 955; outpatient services, 1763; patient confidentiality, 875; proton-pump inhibitors, 2249
- Preservatives;** metacresol; somatropin injections, 1508
- Presidential Advisory Commission on Consumer Protection and Quality in the Health Care Industry;** guidelines; health care quality, 1669
- Pricing**  
drugs; prospective, 1850  
warfarin sodium; generic equivalency, 729
- Primary care**  
anticoagulants; pharmacists' training, 1033  
clinical pharmacists; outcomes research, 62; VA centers, 68  
pharmacists; role, 17
- Primers,** 471, 930, 2397
- Product withdrawal**  
bromfenac sodium; liver failure, 1548  
mibefradil dihydrochloride; interactions, 1445
- Professional advancement;** pharmacists; priorities, 782
- Professional competence**  
clinical pharmacists; anticoagulation clinics, 1033  
health professions; formulary system development, 1308; Pew Health Professions Commission, 2454  
pharmacists; interdisciplinary team, 1369; nontraditional Pharm.D., 1281  
pharmacists; hospital; patient consultation, 1792
- Professional fees;** disease management; Medicaid reimbursement, 1238
- Professionalism**  
pharmacists; excellence, 782; public relations, 1569; reprofessionalization, 1302  
pharmacists; institutional; caregivers, Nov 1 suppl S26  
students; investigational drug services, 2611
- Professions**  
hospital pharmacy; ASHP public relations, 1570  
pharmacy; public relations, 1569
- Profits**  
health-benefit programs; managed care principles, 1490  
health care; pharmacist layoffs, 2387  
home health care; U.S. economics, 2019  
hospital pharmacy; taxes, 772  
prescription drugs; direct-to-consumer advertising, 594
- Propellants;** inhalers; metered dose, 226, 276
- Propylene ethylene copolymer;** incompatibilities; somatropin, 1508
- Prostaglandins;** glaucoma; costs, 272
- Protocols**  
algorithms; phenytoin blood levels, 2392  
alternative medicine; hospital pharmacy, 1266  
American Society of Health-System Pharmacists; antithrombotic therapy, 376  
aminoglycosides; extended-interval dosage, 397  
antidepressants; ASHP, 2514  
antineoplastic agents; compassionate-use protocols, 651; medication orders, 137  
antipsychotic agents; prescription cap, Dec 15 suppl S19  
antiretroviral agents; prophylaxis, 1921  
blood levels; monitoring, 1306  
Centers for Disease Control and Prevention; health professions' immunization, 760  
drugs; pharmacist managed, 1826; pharmacokinetics monitoring, 2027  
drugs, investigational; hospital pharmacy rotations, 2611  
enterocolitis; ASHP, 1407  
gentamicin; neonates, 2280  
health maintenance organizations; physician prescribing, 2234  
heparin; dosage, 159; weight-based, Dec 15 suppl S29  
heparin sodium; laboratory tests, 2002  
hospitals; outpatient services, 669  
hypertension; therapy, 382  
Institute of Medicine; vitamins, 981
- iron dextran; cost-benefit analysis, Dec 15 suppl S12
- medicinal plants; formularies, 435
- methadone; NIH, 208
- metronidazole; pseudomembranous enterocolitis, 1365
- vaccines; pediatrics, 563
- vancomycin; pseudomembranous enterocolitis, 1365
- Pseudomonas aeruginosa**  
ceftazidime; MIC, 145  
contamination; toptecan, 1584
- Psoriasis;** cyclosporine; blood levels, 1598
- Psychiatric facilities;** charity; indigent care program, 1293
- Psychology;** addicts; methadone therapy, 208
- Psychopharmacology**  
pharmacists; specialties, 1594  
specialties; pharmacist certification, 427
- Psychotherapeutic agents**  
Alzheimer's disease; pharmaceutical care, Nov 1 suppl S26  
mental disorders; future, 83  
prescriptions; indigent care program, 1293
- Psychotic disorders;** olanzapine; review, 1003
- Public Citizen Health Research Group;** patient information; FDA labeling regulations, 1552
- Publications**  
*American Journal of Health-System Pharmacy;* content selection, 1773  
*Drug Information Handbook;* cisapride-antifungals interactions, 2418  
Joint Commission on Accreditation of Healthcare Organizations; Sentinel Event Alert, 764  
meetings; ASHP guidelines, 888
- Public health;** depression; pharmacists' role, 2514
- Public relations**  
American Society of Health-System Pharmacists; campaigns, 1570; pharmacists' role, 1959, 1975  
hospital pharmacy; National Hospital Pharmacy Week, 843  
pharmacy; ethics, 1569  
pharmacy; institutional; poison prevention programs, 1971
- Pulmonary embolism;** tamoxifen; toxicity, 978
- Purchasing**  
drugs; latex free, 437  
group; drug cost projections, 127
- Purity**  
dietary supplements; quality control, 2341; USP standards, 2330  
medicinal plants; USP standards, 2330
- PVC;** see **Polyvinyl chloride**
- Pyrazinamide;** stability; suspensions, 1804
- Pyridine;** decomposition products; ceftazidime incompatibilities, 683

## Q

## Quality assurance

- documentation; anti-infective prophylaxis, 993  
health care; consumers' influence, 876; measurement, 1669; performance measurement, 1348; pharmacists' role, 1123  
home health care; JCAHO standards, 2299  
hospital pharmacy; medication errors, 946; outsourcing guidelines, 1611; patient consultation, 1792  
hospitals; medication errors, 1092; sentinel-event policies, 1112  
managed care systems; customer satisfaction, 986; NCCA standards, 2221  
National Committee for Quality Assurance; managed care systems, 2351  
parenteral nutrition; automated compounding, 1503  
patient care; diabetes mellitus, Dec 15 suppl S27; integrated health care, 665; standards, 585  
pharmacists; medication errors, 347  
pharmacists, institutional; managed care systems, 441  
pharmacy, institutional; pharmacokinetics services, 2027  
warfarin sodium; generic equivalency, 727
- Quality control;** see **Control, quality**
- Quality improvement;** see **Quality assurance**
- Quality of life**  
antineoplastic agents; outpatient survey, 1903  
diabetes mellitus; pharmaceutical care, 10  
patients; pharmacists' consultation, 2615
- Questions and Answers,** 433, 651, 888, 1112, 1760, 2472

Accessing investigational anticancer agents outside of clinical trials, 651  
 Expiration and beyond-use dates, 433  
 FDA's Rx for keeping educational programs free of industry bias, 2472  
 The Joint Commission's revised sentinel-event policy, 1112  
 Learning how to use ASHP's Clinical Skills Program, 1760  
 Presenting new practice ideas at ASHP meetings, 888  
**Quinidine sulfate**; stability; suspensions, 1804  
**Quinolones**; gatifloxacin hydrochloride; FDA approvals, 20

## R

**Race**; patients; cardiovascular circadian rhythm, Nov 15 suppl S5; drug-related injuries, 1158  
**Radiation**; toxicity; diarrhea, 1573  
**Radio**; public relations; ASHP, 1959  
**Radiopharmaceuticals**; contract services; hospital pharmacy, 2537  
**Radiopharmacy**; contract services; hospital pharmacy, 2537  
**Raloxifene hydrochloride**; approvals; FDA, 104  
**Ranitidine**  
     substitution; therapeutic, 1382  
     ulcers; NSAIDs toxicity, 883  
**Ranitidine hydrochloride**; adsorption; filters, 840  
**Rational Pharmaceutical Management Russia Project**; pharmacy system; development, 1308  
**Rational therapy**  
     antibiotics; pseudomembranous enterocolitis, 1365  
     anti-infective agents; infection control, 1724  
     drugs; blood level monitoring, 1306  
     drug use; geriatrics, 1654  
     ketorolac tromethamine; pharmacists' interventions, 1274  
     metronidazole; pseudomembranous enterocolitis, 1407  
     nursing homes; reports, 330  
     prescribing; physicians, 2234  
     psychotherapeutic agents; Alzheimer's disease, Nov 1 suppl S26  
     urokinase; arterial occlusive diseases, 2414  
**Reconstitution**, see **Drugs**; **reconstitution**  
**Records**  
     anti-infective agents; surgical prophylaxis, 993  
     medical; allergy documentation, 289; patient confidentiality, 895; pharmacists' role, 878; pharmacy referral forms, 2500  
     prescriptions; patient confidentiality, 875  
**Reference books**  
     drug information; hospital pharmacy, 1164  
     *Drug Information Handbook*; cisapride-antifungal interactions, 2418  
**References**; drug information; formulary decisions, 50  
**Reflections**, 176, 1825  
**Regulations**  
     amifostine; approvals, 1827  
     antineoplastic agents; compassionate-use protocols, 651  
     clinical studies; conflict of interest, 642  
     dietary supplements; labeling regulations, 1239  
     drugs, investigational; hospital pharmacy rotations, 2611  
     Food and Drug Administration; compounding, 1859; drugs, unlabeled use, 1449  
     generic drugs; narrow therapeutic index, 686  
     Health Care Financing Administration; hospitals, 1092; medication errors, 1123  
     hospital pharmacy; history, 229; outsourcing guidelines, 1611; pharmacists liability, 1874; residency reimbursement, 1620  
     industry, pharmaceutical; educational programs, 426, 2472; immune globulin imports, 2228  
     Internal Revenue Service; hospital pharmacy taxes, 772  
     labeling; beyond-use vs. expiration dates, 433; error prevention, 1968  
     latex; labeling, 2059  
     Medicaid; disease management, 1238, 2452  
     methadone; narcotics dependence, 208  
     patient information; FDA, 1552  
     pharmacists; APhA policies, 878; collaborative drug therapy management, 1859  
     pharmacists, institutional; patient consultation, 2485

propellants; metered-dose inhalers, 226, 276  
 psychotherapeutic agents; rational therapy, Nov 1 suppl S26  
 radiopharmaceuticals; hospital pharmacy, 2537  
 suicides; physician assisted, 543  
 thalidomide; prescribing, 1746

## Reimbursement

antiretroviral agents; HIV infections, 661  
 hospital pharmacy; residencies, 1620; residency funding, 1618  
 Medicaid; disease management, 2452; pharmaceutical services, 1238  
 Medicare; prospective-pricing system, 1645  
 pharmaceutical care; community pharmacists, 10;  
 community pharmacy, 635  
 pharmaceutical services; managed care systems, 523

**Religion**; suicides; physician assisted, 551

## Replacement solutions

calcium gluconate; metal contamination, 150  
 potassium chloride; metal contamination, 150  
 prescribing; emergency room therapy, 1158  
 sodium chloride; metal contamination, 150

## Reports

American Society of Health-System Pharmacists; managed care conference, 1492; strategic planning, 1717; Task Force on Science, 2519  
 Department of Health and Human Services; nursing homes, 330  
 drugs, adverse reactions; FDA, 477; hospital pharmacy, 1164  
 errors, medication; JCAHO Sentinel Event Alert, 764; pharmacists' role, 1123  
 hospitals; sentinel-event policies, 1112  
 integrated health care; statistics, 1450  
 Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure; hypertension protocols, 382  
 managed care systems; NCQA standards, 2221  
 palliative care; NIH, 640  
 Pew Health Professions Commission; health profession competence, 2454

## Research

Alzheimer's disease; overview, Nov 1 suppl S5  
 clinical studies; ASHP guidelines, 369  
 palliative care; NIH reports, 640

**Residencies**, see **Education**, **pharmaceutical**; **residencies**

## Resistance

anti-infective agents; otitis media, 1881  
 antiretroviral agents; HIV infections, 1817  
 delavirdine mesylate; HIV infections, 283  
 fluconazole; *C. albicans*, 279  
 nevirapine; HIV infections, 283  
 penicillin; *S. pneumoniae*, 1987  
 protease inhibitors; HIV, 1728; review, 233  
 vancomycin; *Enterococcus* species, 1407; pseudomembranous enterocolitis, 1365

**Respiratory syncytial virus infections**; palivizumab; FDA approvals, 1654

**Riboflavin**; concentration; amino acid stability, 1288

## Rifampin

otitis media; review, 1881  
 stability; suspensions, 1804

**Ringer's injection, lactated**; incompatibilities; adenosine, 466

**Risedronate sodium**; approvals; FDA, 984

**Risk management**; pharmacists; expanded role, 585

**Risperidone**; schizophrenia; cost comparisons, Dec 15 suppl S17

**Ritonavir**; HIV infections; review, 233

**Rituximab**; approvals; FDA, 110

**Rivastigmine**; Alzheimer's disease; overview, Nov 1 suppl S22

**Rizatriptan benzoate**; approvals; FDA, 1656

**Robotics**; hospital pharmacy; personnel survey, 1907

**Roche Laboratories**; mibefradil; interactions warnings, 210

**Rotavirus vaccines**; approvals; FDA, 2226

**Russia**; formulary system; development, 1308

## S

**Sacrosidase**; approvals; FDA, 1102

## Safety

guidelines; automated distribution systems, 1403

radiopharmaceuticals; contract services, 2537

**Salaries**; pharmacists, institutional; layoffs, 2387

## Sales

drugs; 1997, 880

hospital pharmacy; outpatient prescriptions, 772  
 intravenous therapy; home health care, 2019

**Samples**; nutrition; infant formulas, 84

**Saquinavir**; toxicity; paranoid disorders, 2016

**Saquinavir mesylate**; HIV infections; review, 233

## Schizophrenia

fluphenazine decanoate; cost comparisons, Dec 15 suppl S17

haloperidol decanoate; cost comparisons, Dec 15 suppl S17

olanzapine; review, 1003

risperidone; cost comparisons, Dec 15 suppl S17

**Schools**; pharmacy; drug information centers, 1146

**Science**; reports; ASHP Task Force, 2519

**Selegiline**; Alzheimer's disease; overview, Nov 1 suppl S11

## Serotonin agonists

natriatriptan hydrochloride; FDA approvals, 638

rizatriptan benzoate; FDA approvals, 1656

zolmitriptan; FDA approvals, 110

## Serums

albumin human; interferon alfa-2b stability, 1602

globulin immune; shortages, 1341, 2090, 2228

**Sex**; patients; cardiovascular circadian rhythm, Nov 15 suppl S5; drug-related injuries, 1158

**Sexual dysfunction**; serotonin-reuptake inhibitors; toxicity, 1167

**Sibrafiban**; cardiovascular diseases; review, 2363

**Sickle cell trait**; hydroxyurea; FDA approvals, 875

## Sildenafil citrate

approvals; FDA, 981

toxicity; cardiovascular diseases, 2080

## Simple syrup

**Site of action**; antibiotics; pneumococcal infections, 1987

**Skeletal muscle relaxants**; cisatracurium besylate; incompatibilities, 1037

**Skilled-nursing facilities**; reimbursement; prospective-pricing system, 1645

## Smoking

cessation; nicotine dosage, 1413

cigarettes; Healthy People 2000, 477

**Smoking cessation**; disease management; guidelines, 1943

## Sociology

addicts; methadone therapy, 208

drug abuse; pharmacists' role, 1721

low income; antiretrovirals, 661; drug dispensing, 1445; prescription-assistance program, 1293

managed care systems; institutional pharmacy, 27

pharmacy; reprofessionalization, 1302

**Sodium**; concentration; automated TPN compounding, 1503

## Sodium chloride

catheters; comparisons, 570

diluents; acyclovir, 574; lorazepam incompatibilities, 2013

incompatibilities; adenosine, 466, 1161; ceftazidime, 683; cisatracurium, 1037

injections; metal contamination, 150

**Sodium metabisulfite**; concentration; amino acid stability, 1288

**Solubility**; lorazepam; injections, 2305

**Solubilizing agents**; polyethylene glycol 400; lorazepam incompatibilities, 2305

## Solutions, ophthalmic

anti-infective agents; compounding, 463

vancomycin hydrochloride; stability, 1386

## Somatropin

administration systems; reconstitution, 134

incompatibilities; plastic syringes, 1508

**Spain**; amifostine; approvals, 1827

## Specialties

pharmacists; reprofessionalization, 1302

pharmacy; certification, 427

psychopharmacology; certification examinations, 1594

**Spectrum microbial**; ceftazidime; infusion pumps, 145

**Sphygmomanometers**; blood pressure; monitoring, Nov 15 suppl S12

## Stability

acyclovir sodium; incompatibilities, 574

adenosine; decomposition, 1161; incompatibilities, 466

alprazolam; oral liquids, 1915

chloroquine phosphate; oral liquids, 1915

amino acids; photodecomposition, 1288

anti-infective agents; ophthalmic solutions, 463

antineoplastic agents; oral liquids, 735

carboplatin; injections, 602

ceftazidime; decomposition products, 683; infusion pumps, 145



cisapride; oral liquids, 1915  
 cisatracurium besylate; incompatibilities, 1037  
 dietary supplements; beyond-use vs. expiration dates, 433  
 droperidol; incompatibilities, 2630  
 drugs; *American Journal of Health-System Pharmacy*, 1773; labeling, 433  
 enalapril maleate; oral liquids, 1915; suspensions, 1155  
 enoxaparin sodium; syringes, 1296  
 fentanyl citrate; parenteral nutrition, 1194  
 granisetron hydrochloride; suspensions, 2511  
 hydralazine hydrochloride; oral liquids, 1915  
 indomethacin sodium; incompatibilities, 154  
 interferon alfa-2b; syringes, 1602  
 lorazepam; containers, diluents, 2013; precipitation, 2305  
 mycophenolate mofetil; oral suspensions, 926  
 nifedipine; powders, 1299  
 ondansetron hydrochloride; incompatibilities, 2630  
 prescription drugs; USP standards, 1554  
 ranitidine hydrochloride; filter adsorption, 840  
 solutions; organ preservation solutions, 266  
 somatropin; plastic syringes, 1508  
 suspensions; compounding, 1804  
 topotecan hydrochloride; injections, 1584  
 torsemide; injections, 1042  
 vancomycin hydrochloride; ophthalmic solutions, 1386

**Staff development**  
 hospital pharmacy; ASHP Clinical Skills Program, 1760; cleanrooms, 458; integrated health care, 669  
 patient information; pharmacists' consultation, 1792  
 pharmacists; community; pharmaceutical care, 635  
 technicians; clinical services, 1375

**Standards**  
 accreditation; pharmacist certification programs, 1856  
 American Society of Health-System Pharmacists; *Healthy People 2000*, 477; ketorolac repackaging, 388; pharmacy practice, 1879  
 antineoplastic agents; medication orders, 137  
 cleanrooms; hospital pharmacy, 458  
 dietary supplements; quality control, 2330  
 home health care; quality assurance, 2299  
 hospitals; accreditation, 173  
 medicinal plants; quality control, 2330  
 National Committee for Quality Assurance; managed care accreditation, 2221; managed care systems, 1351  
 organizations; performance measurement, 1348  
 packaging; error prevention, 1968  
 pharmacy; Africa, 1928  
 quality assurance; patient care, 585  
 United States Pharmacopeia; prescription drug storage, 1554

**Staphylococcus aureus**; contamination; topotecan, 1584

**States**; laws; pharmacists' prescribing, 585; physician-assisted suicide, 543

**Statistics**; integrated health care; survey, 1450

**Sterile products**  
 compounding; laminar-flow ceiling, 182; latex allergies, 1462  
 hospital pharmacy; cleanrooms, 458

**Sterility**  
 enoxaparin sodium; syringes, 1296  
 syringes; disposable, 956

**Steroids, cortico-**  
 dexamethasone sodium phosphate; incompatibilities, 266  
 prednisone; emergency room prescribing, 1158; pleural effusion, 2304

**Storage**  
 abxiximab; vials, 2026  
 acyclovir sodium; incompatibilities, 574  
 adenosine; decomposition, 1161; incompatibilities, 466  
 alprazolam; stability, 1915  
 anti-infective agents; ophthalmic solutions, 463  
 antiretroviral agents; HIV infections, 1817  
 carboplatin; injections, 602  
 ceftazidime; stability, 683  
 chloroquine phosphate; stability, 1915  
 cisapride; stability, 1915  
 cisatracurium besylate; incompatibilities, 1037  
 dietary supplements; beyond-use vs. expiration dates, 433  
 disinfectants; microbiological contamination, 2534  
 droperidol; incompatibilities, 2630

drug distribution systems; automation guidelines, 1403  
 drugs; error prevention, 1968; stability, 433  
 enalapril maleate; stability, 1915; suspensions, 1155  
 enoxaparin sodium; syringes, 1296  
 granisetron hydrochloride; suspensions, 2511  
 hydralazine hydrochloride; stability, 1915  
 indomethacin sodium; incompatibilities, 154  
 interferon alfa-2b; syringes, 1602  
 lorazepam; containers, diluents, 2013  
 mycophenolate mofetil; oral suspensions, 926  
 nifedipine; powders, 1299  
 ondansetron hydrochloride; incompatibilities, 2630  
 prescription drugs; USP standards, 1554  
 somatropin; stability, 1508  
 suspensions; stability, 1804  
 topotecan hydrochloride; stability, 1584  
 torsemide; injections, 1042  
 vancomycin hydrochloride; stability, 1386

**Strategic planning**  
 American Society of Health-System Pharmacists; reports, 1717; Task Force on Science, 2519  
 health care; pharmacists' role, 441

**Streptococcus pneumoniae**; resistance; anti-infective agents, 1881; penicillin, 1987

**Streptokinase**; thrombophlebitis; comparisons, 1995

**Substitution**  
 drugs; ethics, 875  
 generic drugs; narrow therapeutic index, 686

**Sucrose**  
 incompatibilities; granisetron suspensions, 2511  
 vehicles; itraconazole suspensions, 261

**Suicides**  
 ethics; assisted, 539; physician assisted, 551, 578  
 laws; assisted, 318; physician assisted, 1235  
 physicians; assisted, 543, 547

**Sulfamethoxazole**; combination, trimethoprim; resistance, 1881

**Sulfonylureas**; diabetes mellitus; combined therapy, 905

**Surgery**  
 antiarrhythmic agents; neoplasms, 1573  
 anti-infective agents; documentation, 993  
 flurbiprofen; cataract, Dec 15 suppl 523  
 platelet aggregation inhibitors; cardiovascular diseases, 2363  
 surgical wound infection; hospitals, 777

**Surgical supplies**; purchasing; latex-free products, 437

**Surgical wound infection**; inpatients; rates, 777

**Suspending agents**  
 compounding; stability, 1804  
 incompatibilities; enalapril, 1155  
 methylcellulose; granisetron suspensions, 2511

**Suspensions**  
 carbamazepine; loading dose, 1134  
 compounding; stability, 1804  
 enalapril maleate; stability, 1155  
 granisetron hydrochloride; stability, 2511  
 itraconazole; compounding, 261  
 mycophenolate mofetil; stability, 926

**Sustained-action medications**  
 nifedipine; powder content uniformity, 1299  
 verapamil hydrochloride; cardiovascular diseases, Nov 15 suppl 517

**Sweetening agents**  
 compounding; stability, 1804  
 incompatibilities; enalapril, 1155; granisetron suspensions, 2511  
 syrups; oral liquid compounding, 1915

**Sympatholytic agents**  
 $\beta$ -blockers; congestive heart failure, 676; glaucoma, 272; hypertension protocols, 382; mibefradil interactions, 210  
 yohimbine; SSRI toxicity, 1167

**Symphathomimetic agents**; glaucoma; costs, 272

**Symphylum species**; monographs; USP, 527

**Syringes**  
 contamination; microbiological, 956  
 enoxaparin sodium; stability, 1296  
 oral; antineoplastic agents, 735  
 plastics; cisatracurium incompatibilities, 1037; ondansetron incompatibilities, 2630  
 polyethylene; lorazepam incompatibilities, 2013  
 polypropylene; adenosine incompatibilities, 466; indomethacin incompatibilities, 154; interferon alfa-2b stability, 1602; somatropin incompatibilities, 1508  
 propylene ethylene copolymer; somatropin incompatibilities, 1508  
 somatropin; administration systems, 734

## Syrups

cherry syrup; mycophenolate suspensions, 926  
 sweetening agents; oral liquid compounding, 1915

## T

### Tablets

antineoplastic agents; oral liquid compounding, 735  
 carbamazepine; loading dose, 1134  
 compounding; suspensions, 1804  
 drugs; glaucoma, 272  
 enalapril maleate; compounding, 1155  
 granisetron hydrochloride; suspension compounding, 2511  
 nifedipine; powder content uniformity, 1299  
 warfarin sodium; generic equivalency, 727, 729

**Tacrine**; Alzheimer's disease; cost-benefit analysis, Nov 1 suppl 517; overview, Nov 1 suppl 522

**Tacrolimus**; interactions; mibefradil, 210

**Tamoxifen**; breast neoplasms; overview, 2326; prophylaxis, 978

**Taxes**; hospital pharmacy; outpatient prescription dispensing, 772

**Taxonomy**; pharmacy; practice activity classification, 642

### Team

ambulatory care; pharmacists, 35  
 health care; interdisciplinary, 1369  
 health professions; HMOs, 2234  
 hospitals; allergy documentation, 364; patient information, 114; pharmacy technicians, 1810  
 patient care; telephone services, 453  
 primary care; pharmacists, 17

**Technicians, pharmacy**; see **Personnel, pharmacy; supportive**

### Technology

automation; pharmacy practice, 782  
 information; uniformity, 1850  
 pharmacy; institutional; managed care systems, 27  
 telemedicine; pharmaceutical services, 1512

**Telemedicine**; technology; pharmaceutical services, 1512

**Telepharmacy**; pharmaceutical services; ambulatory care, 1512

**Telephone**  
 patient information; pharmaceutical services, 453  
 pharmaceutical services; patient consultation, 2245; patient satisfaction, 1025

**Television**; pharmacy; community; patient information, 536

**Temperature**

acyclovir sodium; incompatibilities, 574  
 adenosine; stability, 466; decomposition, 1161  
 alprazolam; stability, 1915  
 anti-infective agents; ophthalmic solutions, 463  
 carboplatin; stability, 602  
 ceftazidime; decomposition products, 683  
 chloroquine phosphate; stability, 1915  
 cisapride; stability, 1915  
 cisatracurium besylate; incompatibilities, 1037  
 enalapril maleate; stability, 1915; suspensions, 1155  
 enoxaparin sodium; stability, 1296  
 granisetron hydrochloride; storage, 2511  
 hydralazine hydrochloride; stability, 1915  
 indomethacin sodium; incompatibilities, 154  
 injections; flow-restricting devices, 351  
 mycophenolate mofetil; oral suspensions, 926  
 nicotine; absorption, 1413  
 nifedipine; powder content uniformity, 1299  
 ondansetron hydrochloride; stability, 2630  
 organ preservation solutions; storage, 266  
 prescription drugs; USP standards, 1554  
 topotecan hydrochloride; stability, 1584  
 vancomycin hydrochloride; stability, 1386

**Teratogenicity**; thalidomide; pregnancy, 1746

**Tests, laboratory**

blood levels; sampling time, 1306  
 heparin sodium; blood levels, 2002  
 parenteral nutrition; quality assurance, 1503  
 pregnancy; thalidomide regulations, 1746

**Tetracycline hydrochloride**; stability; suspensions, 1804

**Tetracyclines**; tetracycline hydrochloride; suspensions, 1804

**Texas**; education, pharmaceutical; nontraditional Pharm.D., 530

**Thalidomide**; approvals; FDA, 1746

**Therapy Consultation**, 171, 598, 1167, 1516

**Thrombocytopenia**  
 lepirudin; FDA approvals, 1444

oprelvekin; FDA approvals, 107  
**Thrombocytosis**; anagrelide hydrochloride; review, 1979  
**Thrombolytic agents**  
 coronary disease; comparisons, 2402  
 streptokinase; thrombophlebitis, 1995  
 urokinase; arterial occlusive diseases, 2414  
**Thrombophlebitis**  
 heparin; comparisons, 1995  
 streptokinase; comparisons, 1995  
**Thrombosis**  
 disease management; guidelines, 1943  
 tamoxifen; toxicity, 978  
**Ticlopidine**  
 cerebrovascular disorders; overview, Oct 1 suppl S17  
 coronary disease; review, Oct 1 suppl S8  
 peripheral vascular diseases; overview, Oct 1 suppl S21  
**Time studies**  
 administration systems; somatropin reconstitution, 734  
 hospital pharmacy; planning and design, 2505  
**Tirofiban**; cardiovascular diseases; review, 2363  
**Tirofiban hydrochloride**; approvals; FDA, 1440  
**Tobramycin**; dosage schedules; extended interval, 397  
**Tobramycin sulfate**; incompatibilities; artificial tears, 463  
**Tolcapone**; approvals; FDA, 524  
**Topical preparations**; flurbiprofen; cost-benefit analysis, Dec 15 suppl S23  
**Topiramate**; epilepsy; review, 554  
**Topotecan hydrochloride**; contamination; microbiological, 1584  
**Torsades de pointes**; cisapride; interactions, 2418  
**Torsemide**; incompatibilities; dextrose, 1042  
**Toxicity**  
 see also **Drugs, adverse reactions**  
 acetaminophen; overdose, 1516  
 albuterol; overview, 598  
 albumin; dilutions, 2078  
 aldesleukin; overview, 1520  
 alendronate sodium; esophagitis, 892  
 alternative medicine; protocols, 1266  
 amifostine; clinical studies, 1827  
 aminoglycosides; extended-interval dosage, 397  
 amphotericin B; lipid formulations, 2078  
 anagrelide hydrochloride; review, 1979  
 anastrozole; review, 445  
 antibiotics; pseudomembranous enterocolitis, 1365, 1407  
 antidepressants; geriatrics, 2481, 2514  
 antiarrhythmic agents; review, 1573  
 antineoplastic agents; anemia, 1898; antiemetic prophylaxis, 1269; dolasetron therapy, 18; outpatient survey, 1903  
 antiretroviral agents; patient compliance, 1817; patient consultation, 661; pharmacists' consultation, 955  
 aspirin; overview, Oct 1 suppl S17  
 astemizole; labeling changes, 526  
 atorvastatin calcium; review, 2253  
 basiliximab; overview, 1444  
 bromfenac sodium; labeling changes, 526; liver failure, 1548  
 carbamazepine; loading dose, 1134  
 cardiac drugs; home health care, 930  
 carvedilol; clinical pharmacy services, 1626  
 cholinesterase inhibitors; Alzheimer's disease, Nov 1 suppl S22  
 cisapride; antifungal interaction, 2418  
 citalopram hydrobromide; overview, 1963  
 daunorubicin citrate; lipid formulations, 2078  
 delavirdine mesylate; overview, 283  
 dietary supplements, 2330  
 diphtheria and tetanus toxoids and pertussis vaccines; pediatrics, 563  
 dipyrindamole; overview, Oct 1 suppl S17  
 docetaxel; review, 1777  
 dolasetron mesylate; overview, 18  
 doxorubicin hydrochloride; lipid formulations, 2078  
 drug interactions; food, 114, 122  
 drugs; Alzheimer's disease, Nov 1 suppl S3; clinical pharmacists' monitoring, 1753; costs, 1588; emergency room visits, 1158; pharmaceutical care, 62; pharmacists' role, 1850; sentinel-event policies, 1112  
 efavirenz; overview, 2458  
 eptifibatide; overview, 1440  
 ethylene glycol; antidotes, 110  
 fomepizole; overview, 110  
 gene therapy; review, 899

grepafloxacin hydrochloride; overview, 20  
 heparin; comparisons, 1995; hemorrhage, Dec 15 suppl S29; thrombocytopenia, 1444  
 heparins; interactions, 210  
 heparin sodium; i.v. catheters, 570  
 HMG-CoA reductase inhibitors; costs, 995  
 hydroxyurea; overview, 875  
 ibutilide fumarate; review, 255  
 infliximab; overview, 2073  
 imipramine; dosage, 1552  
 juices; grapefruit, 1581  
 ketorolac tromethamine; pharmacists' DUE interventions, 1274; repackaging, 388  
 leflunomide; overview, 2225  
 lepirudin; overview, 1444  
 medicinal plants, 2330  
 mesalamine; pleural effusion, 2304  
 mibefradil; interactions, 210  
 mibefradil dihydrochloride; product withdrawal, 1445  
 mirtazapine; review, 44  
 misoprostol; clinical studies, 883  
 montelukast sodium; overview, 759  
 morphine; pancreatitis pain, 480  
 nevirapine; overview, 283  
 nicotine; transdermal patches, 1413  
 nomenclature; ASHP draft, 165  
 nonsteroidal anti-inflammatory agents, 2289  
 olanzapine; review, 1003  
 omeprazole; clinical studies, 883  
 oprelvekin; overview, 107  
 palivizumab; overview, 1654  
 parasympathomimetic agents; overview, Nov 1 suppl S11  
 parenteral nutrition; metal contamination, 150  
 platelet aggregation inhibitors; review, Oct 1 suppl S8  
 potassium chloride; injections, 1098  
 praziquantel; overview, 598  
 prescriptions; patients' comprehension, 1389  
 protease inhibitors; review, 233  
 proton-pump inhibitors; review, 2268  
 psychotherapeutic agents; Alzheimer's patients, Nov 1 suppl S26  
 raloxifene hydrochloride; overview, 104  
 ranitidine; clinical studies, 883  
 risenedronate sodium; overview, 984  
 rituximab; overview, 110  
 rizatriptan benzoate; overview, 1656  
 rotavirus vaccines; overview, 2226  
 saquinavir; paranoid disorders, 2016  
 serotonin-reuptake inhibitors; sexual dysfunction, 1167  
 sildenafil citrate; cardiovascular diseases, 2080; overview, 981  
 sodium chloride; i.v. catheters, 570  
 streptokinase; comparisons, 1995  
 tamoxifen; breast cancer prophylaxis, 978  
 thalidomide; overview, 1746  
 ticlopidine; overview, Oct 1 suppl S17  
 tirofiban hydrochloride; overview, 1440  
 tolcapone; overview, 524  
 topiramate; review, 554  
 troglitazone; review, 905  
 urokinase; overview, 2414  
 vaccines; pediatrics, 563  
 warfarin; grapefruit juice interactions, 1581  
 zolmitriptan; overview, 110  
**Toxicity, environmental**  
 antineoplastic agents; health professions, 735  
 chlorofluorocarbons; metered-dose inhalers, 276  
 HIV infections; occupational exposure, 1921  
 injections; syringe barrels, 956  
**Transplantation**  
 bone marrow; diarrhea-related infections, 1573  
 organs; preservation solutions, 266  
 renal; basiliximab, 1444; daclizumab, 207  
**Transportation**; prescription drugs; USP standards, 1554  
**Trastuzumab**; breast neoplasms; overview, 2326  
**Trichlorfon**; Alzheimer's disease; overview, Nov 1 suppl S22  
**Trimethoprim**; combination, sulfamethoxazole; resistance, 1881  
**Troglitazone**  
 diabetes mellitus; review, 905  
 interactions; warfarin, 1071  
**Turbidity**; somatropin; incompatibilities, 1508

## U

**Ulcers**  
 cimetidine; cost-benefit analysis, Dec 15 suppl S8  
 disease management; guidelines, 1943  
 famotidine; cost-benefit analysis, Dec 15 suppl S8  
 misoprostol; NSAIDs toxicity, 883  
 nonsteroidal anti-inflammatory agents; toxicity, 883  
 omeprazole; NSAIDs toxicity, 883  
 ranitidine; NSAIDs toxicity, 883  
**United States**  
 data collection; drug-related injuries, 1158  
 drugs; 1997 sales, 880  
 globulin immune; shortages, 1341, 2228  
 health care; policies, 17  
 home health care; economics, 2019  
 hospital pharmacy; history, 229  
 military; pharmacy programs, 1656  
 pharmacists; hospital; job satisfaction, 360; P. Parker, 1344  
 vaccines; pediatric protocols, 563  
**United States House of Representatives**  
 drug distribution; globulin immune shortages, 1341  
 pharmacists; role, 1850  
**United States Pharmacopeia**  
 labeling; beyond-use vs. expiration dates, 433  
 monographs; botanical products, 527  
 pharmaceutical standards; ketorolac repackaging, 388; warfarin, 727  
 standards; prescription drug storage, 1554; dietary supplements, 2330  
**United States Public Health Service**  
 Advisory Committee on Immunization Practices; vaccine protocols, 563  
 fellowships; primary care, 17  
**University of Florida College of Pharmacy**  
 Doctor of Pharmacy; nontraditional program, 530  
**Urethritis**; grepafloxacin hydrochloride; FDA approvals, 20  
**Urokinase**; arterial occlusive diseases; overview, 2414  
**U.S. Department of Veterans Affairs**; hospital pharmacy; residency funding, 1618

## V

**Vaccines**  
 diseases; health professions' immunization, 760  
 otitis media; review, 1881  
 pneumococcal; *S. pneumoniae* immunization, 1987  
 protocols; pediatrics, 563  
 rotavirus, 2226  
 varicella; cost-benefit analysis, Dec 15 suppl S4  
**Valerian**; monographs; USP, 527  
**Valeriana species**; monographs; USP, 527  
**Vancomycin**  
 enterocolitis; pseudomembranous, 1365  
 otitis media; review, 1881  
 resistance; *Enterococcus* species, 1407  
**Vancomycin hydrochloride**  
 incompatibilities; artificial tears, 463  
 stability; ophthalmic solutions, 1386  
**Varicella vaccines**  
 health professions; CDC protocols, 760  
 immunization; cost-benefit analysis, Dec 15 suppl S4  
**Vascular diseases**; clopidogrel bisulfate; atherosclerosis, 207  
**Vasodilating agents**; sildenafil citrate; FDA approvals, 981; toxicity, 2080  
**Vehicles**  
 alcohols, polyvinyl; incompatibilities, 463  
 artificial tears; vancomycin ophthalmic solution, 1386  
 cherry syrup; oral liquid compounding, 1915; suspensions, 1804  
 sucrose; granisetron suspensions, 2511  
 water; enalapril suspensions, 1155; mycophenolate incompatibilities, 926  
 water for injection; fentanyl injections, 1194  
**Vendors**; equipment; automated distribution systems, 1403  
**Verapamil**; interactions; clarithromycin, 2417  
**Verapamil hydrochloride**; cardiovascular diseases; circadian rhythm, Nov 15 suppl S17  
**Vials**  
 glass; indomethacin incompatibilities, 154; ondansetron incompatibilities, 2630  
 incompatibilities; cisatracurium, 1037

injections; latex-free closures, 437  
multiple dose; abciximab, 2026  
**Vitamin E**; Alzheimer's disease; overview, Nov 1 suppl S11  
**Vitamins**  
  cyanocobalamin; protocols, 981  
  folic acid; generic equivalency, 1415; protocols, 981  
  labeling; FDA regulations, 1239  
  multiple; metal contamination, 150  
  vitamin E; Alzheimer's disease, Nov 1 suppl S11  
**Volume of distribution**, see **Drugs, body distribution**  
**Vomiting**  
  antineoplastic agents; outpatient survey, 1903  
  dolasetron mesylate; FDA approvals, 18  
  granisetron; antineoplastics toxicity, 1269

**W**

**Warfarin**  
  atrial fibrillation; protocols, 376  
  interactions; grapefruit juice, 1581  
**Warfarin sodium**  
  equivalency, generic; overview, 729; standards, 727  
  interactions; troglitazone, 1071  
**Wastage**; somatotropin; administration systems, 734  
**Waste disposal**; radiopharmaceuticals; contract services, 2537

**Water**  
  contamination; microbiological, 2534  
  incompatibilities; lorazepam, 2305  
  vehicles; enalapril suspensions, 1155; mycophenolate suspensions, 926  
**Water for Injection**  
  diluents; indomethacin, 154; interferon alfa-2b, 1602  
  vehicles; fentanyl injections, 1194  
**Weight**  
  folic acid; capsules, 1415  
  neonates; gentamicin pharmacokinetics, 2280  
  patients; cyclosporine blood levels, 1598; heparin dosage, 159; heparin protocols, Dec 15 suppl S29  
**Weight loss**; guidelines; obesity, 1663  
**Wisconsin**; managed care systems; contracts, 523  
**Women**  
  contraceptives; thalidomide, 1746  
  patients; drug-related injuries, 1158  
**Workload**  
  hospital pharmacy; cleanrooms, 458; planning and design, 2505  
  pharmacists, hospital; clinical technicians, 1375; inpatient consultation, 1127  
**World Health Organization**; nutrition; infant formulas, 84  
**World Wide Web**  
  American Society of Health-System Pharmacists; journal content, 1773; public relations, 1975  
  information; disease management guidelines, 1943  
**World Wide Web Review**, 95, 194

American Medical Association, 95  
Virtual Library Pharmacy, 194  
**Writing**  
  *American Journal of Health-System Pharmacy*; content selection, 1773  
  education, pharmaceutical; examinations, 2397  
**Wyeth-Ayerst**; product withdrawal; bromfenac, 1548  
**Wyoming**; Medicaid; prescription cap, Dec 15 suppl S19

**X**

**Xemilofiban**; cardiovascular diseases; review, 2363

**Y**

**Yohimbine**; sexual dysfunction; SSRI toxicity, 1167

**Z**

**Zinc**; contamination; parenteral nutrition, 150  
**Zollinger-Ellison syndrome**; gastrointestinal drugs; comparisons, 2289  
**Zolmitriptan**; approvals; FDA, 110

## Author Index

## A

- Abernathy, Gill B.** Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Analysis of abxiximab use in a community teaching hospital, Dec 15 suppl S35
- Acosta, Edward P.** see Kakuda, Thomas N., 2639
- Al-Achi, Antoine** Testing commercially available folic acid capsules (letter), 1415
- Albraant, Daniel H.** see Knapp, Katherine K., 1141
- Algozzine, Thomas** Opinions of disease management programs among medical directors of managed care organizations, 1029
- Alkhouri, Nabil** see Higa, Gerald M., 445
- Allen, Jody H.** Pharmacy in managed care: vision for the future. Preconference survey: reactor panel, 1490
- Allen, Loyd V. Jr.** Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids, 1915
- Allen, Loyd V. Jr.** Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids, 1804
- Allwood, Michael C.** Fluorouracil precipitate (letter), 1315
- Almeida, Sandra** see Sesin, G. Paul, 2304
- Alsuwaidan, Salem** Characteristics of ambulatory care clinics and pharmacists in Veterans Affairs medical centers, 68
- Amador, Fatima Diaz** Stability of carboplatin in polyvinyl chloride bags (letter), 602
- Anaizi, Nasr H.** Stability of mycophenolate mofetil in an extemporaneously compounded oral liquid, 926
- Ansell, Caroline J.** see Volles, David F., 2002
- Andrusko-Furphy, Kathryn T.** Oryx and performance measurement in home care, 2299
- Anneccchini, Linda M. Cortese** Funding of pharmacy residency programs—1996, 1618
- Aparasu, Rajender R.** Drug-related-injury visits to hospital emergency departments, 1158
- Appenheimer, Michelle M.** Stability of albumin-free interferon alfa-2b for 42 days, 1602
- Armstrong, Christine** see Dupuis, L. Lee, 735
- Armstrong, Edward P.** see Schwarz, Harald O., 1308
- Arnaud, Philippe** see Combeau, Dominique, 1606
- Arnaud, Philippe** see also Fontan, Jean-Eudes, 182
- Asimwe, Donna** see Capes, David F., 351
- Astier, Alain** see Naud, Carole, 1161
- Austin, Mauricio L.** see Murphy, John E., 2280
- Azzati, Esperanza Sevilla** see Amador, Fatima Diaz, 602

## B

- Bailey, Elaine M.** Managing *C. difficile*-associated diarrhea (editorial), 1365
- Bakst, Alan** see DiPiro, Joseph T., 777
- Bar-Din, Miriam** see Bozek, Pamela S., 1151
- Barner, Jamie C.** Participation and influence of individuals and committees that decide on drug availability in HMOs, 56
- Barner, Jamie C.** Tools, information sources, and methods used in deciding on drug availability in HMOs, 50
- Barnett, Timothy S.** Pharmacy-managed extended-interval aminoglycoside program in a community hospital (letter), 397
- Barnette, Debra J.** see Carter, Barry L., 62
- Basskin, Lorne E.** see Lundquist, Steve, Dec 15 suppl S38
- Bates, Edric R. Sr.** Replacement of divalproex sodium with valproic acid not clear-cut (letter), 1073
- Bauer, Larry A.** Book review, 94
- Beal, Frederick C.** Herbs and homeopathic remedies as formulary items? (Management Consultation), 1266
- Beck, Joni K.** Development of an interdisciplinary, telephone-based care program, 453
- Belgado, Bernadette S.** see Hatton, Randy C., 1198
- Bell, Heather M.** Provision of pharmaceutical care by community pharmacists in Northern Ireland, 2009

- Benson, Steven R.** Differences in warfarin products are not the issue (letter), 1935
- Benson, Steven R.** In favor of Coumadin over generic warfarin, 727
- Berardi, Rosemary R.** Proton-pump inhibitors in acid-related diseases, 2289
- Berchou, Richard C.** Book review, 2044
- Berger, James E.** see Frye, Carla B., 1167, 2196
- Bertrand, Dominique** see Simon, Jean M., 173
- Bess, David T.** see Jolley, Monica R., 2418
- Bever, Kristine A.** Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy, 1003
- Bhatia, Jatinder** see Brawley, Vince, 1288
- Billups, Sarah J.** see Alsuwaidan, Salem, 68
- Billups, Sarah J.** see also Carter, Barry L., 62
- Birtcher, Kim** see Bowden, Carol, Dec 15 suppl S29
- Blake, Kathryn** Book Review, 2648
- Blanche, William** Refining a food-drug interaction program (Frontline Pharmacist), 122
- Bland, Sarah E.** Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Treatment of migraine in the emergency room and internal medicine clinic: treatment patterns and patient satisfaction (abstract), Dec 15 suppl S38
- Blaney-Chandramouli, Jane** see McCoy, Shannyn, Dec 15 suppl S8
- Boatwright, Deborah E.** Legal aspects of expanded prescribing authority for pharmacists, 585
- Bootman, J. Lyle** see Harrison, Donald L., 1588
- Botham, Azah** see Lee, Audrey J., 1792
- Bowden, Carol** Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Pharmacoeconomic impact of a weight-based heparin protocol, Dec 15 suppl S29
- Bowman, Jason L.** see Christensen, Keith J., 261
- Boyd, Thomas W.** see Sullivan, Dawn M., 1581
- Bozek, Pamela S.** Effect of pharmacist interventions on medication use and cost in hospitalized patients with or without HIV infection, 1151
- Brawley, Vince** Effect of sodium metabisulfite on hydrogen peroxide production in light-exposed pediatric parenteral amino acid solutions, 1288
- Brehio, Renée M.** National Pharmacy Week—all year long (editorial), 1570
- Brehio, Renée M.** Showing pharmacy's best side to the world (editorial), 1570
- Breitigan, Janice M.** Counseling about chlorofluorocarbon-free inhalers (Frontline Pharmacist), 226
- Breitigan, Janice M.** Protecting children in the community from poisons (Frontline Pharmacist), 1971
- Brion, Françoise** see Combeau, Dominique, 1606
- Brion, Françoise** see also Fontan, Jean-Eudes, 182
- Brossard, Denis** see Corbion, Valérie, 1316
- Brown, Charles H.** Drawing on university resources to train hospital pharmacists in anticoagulant drug monitoring (letter), 396
- Brown, Ronald R.** Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with non-insulin-dependent diabetes mellitus, Dec 15 suppl S24
- Brown, Sheldon T.** see Fung, Horatio B., 955
- Brubaker, Mary L.** Setting up the herbal formulary system for an alternative medicine clinic (Managed Care Forum), 435
- Brunner, Felix** see Kaeser, Yolanda A., 2417
- Bubán, Jennifer** see Bowden, Carol, Dec 15 suppl S29
- Bublin, Janice G.** see Gales, Mark A., 2038
- Buice, Robert G.** see Christensen, Keith J., 261
- Burford, Bill** see Tidwell, Bill H., 163
- Burke, Cassandra E.** Inconsistent documentation of drug-related allergies and adverse effects in patient charts (letter), 289
- Burstein, Aaron H.** see Grace, Karen A., Dec 15 suppl S27

## C

- Calderón, Javier** see Burke, Cassandra E., 289
- Campbell, Gerard M.** Using process control charts to monitor dispensing and checking errors, 946
- Canaday, Bruce R.** Bold in our C.A.R.E. (commitment, advocacy, relationships, education), 1697
- Capes, David F.** Performance of selected flow-restricting infusion devices, 351
- Carson, Stanley W.** see Cranor, Carole W., 1073
- Carter, Barry L.** The expanding role of cardiovascular

- lar chronotherapeutics. Introduction, Nov 15 suppl S3
- Carter, Barry L.** The expanding role of cardiovascular chronotherapeutics. Optimizing delivery systems to tailor pharmacotherapy to cardiovascular circadian events, Nov 15 suppl S17
- Carter, Barry L.** Highlights of the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 382
- Carter, Barry L.** The IMPROVE study: background and study design, 62
- Carter, Barry L.** see also Alsuwaidan, Salem, 68
- Carter, Kent** see Bowden, Carol, Dec 15 suppl S29
- Caryer, Keith E.** Book review, 858
- Castillo-Romera, Isabel** see Santolaya-Perrin, Rosario, 1827
- Cawood, Christi L.** Realizing pharmacists' potential in the outpatient clinic arena (Management Consultation), 1763
- Chamberlain, Marvin A.** The vertically integrated pharmacy department, 669
- Charland, Scott L.** Activity of enoxaparin sodium in tuberculin syringes for 10 days, 1296
- Charlton, Judie F.** Storage of extemporaneously prepared ophthalmic antimicrobial solutions, 463
- Chase, Jennifer L.** Lowering the risk of esophagitis from alendronate therapy (Frontline Pharmacist), 892
- Chase, Sandra L.** Therapeutic-interchange program for oral histamine H<sub>2</sub>-receptor antagonists, 1382
- Chelliam, Kezia** see Bowden, Carol, Dec 15 suppl S29
- Chen, Connie** Trogitazone: an antidiabetic agent, 905
- Chen, Dennis A.** see Ray, Lisa R., 1508
- Chen, Julie L.** Filtration recommendations for i.v. medications (letter), 1313
- Chen, Tracy T.** see Mueller, Bradford J., 266
- Chong, Kenneth** see Weber, Jeffrey J., 2414
- Chong, Pang H.** Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases, 2363
- Choy, Melissa** Comparing a mass-balance algorithm with a Bayesian regression analysis computer program for predicting serum phenytoin concentrations, 2392
- Chrischilles, Elizabeth A.** see Kuehl, Angela K., 1017
- Christensen, Keith J.** Relative bioavailability of itraconazole from an extemporaneously prepared suspension and from the marketed capsules, 261
- Cluffio, Joseph D.** see Moshfeghi, Mersedeh, 1194
- Clark, Toby G.** see Crawford, Stephanie Y., 1907
- Cody, Marisue** The Kaiser Permanente/USC Patient Consultation Study: change in quality of life, 2615
- Cody, Marisue** see also Johnson, Kathleen A., 2621
- Cody, Marisue** see also McCombs, Jeffrey S., 2485
- Cohen, Henry** Feasibility and pharmacokinetics of carbamazepine oral loading doses, 1134
- Coleman, Rebecca L.** see Holtzer, Christopher D., 283
- Coles, Barbara Jo** see Johnson, Ruth, 1503
- Combeau, Dominique** Accuracy of two filling systems for parenteral nutrient solutions, 1606
- Conley, Robert R.** see Moore, David B., Dec 15 suppl S17
- Connelly, Julie F.** see Mellenger, Michelle R., 171
- Cook, E. Charlene**, see Beck, Joni K., 453
- Cooke-Ariel, Hannah** The expanding role of cardiovascular chronotherapeutics. Circadian variations in cardiovascular function and their relation to the occurrence and timing of cardiac events, Nov 15 suppl S5
- Cooper, Sue** see Marshall Peter S., 2234
- Corbion, Valérie** Fluorouracil precipitate (letter), 1316
- Cornish, Laura A.** see Montgomery, Patricia A., 1042
- Couldry, Rick** Continuous infusion of ceftazidime with an elastomeric infusion device, 145
- Courcier, Catherine** see Corbion, Valérie 1316
- Cox, Emily R.** see Harrison, Donald L., 1588
- Craig, Samuel B.** see Patel, Kamlesh, 1584
- Crane, Vicki S.** Shifting paradigms of antiplatelet therapy: assessing new drugs versus old. Formulary and economic considerations in the selection of antiplatelet agents, Oct 1 suppl S28
- Cranor, Carole W.** Replacement of divalproex sodium with valproic acid not clear-cut (letter), 1073
- Crauste-Manciet, Sylvie** see Corbion, Valérie, 1316
- Crawford, Stephanie Y.** Staff attitudes about the



use of robots in pharmacy before implementation of a robotic dispensing system, 1907  
**Crismon, M. Lynn** Psychiatric pharmacy practice specialty certification process, 1594  
**Crowling, George H. Jr.** see Kay, Brett, 1482

## D

**Dalla, Kumar P.** see Charlton, Judie F., 463  
**Darlington, Margaret Raburn** Pharmacist-managed carvedilol heart failure clinic (letter), 1626  
**Davies, Martha** Presenting new practice ideas at ASHP meetings (Questions and Answers), 888  
**Davis, Diane D.** see Charland, Scott L., 1296  
**Dearing, Curt J.** Book review, 510  
**Decker, Edward L.** Managing the shortage of intravenous immune globulin (Management Consultation), 2090  
**Deffenbaugh, Joseph H.** The Joint Commission's revised sentinel-event policy (Questions and Answers), 1112  
**Dentinger, Paul J.** see Anaizi, Nasr H., 926  
**Deutsch, Thomas A.** see Gaynes, Bruce I., Dec 15 suppl S23  
**Devinsky, Orrin** see Cohen, Henry, 1134  
**Dib, Jean G.** Resident's perspective on pharmacist-managed drug therapy protocols (letter), 1826  
**DiPiro, Joseph T.** Infection in surgical patients: effects on mortality, hospitalization, and postdischarge care, 777  
**Dixon, Kathleen Marie** Longing for mercy, requesting death: pharmaceutical care and pharmacologically assisted death, 578  
**Doering, Paul L.** see Hattson, Randy C., 1198  
**Douglas, J. B.** Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Operational redesign of pharmaceutical services for open-heart-surgery patients (abstract), Dec 15 suppl S39  
**Drewe, Jürgen** see Kaeser, Yolanda A., 2417  
**Dries, Terry J.** see Beck, Joni K., 453  
**Driver, Paul S.** Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood, Dec 15 suppl S12  
**Dunham, Deborah B.** see Vermeulen, Lee C., 1934  
**Dunn, Eddie B.** see Johnson, Jill T., 1728  
**Dupuis, L. Lee** Oral syringe for extemporaneously preparing doses (letter), 735  
**Dvorak, Sonya R.** Continuity of care from acute to ambulatory care setting, 2500

## E

**Early, John J.** see Cranor, Carole W., 1073  
**Edwards, Kathleen** see Shinohara, Y. Todd, 1921  
**Epstein, Jay** see Pierce, L. Ross, 1057  
**Erickson, Martin A. III** see Allen, Loyd V. Jr., 1804, 1915  
**Ernst, Erika J.** see Lund, Brian C., 1987  
**Evans, Sharon S.** see Appenheimer, Michelle M., 1602

## F

**Faccinetti, Neil J.** see Campbell, Gerard M., 946  
**Fallavollita, Alfred Jr.** see Kohler, David R., 137  
**Fallavollita, Alfred** see also Montello, Michael J., 651  
**Fankhauser, Martha P.** see Crismon, M. Lynn, 1594  
**Farab, Andy** Lack of sexual adverse effects with mirtazapine (letter), 2195  
**Farlow, Martin R.** Clinical frontiers: new advances in the treatment of Alzheimer's disease. Etiology and pathogenesis of Alzheimer's disease, Nov 1 suppl S5  
**Feinberg, Madeline V.** Clinical frontiers: new advances in the treatment of Alzheimer's disease. Clinical and regulatory concerns in Alzheimer's disease management: role of the pharmacist, Nov 1 suppl S26  
**Feinberg, Madeline V.** Clinical frontiers: new advances in the treatment of Alzheimer's disease. Introduction, Nov 1 suppl S3  
**Feng, Weiwei** see McCombs, Jeffrey S., 2485  
**Fernandez, Christine** see Naud, Carole, 1161  
**Finlayson, James A.** Acute paranoid reaction to saquinavir, 1616

**Finley, Rebecca S.** see Trovato, James A., 1269  
**Fiscella, Richard G.** Costs of glaucoma medications, 272  
**Fish, Douglas N.** see Hilt, Alexandra E., 2528  
**Fitzpatrick, Kimberly A.** see Montgomery, Patricia A., 1042  
**Fleming, Ronald A.** see Share, Michael J., 2013  
**Fletcher, Courtney V.** see Kakuda, Thomas N., 2639  
**Fletcher, Deborah M.** see Mullin, Shantel M., 1903  
**Flynn, Barbara** Book review, 308  
**Foistad, Joyce** see Share, Michael J., 2013  
**Fong, Nancy T.** Book review, 308  
**Fontan, Jean-Eudes** Laminar-airflow ceiling in a hospital pharmacy cleanroom (letter), 182  
**Fontan, Jean-Eudes** see also Combeau, Dominique, 1606  
**Ford, Majorie A.** see Sullivan, Dawn M., 1581  
**Foster-Nora, Jessica A.** see Siden, Rivka, 1827  
**Fox, Janet L.** see Stewart, James T., 2630  
**Fox, Janet L.** see also Xu, Quanyun A., 1037  
**Frear, Raulo S.** Proton-pump inhibitors in managed care (editorial), 2249  
**Frye, Carla B.** Lack of sexual adverse effects with mirtazapine (letter), 2196  
**Frye, Carla B.** Treatment of sexual dysfunction induced by selective serotonin-reuptake inhibitors, 1167  
**Frye, Reginald F.** see Murphy, John E., 2280  
**Fuhrman, L. Clifton** Stability of vancomycin in an extemporaneously compounded ophthalmic solution, 1386  
**Fung, Horatio B.** HIV pharmacotherapy clinic (letter), 955

## G

**Gaines, Ann** see Pierce, L. Ross, 1057  
**Gales, Barry J.** see Gales, Mark A., 2038  
**Gales, Mark A.** How to get the most out of poster sessions at ASHP meetings (How To), 2038  
**Gans, John A.** The patient is waiting, 1675  
**Garnett, William R.** Considerations for long-term use of proton-pump inhibitors, 2268  
**Garrity, Maureen** Comparison of electronic drug information resources (letter), 1197  
**Gayman, Jayne** Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. A cost-effectiveness model for analyzing two varicella vaccination strategies, Dec 15 suppl S4  
**Gaynes, Bruce I.** Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Cost-effectiveness of topical 0.03% flurbiprofen in outpatient cataract surgery as measured by surgical time and vitreous loss, Dec 15 suppl S23  
**George, Kenneth** Book review, 404  
**George, Thomas** Book review, 191  
**Gibson, Robert D.** "Intelligence" is a relative term, 1825  
**Gilbert, Colleen J.** see Meadowcroft, Amy M., 1898  
**Gilbert, Doward L.** see Xu, Quanyun A., 1037  
**Gilbert, Doward L.** see also Zhang, Yanping, 574  
**Glover, Jon** Reducing expenditures for statin-type lipid-lowering agents (Managed Care Forum), 995  
**Glover, Vera Houston** Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Pharmacoeconomic evaluation of a pharmacist's role in a centralized call center (abstract), Dec 15 suppl S38  
**Goldfrank, Lewis R.** see Cohen, Henry, 1134  
**Goldspiel, Barry R.** see Kohler, David R., 137  
**Goll, Eric** see Steedman, Susan, 2611  
**Gonzalez, Edgar R.** Shifting paradigms of antiplatelet therapy: assessing new drugs versus old. Atherosclerosis: a unifying disorder with diverse manifestations, Oct 1 suppl S4  
**Gonzalez, Edgar R.** Shifting paradigms of antiplatelet therapy: assessing new drugs versus old. Introduction, Oct 1 suppl S3  
**Goode, Donald L.** see Tullio, Carl J., 1769  
**Goode, Jean-Venable R.** see Ling, Con Ann, 1943  
**Gorko, Mary Ann** see Mueller, Bradford J., 266  
**Gouveia, William A.** Transition to managed care (editorial), part 1, 229; part 2, 347; part 3, 441  
**Gouveia, William A.** see also Decker, Edward L., 2090  
**Grace, Karen A.** Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Diabetes care and cost of pharmacotherapy versus medical services, Dec 15 suppl S27

**Granberry, Mark C.** Ibutilide: a new class III antiarrhythmic agent, 255  
**Graves, Sharon M.** see Nelson, Tom J., 570  
**Gray, Shari** see Walker, Scott E., 154  
**Green, Laurence** see Kohler, David R., 137  
**Greenblatt, Jay** see Montello, Michael J., 651  
**Greenwood, Robert** see Al-Achi, Antoine, 1415  
**Griffith, Niesha L.** Survey of inpatient counseling by hospital pharmacists, 1127  
**Groschen, Susan L.** see McCombs, Jeffrey S., 2485  
**Grussing, Paul G.** see Crawford, Stephanie Y., 1907  
**Gubbins, Paul O.** see Christensen, Keith J., 261  
**Gubbins, Paul O.** see also Penzak, Scott R., 279  
**Guessford, Stacey A.** see Mueller, Bradford J., 266  
**Gulliford, Sandra M.** Using telemedicine technology for pharmaceutical services to ambulatory care patients, 1512  
**Gurley, Bill J.** see Christensen, Keith J., 261  
**Gutfield, Marcia B.** see Rice, Stephen P., 1462

## H

**Haefeli, Walter E.** see Kaeser, Yolanda A., 2417  
**Haines, Stuart T.** Reflections on generic warfarin, 729  
**Hak, Emily B.** Chromium and zinc contamination of parenteral nutrient solution components commonly used in infants and children, 150  
**Hambright, John S.** see Knapp, Katherine K., 1141  
**Hamerly, John P.** Views on assisted suicide. Perspectives of the AMA and the NHQ, 543  
**Hammond, Raymond W.** see Raisch, Dennis W., 1274  
**Hammonds, Barbara L.** Learning how to use ASHP's Clinical Skills Program (Questions and Answers), 1760  
**Harbison, John W.** Shifting paradigms of antiplatelet therapy: assessing new drugs versus old. Clinical considerations in selecting antiplatelet therapy in cerebrovascular disease, Oct 1 suppl S17  
**Harrison, Donald L.** Cost-effectiveness of consultant pharmacists in managing drug-related morbidity and mortality at nursing facilities, 1588  
**Harrison, Robert D.** see Share, Michael J., 2013  
**Hart, Susan M.** see Tisdale, James E., 1534  
**Hasegawa, Guy R.** Book review, 619  
**Hasegawa, Guy R.** Truth in advertising (editorial), 1569  
**Hatfield, Susan** see Mehta, Shilpa S., 598  
**Hattson, Randy C.** Comparison of electronic drug information resources (letter), 1198  
**Hay, Joel W.** see McCombs, Jeffrey S., 2485  
**Hayakawa, Taro** see Shibata, Nobuhito, 1598  
**Hayward, Shelly L.** see Meadowcroft, Amy M., 1898  
**Hazlet, Thomas K.** Book review, 744  
**Hazlet, Thomas K.** Repackaging ketorolac injection, 388  
**Helin, Minna M.** Content uniformity and stability of nifedipine in extemporaneously compounded oral powders, 1299  
**Helms, Richard A.** see Hak, Emily B., 150  
**Herreros de Tejada y Lopez-Coterilla, Alberto** see Amador, Fatima Diaz, 602  
**Herson, Victor C.** see Mouser, Jay F., 1071  
**Hewitt, Kathleen Kimberlin** see Abernathy, Gill B., Dec 15 suppl S35  
**Hicks, Allen R.** Helping HIV-infected patients at the clinic (Frontline Pharmacist), 661  
**Higa, Gerald M.** Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer, 445  
**High, Joseph L.** see Kohler, David R., 137  
**Hilleman, Daniel E.** Shifting paradigms of antiplatelet therapy: assessing new drugs versus old. Management of peripheral arterial disease, Oct 1 suppl S21  
**Hilt, Alexandra E.** Dosage adjustment of antiretroviral agents in patients with organ dysfunction, 2528  
**Hinkle, George H.** see Crismon, M. Lynn, 1594  
**Hipple, Thomas F.** see Nahata, Milap C., 1155, 2511  
**Hirokawa, William T.** see Hazlet, Thomas K., 388  
**Ho, Susan S.** Pharmacy-based drug information services in Hong Kong hospitals, 1164  
**Hoen, Ellen T.** Director-to-consumer advertising: for better profits or for better health? 594  
**Hoffman, Robert S.** see Cohen, Henry, 1134  
**Holiday-Goodman, Monica** see Kahaleh, Abir A., 2387  
**Hollarbush, Janet L.** see Raisch, Dennis W., 1274  
**Holtzer, Christopher D.** Use of nonnucleoside reverse-transcriptase inhibitors, 283

## Annual Index

**Hopefl, Alan** Differences in warfarin products are not the issue (letter), 1935  
**Hoppe, Heather L.** Otitis media: focus on antimicrobial resistance and new treatment options, 1881  
**Hoshino, Nobuo** see Shibata, Nobuhito, 1598  
**Hotchkiss, Brian D.** Pharmacy coordination of an indigent care program in a psychiatric facility, 1293  
**Howland, Mary Ann** see Cohen, Henry, 1134  
**Hughes, Carmel M.** see Bell, Heather M., 2009  
**Humphries, John E.** see Volles, David F., 2002  
**Hunt, Charmaine** see Nutescu, Edith, 364  
**Huntley, Carl** see Kohler, David R., 137

## I

**Icaza, Luis A** vision for psychopharmacology (letter), 83  
**Ippoliti, Cindy** Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients, 1573  
**Isenhowe, Holly L.** Selection of narcotic analgesics for pain associated with pancreatitis, 480  
**Iwaki, Masahiro** see Kawabata, Atsufumi, 360

## J

**Jacobsen, Mary Ann** see Glover, Vera Houston, Dec 15 suppl S38  
**Jann, Michael W.** Clinical frontiers: new advances in the treatment of Alzheimer's disease. Pharmacology and clinical efficacy of cholinesterase inhibitors, Nov 1 suppl S22  
**Jann, Michael W.** see also Crismon, M. Lynn, 1594  
**Jarco, Patricia E.** see Mitzryk, Beatriz, 491  
**Jesse, Lois** see Mehta, Shilpa S., 598  
**Johnson, Cary E.** see Hoppe, Heather L., 1881  
**Johnson, Cary E.** see also Montgomery, Patricia A., 1042  
**Johnson, Jill T.** Two antiretroviral drugs likely to be confused (letter), 1728  
**Johnson, Kathleen A.** The Kaiser Permanente/USC Patient Consultation Study: patient satisfaction with pharmaceutical services, 2621  
**Johnson, Kathleen A.** see also McCombs, Jeffrey S., 2485  
**Johnson, Ruth** Accuracy of three automated compounding systems determined by end-product laboratory testing and comparison with manual preparation, 1503  
**Johnson, William** see Mitchell, Steven, 2360  
**Jolley, Monica R.** Drug interaction inconsistency in *Drug Information Handbook* (letter), 2418  
**Jones, Holly D.** Book review, 192  
**Jorgenson, James A.** see Gulliford, Sandra M., 1512  
**Juni, Howard** see Crismon, M. Lynn, 1594

## K

**Kaeser, Yolanda A.** Severe hypotension and bradycardia associated with verapamil and clarithromycin (letter), 2417  
**Kafka, Patrick S.** see Schumock, Glen T., 458  
**Kahaleh, Abir A.** Downsizing of health-system pharmacist positions, 2387  
**Kakehi, Kazuaki** see Kawabata, Atsufumi, 360  
**Kakuda, Thomas N.** Potential confusion with antiretroviral drugs (letter), 2639  
**Kakuda, Thomas N.** Protease inhibitors for the treatment of human immunodeficiency virus infection, 233  
**Kamiya, Akira** see Oie, Shigeharu, 2534  
**Kannawurf, Barbara S.** see Gonzalez, Edgar R., Oct 1 suppl S4  
**Karczmarsky, Rosalie M.** see Mueller, Bradford J., 266  
**Karp, Warren B.** see Brawley, Vince, 1288  
**Katzman, Harvey** see Knapp, Katherine K., 1141  
**Kaufenberg, Anthony J.** Role of cimetidine in the treatment of acetaminophen poisoning, 1516  
**Kaufman, Michele B.** World Wide Web review, 95, 194  
**Kawabata, Atsufumi** Importance of clinical activities to job satisfaction in Japanese pharmacists, 360  
**Kay, Brett** Pharmacy in managed care: vision for the future. Perspectives on pharmacy's role in managed care, 1482  
**Keeney, Beth E.** see Lee, Audrey J., 1792  
**Keller, William J.** Book review, 862, 1430  
**Kelly, Deanna L.** see Moore, David B., Dec 15 suppl S17  
**Kennedy, Daniel T.** see Ling, Con Ann, 1943

**Kepple, Stephen R.** The last voice was the first, 176  
**Kepple, Stephen R.** Pharmacists in Asheville, North Carolina, pick up city paychecks for diabetes services (News), 10  
**Kepple, Stephen R.** San Diego VA pharmacists find room in ambulatory care clinics (News), 1753  
**Kershaw, Vicki L.** see Kay, Brett, 1482  
**Ketkar, Vaishali A.** Stability of undiluted and diluted adenosine at three temperatures in syringes and bags, 466  
**Kienle, Patricia C.** see Allen, Jody H., 1490  
**Kier, Karen L.** see Dixon, Kathleen Marie, 578  
**King, Deanne T.** see Stewart, James T., 2630  
**King, Julie L.** Patients' knowledge of medication care plans after hospital discharge, 1389  
**Kjonnicksen, Inge** see Stendal, Tove L., 683  
**Klem, Wendy** see Stendal, Tove L., 683  
**Klepser, Michael E.** see Lund, Brian C., 1987  
**Kline, Sandra** see Garrity, Maureen, 1197  
**Klutman, Neil E.** see Coultery, Rick, 145  
**Knapp, Katherine K.** Community pharmacist interventions in a capitated pharmacy benefit contract, 1141  
**Kniska, Alicia** see Charlton, Julie F., 463  
**Knoell, Daren L.** Human gene therapy for hereditary diseases: a review of trials, 899  
**Knowlton, Calvin H.** Pharmacy in managed care: vision for the future. Pharmaceutical care in 2000: engaging a moral covenant in turbulent times, 1477  
**Koch, Karen E.** Clinically oriented pharmacy technicians to augment clinical services, 1375  
**Kohler, David R.** Standardizing the expression and nomenclature of cancer treatment regimens, 137  
**Kolling, William M.** see Ketkar, Vaishali A., 466  
**Kontra, Kersi M.** see Helin, Minna M., 1299  
**Korman, Nancy E.** see Lee, Audrey J., 1792  
**Korth-Bradley, J. M.** Book review, 94  
**Kozma, Chris M.** see Algozzine, Thomas, 1029  
**Kozma, Chris M.** see also Reeder, C. E., 35  
**Kralsinger, Marijo** Update on childhood immunization, 563  
**Kratzer, Anisa M.** Nicotine patch needs to breathe (letter), 1413  
**Krinsky, Daniel L.** Natural products: show me the data (editorial), 125  
**Kuehl, Angela K.** System for exchanging information among pharmacists in different practice environments, 1017  
**Kutt, Henn** see Cohen, Henry, 1134  
**Kwan, Florence K. P.** see Ho, Susan S. S., 1164

**L**

**Laing, Robert B. S.** see Finlayson, James A., 2016  
**Landis, Nancy Tarleton** Mississippi moves forward with disease-specific credentialing (News), 2452  
**Landis, Nancy Tarleton** NCPA's TV network primes consumers, pharmacists for pharmaceutical care (News), 536  
**Landis, Nancy Tarleton** Oregon groups devise rules, policies on assisted suicide (News), 1235  
**Landis, Nancy Tarleton** Oregon voters confirm support for physician-assisted suicide; pharmacists and physicians struggle over implementation (News), 318  
**Landis, Nancy Tarleton** Paul Parker, a pioneer in twentieth-century pharmacy, dies (News), 1344  
**Landis, Nancy Tarleton** Pharmacy organizations form credentialing council to integrate efforts (News), 2444  
**Landis, Nancy Tarleton** Prospective pricing system for nursing facilities begins (News), 1645  
**Landis, Nancy Tarleton** Seattle pilot project makes emergency contraception available directly from pharmacists (News), 520  
**Landis, Nancy Tarleton** Texas Society rebuts anti-substitution articles (ASHP Affiliates), 428  
**Landis, Nancy Tarleton** University of Florida signs up Pharm.D. students for Texas, Illinois sites (News), 530  
**Landis, Nancy Tarleton** We're here—use us, pharmacists tell consumers (News), 1959  
**Landis, Nancy Tarleton** Wisconsin health plan rolls out comprehensive pharmacy provider contract (News), 523  
**Larson, Jeffrey W.** Patient satisfaction with delivery of products and information by an ambulatory care pharmacy, 1025  
**Leader, W. Greg** Pearls in therapeutic drug monitoring (letter), 2027  
**Lee, Audrey J.** Staff development in pharmacist-

conducted patient education and counseling, 1792  
**Lee, Barbara Coombs** Views on assisted suicide. The aid-in-dying perspective, 547  
**Lee, Pam (Yu-Ping)** Book review, 2047  
**Letendre, Donald E.** see Ancechini, Linda M., Cortese, 1618  
**Leung, Lucas K. H.** see Cohen, Henry, 1134  
**Levanda, Matthew** Noticeable difference in admixtures prepared from lorazepam 2 and 4 mg/mL (letter), 2305  
**Lima, Hetty A.** Disease management in the alternate-site health care setting, 471  
**Ling, Con Ann** In search of literature on clinical practice guidelines for the provision of pharmaceutical care (Current Literature), 1943  
**Lisitano, Richard** see Hotchkiss, Brian D., 1293  
**Liu, Gordon** see McCombs, Jeffrey S., 2485  
**Lively, Buford T.** see Kahaleh, Abir A., 2387  
**Love, Raymond C.** see Crismon, M. Lynn, 1594  
**Love, Raymond C.** see also Moore, David B., Dec 15 suppl S17  
**Lucas, Kathi Salmon** Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Outcomes evaluation of a pharmacist discharge medication teaching service, Dec 15 suppl S32  
**Luciano, Daniel J.** see Cohen, Henry, 1134  
**Lui, Augustine C. Y.** see Ho, Susan S. S., 1164  
**Lund, Brian C.** Strategies in the treatment of penicillin-resistant *Streptococcus pneumoniae*, 1987  
**Lundquist, Steve** Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Outcomes in chemotherapy-induced neutropenic patients when filgrastim is discontinued at different absolute neutrophil counts (abstract), Dec 15 suppl S38

**M**

**MacKinnon, George E. III** see Zgarrick, David P., 1281  
**Magnus, Gary H.** Working in a latex-safe environment (Frontline Pharmacist), 437  
**Malerba, Richard** Sheath for disposable syringes (letter), 956  
**Malesker, Mark A.** see Malone, Patrick, M., 1146  
**Mallinowski, Jennifer M.** Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor, 2253  
**Malone, Daniel C.** see Alsuwaidan, Salem, 68  
**Malone, Daniel C.** see also Carter, Barry L., 62  
**Malone, Patrick, M.** Wide-area network connecting a hospital drug informatics center with a university, 1146  
**Manasse, Henri R. Jr** Leading health-system pharmacy into the next century, 1703  
**Manasse, Henri R. Jr.** see also Allen, Jody H., 1490  
**Maravich-May, Diana** see Meadowcroft, Amy M., 1898  
**Markind, Jan E.** Topiramate: a new antiepileptic drug, 554  
**Marshall, Peter S.** Influencing physician prescribing through academic detailing with benchmarks (Managed Care Forum), 2234  
**Marti, Barbara** see Naud, Carole, 1161  
**Martindale, Robert G.** see DiPiro, Joseph T., 777  
**Martinez, Christine M.** see Chen, Julie L., 1313  
**Martinez, J. Frank** see Xu, Quanyun A., 1037  
**Martinez, Juan F.** see Zhang, Yanping, 574  
**Masahiko, Mishima** see Kawabata, Atsufumi, 360  
**Matuschka, Paul** Improving documentation of preoperative antimicrobial prophylaxis (Management Consultation), 993  
**Mays, David A.** see Reed, Shelby D., 2409  
**McBride, Michael G.** see Patel, Kamlesh, 1584  
**McCloskey, William W.** Drug information resources in managed care organizations, 2007  
**McCloskey, William W.** Use of intravenous inotropic therapy in the home, 930  
**McCombs, Jeffrey S.** The Kaiser Permanente/USC Patient Consultation Study: change in use and cost of health care services, 2485  
**McCombs, Jeffrey S.** see also Cody, Marisue, 2615  
**McCombs, Jeffrey S.** see also Johnson, Kathleen A., 2621  
**McCoy, Randall A.** see Dvorak, Sonya R., 2500  
**McCoy, Shanyan** Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Using multiple pharmacoeconomic methods to conduct a cost-effectiveness analysis of histamine H<sub>2</sub>-receptor antagonists, Dec 15 suppl S8

- McElroy, James C. see Bell, Heather M., 2009
- McGee, Christine M. see Steedman, Susan, 2611
- McPherson, Mary Lynn see Grace, Karen A., Dec 15 suppl S27
- Meadowcroft, Amy M. Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy, 1898
- Mehl, Bernhard Projecting future drug expenditures—1998, 127
- Mehlberg, Jennifer National survey of training and credentialing methods in pharmacist-managed anticoagulation clinics, 1033
- Mehta, Shilpa S. Albendazole versus praziquantel for neurocysticercosis, 598
- Mellenger, Michelle R. Use of methotrexate in ectopic pregnancy, 171
- Michael, Katherine A. see Volles, David F., 2002
- Mitchock, Robert J. see Feinberg, Madeline V., Nov 1 suppl S3, S26
- Milillo, Deborah National Hospital Pharmacy Week, 1997 (letter), 843
- Miller, Douglas E. Understanding reimbursement for pharmacy residents, 1620
- Miller, Jane L. Progress in breast cancer treatment: prevention, new therapies come to forefront (News), 2326
- Miller, Martin T. see DiPiro, Joseph T., 777
- Minouchi, Tokuzo see Shibata, Nobuhito, 1598
- Mishima, Masahiko see Kawabata, Atsumi, 360
- Mitchell, Steven Holding more fruitful staff meetings (Management Consultation), 2360
- Mitzyk, Beatriz Assay reliability (letter), 491
- Mock, E. Dennis see Lee, Audrey J., 1792
- Monk-Tutor, Mary R. Home care practice as a model for providing pharmaceutical care, 486
- Monk-Tutor, Mary R. The U.S. home infusion market, 2019
- Montello, Michael J. Accessing investigational anticancer agents outside of clinical trials (Questions and Answers), 651
- Montello, Michael J. see also Kohler, David R., 137
- Montgomery, Patricia A. Stability of torsemide in 5% dextrose injection, 1042
- Moore, David B. Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone, Dec 15 suppl S17
- Moroso, Richard S. see Nahata, Milap C., 734, 1155, 2511
- Morreale, Anthony P. see Plowman, Brian K., 1071
- Morton, M. Craig Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Outcomes evaluation of guidelines on intravenous maintenance fluid therapy (abstract), Dec 15 suppl S39
- Moshfeghi, Mercedes Visual compatibility of fentanyl citrate with parenteral nutrient solutions (letter), 1194
- Mott, David A. Attitudes of Ohio hospital pharmacy directors toward national voluntary pharmacy technician certification, 1799
- Mott, David A. see also Sutter, Tricia L., 1924
- Mouser, Jay F. Aluminum contamination of neonatal parenteral nutrient solutions and additives (letter), 1071
- Mucciardi, Nick see Sesin, G. Paul, 2304
- Mucha, Lisa see Zacker, Christopher, 1302
- Mueller, Bradford J. Effect of inline filtration on ViaSpan cold-storage solution, 266
- Mueller, Bruce A. see Isenhour, Holly L., 480
- Mullin, Shantel M. Mail-in questionnaire for monitoring nausea and vomiting in oncology outpatients, 1903
- Mullins, C. Daniel see Reed, Shelby D., 2409
- Mullins, Douglas M. see Volles, David F., 2002
- Murakami, Etsuko see Kawabata, Atsumi, 360
- Murphy, John E. Evaluation of gentamicin pharmacokinetics and dosing protocols in 195 neonates, 2280
- Murphy, John E. Rededicating ourselves to service: becoming the 'visible' ingredient in health care, 1692
- Murphy, John E. Therapeutic drug monitoring: observations and recommendations, 1306
- Murray, Louann W. USP to reevaluate its position on botanicals (News), 2330
- Mutnick, Alan see McCoy, Shanyan, Dec 15 suppl S8
- Myers, Charles E. Celebrating ASHP's golden anniversary in best practices (editorial), 1879
- N**
- Naaranlahti, Toivo J. see Helin, Minna M., 1299
- Nahata, Milap C. Somatropin administration by three drug-delivery systems (letter), 734
- Nahata, Milap C. Stability of enalapril maleate in three extemporaneously prepared oral liquids, 1155
- Nahata, Milap C. Stability of granisetron hydrochloride in two oral suspensions, 2511
- Nardviriyakul, Nahathai see Ketkar, Vaishali A., 466
- National Asthma Education and Prevention Program Your metered-dose inhaler will be changing: here are the facts, 276
- Naud, Carole Stability of adenosine 6 µg/mL in 0.9% sodium chloride solution, 1161
- Navarro, Robert P. Forecasting the issues for managed care pharmacy (Managed Care Forum), 27
- Nelson, Tom J. 0.9% Sodium chloride injection with and without heparin for maintaining peripheral indwelling intermittent-infusion devices in infants, 570
- Ng, Chee M. Meta-analysis of streptokinase and heparin in deep vein thrombosis, 1995
- Nichol, Michael B. see McCombs, Jeffrey S., 2485
- Nickman, Nancy A. see Schneider, Judith K., 2505
- Nnadi, M. Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Outcomes of a pharmacist-managed adult asthma service (abstract), Dec 15 suppl S39
- Nolan, Paul E. Jr. see Trujillo, Toby C., 2402
- Norton, Linda L. see Yee, William P., 159, 2026
- Nowlin, Debra B. Refining a food-drug interaction program (Frontline Pharmacist), 114
- Nutescu, Edith Multidisciplinary approach to improving allergy documentation, 364
- Nwangwu, V. U. Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Comparative cost-effectiveness of risperidone, clozapine, and haloperidol in assertive community treatment (abstract), Dec 15 suppl S39
- Nye, Matthew T. see McCombs, Jeffrey S., 2485
- O**
- O'Brian, Sharon E. see Lundquist, Steve, Dec 15 suppl S38
- O'Malley, Colleen H. Pharmacy's vision of its future in managed care (editorial), 1471
- O'Malley, Colleen H. The quest for quality measurement (editorial), 1669
- O'Malley, Colleen see also Reeder, C. E., 35
- Obiaga, Godfrey O. Standards of practice: the African experience, 1928
- Oertel, Maryann D. Anagrelide, a selective thrombocytopenic agent, 1979
- Ogiso, Taro see Kawabata, Atsumi, 360
- Oie, Shigeharu Microbial contamination of benzalkonium chloride products (letter), 2534
- Okamoto, Mark P. Book review, 2578
- Okeke, Claudia C. Expiration and beyond-use dates (Questions and Answers), 433
- Ostrosky, John D. see Tullio, Carl J., 1769
- P**
- Paiapu, Nagesh R. see Patel, Kamlesh, 1584
- Pannone, Robert see Algazzine, Thomas, 1029
- Parker, Joseph P. see Cody, Marisue, 2615
- Parker, Joseph P. see also Johnson, Kathleen A., 2621
- Parker, Joseph P. see also McCombs, Jeffrey S., 2485
- Patel, Kamlesh Microbial inhibitory properties and stability of toptecan hydrochloride injection, 1584
- Patterson, Thomas M. see Tidwell, Bill H., 163
- Patrias, John M. Depression in older adults (editorial), 2481
- Pau, Alice K. New issues in the management of cytomegalovirus retinitis in AIDS patients, 392
- Paul, Muriel see Naud, Carole, 1161
- Pearson, Clarissa see Hotchkiss, Brian D., 1293
- Pecini, Raymond A. see Fung, Horatio B., 955
- Peck, Elizabeth C. see Barnett, Timothy S., 397
- Peddlesden, Jennifer Ethics of supplying starter kits of infant formula (letter), 84
- Penzak, Scott R. Preventing and treating azole-resistant oropharyngeal candidiasis in HIV-infected patients, 279
- Perdue, Beulah E. see Bozek, Pamela S., 1151
- Perry, Paul J. see Bever, Kristine A., 1003
- Peterson, Andrew M. Book review, 2314
- Peterson, Andrew M. see also Chase, Sandra L., 1382
- Phillips, Marjorie A. Shaw see Steedman, Susan, 2611
- Pierce, L. Ross Hemolysis and renal failure associated with use of sterile water for injection to dilute 25% human albumin solution (letter), 1057
- Pierpaoli, Paul G. Pharmacy in managed care: vision for the future. Observations on the conference, 1497
- Piper, John see Burke, Cassandra E., 289
- Piscitelli, Stephen C. see Kakuda, Thomas N., 233
- Plowman, Brian K. Possible troglitazone-warfarin interaction (letter), 1071
- Poleon, Gregory P. see Appenheimer, Michelle M., 1602
- Ponto, James A. Outsourcing radiopharmaceutical services, 2537
- Porter, Julie A. Increasing the use of nonprescription drugs in a group-model HMO (Managed Care Forum), 1357
- Possidente, Carl see Mehlberg, Jennifer, 1033
- Pugh, Carol B. see Szarlej, Dorota K., Dec 15 suppl S38
- Punzi, Henry A. The expanding role of cardiovascular chronotherapeutics. Why ambulatory blood pressure monitoring? Nov 15 suppl S12
- Puzantian, Talia Mirtazapine, an antidepressant, 44
- R**
- Raisch, Dennis W. Effect of a pharmacist-education initiative on ketorolac use and costs in a Medicaid program, 1274
- Raleigh, Fred Book review, 309
- Ray, Lisa R. Stability of somatropin stored in plastic syringes for 28 days, 1508
- Ray, Max D. Shared borders: achieving the goals of interdisciplinary patient care, 1369
- Ray, Max D. see also Crismon, M. Lynn, 1594
- Reed, Shelby D. Difficulties in applying clinical trial information to the practice setting: case of a high-cost drug, 2409
- Reeder, C. E. ASHP survey of ambulatory care responsibilities of pharmacists in integrated health systems—1997, 35
- Repta, Arnold J. see Mueller, Bradford J., 266
- Requena-Caturin, Teresa see Santolaya-Perrin, Rosario, 1827
- Rey, Jean-Baptiste see Combeau, Dominique, 1606
- Rice, James A. see Crawford, Stephanie Y., 1907
- Rice, Stephen P. Preparation of latex-safe sterile products (Management Consultation), 1462
- Riedinger, June see Scott, Christopher J., 2525
- Rietord, André see Combeau, Dominique, 1606
- Rindone, Joseph P. Restricting home glucose-monitoring strips in patients taking oral antidiabetic agents, 2509
- Rivera, Jose O. see Ng, Chee M., 1995
- Robertson, Nancy J. Book review, 744
- Robison, Robert N. see Kay, Brett, 1482
- Rock, William L. Jr. Toward optimal provision of antithrombotic therapy (editorial), 348
- Roffman, David S. see Reed, Shelby D., 2409
- Rubin, Rochelle N. see Cohen, Henry, 1134
- Rybak, Michael J. see Mitzyk, Beatriz, 491
- S**
- Sanborn, Mike see Couldry, Rick, 145
- Santell John P. see Mehl, Bernhard, 127
- Santolaya-Perrin, Rosario Indications for use of amifostine (letter), 1827
- Sarkissian, Nadine see Bowden, Carol, Dec 15 suppl S29
- Saseen, Joseph J. Reducing expenditures for statin-type lipid-lowering agents (Managed Care Forum), 996
- Sasich, Larry D. Book review, 511
- Saulnier, Jean-Louis see Schlatter, Joël, 840
- Savelli, Anthony V. see Schwarz, Harald O., 1308
- Sawyer, William T. see Cranor, Carole W., 1073
- Schepart, Brian S. see Appenheimer, Michelle M., 1602
- Schlatter, Joël Inline filtration of ranitidine hydrochloride solutions (letter), 840
- Schmidt, Barbara. see Walker, Scott E., 154
- Schneider, Judith K. Improved use of time after structural and staffing changes to an ambulatory

- care pharmacy, 2505  
**Schneider, Judith K.** see also Gulliford, Sandra M., 1512  
**Schneider, Phillip J.** HCFA's challenge to improve the medication-use process (editorial), 1123  
**Schommer, Jon C.** see Griffith, Niesha L., 1127  
**Schommer, Jon C.** see also King, Julie L., 1389  
**Schommer, Jon C.** see also Sutter, Tricia L., 1924  
**Schreiber, Mark A.** see Mueller, Bradford J., 266  
**Schultheis, Naomi M.** Writing cognitive educational objectives and multiple-choice test questions, 2397  
**Schumock, Glen T.** Clinical frontiers: new advances in the treatment of Alzheimer's disease. Economic considerations in the treatment and management of Alzheimer's disease, Nov 1 suppl S17  
**Schumock, Glen T.** Design, construction, implementation, and cost of a hospital pharmacy cleanroom, 458  
**Schwartz, Thomas** see Bowden, Carol, Dec 15 suppl S29  
**Schwarz, Harald O.** Workshop for developing drug formularies in Russia, 1308  
**Scott, Christopher J.** Promoting education about complementary or alternative medical therapies, 2525  
**Segouin, Christophe** see Simon, Jean M., 173  
**Self, Robert M.** see Barnett, Timothy S., 397  
**Sellers, Jill A.** AHP's content: making some tough decisions (editorial), 1773  
**Sellers, Jill A.** Community pharmacy strives for continuity of care (News), 635  
**Sesin, G. Paul** Mesalamine-associated pleural effusion with pulmonary infiltration (letter), 2304  
**Share, Michael J.** Stability of lorazepam 1 and 2 mg/mL in glass bottles and polypropylene syringes, 2013  
**Shepherd, Michele F.** see Kaufenberg, Anthony J., 1516  
**Sherr, Jay D.** see Moore, David B., Dec 15 suppl S17  
**Sherrin, Thomas P.** see Sutter, Tricia L., 1924  
**Sheu, Benjamin J. K.** Giving patients privacy in the pharmacy (Frontline Pharmacist), 2245  
**Shi, Jinhai** see McCombs, Jeffrey S., 2485  
**Shibata, Nobuhito** Effect of obesity on cyclosporine trough concentrations in psoriasis patients, 1598  
**Shinohara, Y. Todd** Protocol for initial evaluation of occupational exposure to HIV and initiation of antiretroviral prophylaxis, 1921  
**Shoemaker, Dale** see Montello, Michael J., 651  
**Siden, Rivka** Indications for use of amifostine (letter), 1827  
**Siganga, Walter** see Kahaleh, Abir A., 2387  
**Simon, Jean M.** Hospital accreditation in France, 173  
**Simonson, William** Clinical frontiers: new advances in the treatment of Alzheimer's disease. Promising agents for treating Alzheimer's disease, Nov 1 suppl S11  
**Sintek, Charles D.** see Carter, Barry L., 62  
**Small, Ralph E.** see Ling, Con Ann, 1943  
**Smeenk, David A.** see Mott, David A., 1799  
**Sommerstein, Judy** Drug allergy communication (letter), 1524  
**Sondergeld, Paula G.** Teaching patients about blood glucose meters (Frontline Pharmacist), 1877  
**Sorofman, Bernard A.** see Kuehl, Angela K., 1017  
**Srinivasan, V. Srin** see Okeke, Claudia C., 433  
**Steedman, Susan** Educational rotations in pharmacy-based investigational drug services (Management Consultation), 2611  
**Stein, Gary C.** Assisted suicide: an issue for pharmacists (editorial), 539  
**Stendal, Tove L.** Drug stability and pyridine generation in cefazidime injection stored in an elastomeric infusion device, 683  
**Stewart, James T.** Stability of ondansetron hydrochloride and 12 medications in plastic syringes, 2630  
**Stimmel, Glen L.** see Crismon, M. Lynn, 1594  
**Storm, Michael C.** see Hak, Emily B., 150  
**Strayer, Andy H.** see Couldry, Rick, 145  
**Sroman, Ronald T.** see Fuhrman, L. Clifton, 1386  
**Struble, Kimberly A.** see Kakuda, Thomas N., 233  
**Stull, Dawn Marie** see Trovato, James A., 1269  
**Sullivan, Dawn M.** Grapefruit juice and the response to warfarin, 1581  
**Sundin, David J.** Aldesleukin therapy in HIV-infected patients, 1520  
**Sutherland, Linda Gore** Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Need for therapeutic guidelines for antipsychotics under a prescription cap, Dec 15 suppl S19  
**Sutter, Tricia L.** Discrepancies with automated drug storage and distribution cabinets, 1924  
**Suzuki, Shigeo** see Kawabata, Atsumi, 360  
**Swenson, Chad F.** see Anazi, Nasr H., 926  
**Szarlej, Dorota K.** Studying clinical, humanistic, and economic outcomes: projects from ASHP's Competitive Edge Program. Evaluation of a ciprofloxacin i.v.-to-oral step-down program (abstract), Dec 15 suppl S38  
**T**  
**Takada, Mitsutaka** see Kawabata, Atsumi, 360  
**Talley, C. Richard** ASHP: no longer hospitals only (editorial), 31  
**Talley, C. Richard** Change of perspective (editorial), 665  
**Talley, C. Richard** Confidentiality of patient records (editorial), 895  
**Taniguchi, George** see Icaza, Luis, 83  
**Tankanow, Roberta M.** Docetaxel: a taxoid for the treatment of metastatic breast cancer, 1777  
**Teeters, Janet** see Nutescu, Edith, 364  
**Terry, Derek C.** see Barnett, Timothy S., 397  
**Thomas, Joseph III** see Barner, Jamie C., 50, 56  
**Thompson, Cheryl A.** Congress viewed with a scientist's critical eye (News), 1850  
**Thompson, Cheryl A.** Herbal quality seems to be growing (News), 2341  
**Thompson, Cheryl A.** Medical devices with latex become easier to identify (News), 2059  
**Thompson, Cheryl A.** Pharmacists must seek recognition on primary care team (News), 17  
**Thompson, Cheryl A.** USP moves forward in providing information on botanical products (News), 527  
**Thompson-Bowers, Jean** see Shinohara, Y. Todd, 1921  
**Thomson, Lynda J.** see Szarlej, Dorota K., Dec 15 suppl S38  
**Tidwell, Bill H.** Cimetidine-induced toxic epidermal necrolysis, 163  
**Tillman, Donald J.** see Charland, Scott L., 1296  
**Tisdale, James E.** Book review, 1534  
**Tisdale, James E.** Shifting paradigms of antiplatelet therapy: assessing new drugs versus old. Antiplatelet therapy in coronary artery disease: review and update of efficacy studies, Oct 1 suppl S8  
**Tønnesen, Hanne Hjørth** see Stendal, Tove L., 683  
**Tormo, Vicente J.** see Schumock, Glen T., 458  
**Touchberry, Susan Stirling** see Steedman, Susan, 2611  
**Trevarrow, Brian J.** Pharmacy technicians as members of care teams, 1810  
**Tribble, Dennis A.** see Johnson, Ruth, 1503  
**Trissel, Lawrence A.** Assay reliability (letter), 491  
**Trissel, Lawrence A.** Fluorouracil precipitate (letter), 1314  
**Trissel, Lawrence A.** Hemolysis and renal failure associated with use of sterile water for injection to dilute 25% human albumin solution (letter), 1070  
**Trissel, Lawrence A.** see also Xu, Quanyun A., 1037  
**Trissel, Lawrence A.** see also Zhang, Yanping, 574  
**Trovato, James A.** Outcomes of antiemetic therapy after the administration of high-dose antineoplastic agents, 1269  
**Trujillo, Toby C.** Unfractionated heparin in acute coronary syndromes: has its time come and gone? 2402  
**Tseng, Alice Lin-in** Compliance issues in the treatment of HIV infection, 1817  
**Tullio, Carl J.** Identifying ambulatory care patients with coronary heart disease who need cholesterol management (Managed Care Forum), 1769  
**Tyler, Linda S.** see Mullin, Shantel M., 1903  
**U**  
**Uehara, Masami** see Shibata, Nobuhito, 1598  
**V**  
**Vacani, Paul F.** see DiPiro, Joseph T., 777  
**Valuck, Robert J.** see Carter, Barry L., 62  
**Vance-Bryan, Kyle** see Benson, Steven R., 727, 1935  
**VanDer Kamp, Kirk** see Ketkar, Vaishali A., 466  
**Vanderpool, William H.** see Mott, David A., 1799  
**Varricchio, Frederick** see Pierce, L. Ross, 1057  
**Vaux, Kenneth L.** Views on assisted suicide. An ethicist's perspective, 551  
**Venkateshwaran, T. G.** see Stewart, James T., 2630  
**Vermeulen, Lee C.** Mibefradil and an effective formulary system (letter), 1934  
**Vogel, David** see Mehta, Shilpa S., 598  
**Vogenberg, F. Randy** see McCloskey, William W., 2007  
**Volles, David F.** Establishing an institution-specific therapeutic range for heparin, 2002  
**Voss, Glenn D.** see Dvorak, Sonya R., 2500  
**W**  
**Walker, Scott E.** Stability of reconstituted indomethacin sodium trihydrate in original vials and polypropylene syringes, 154  
**Wallenius, Karl J.** see Helin, Minna M., 1299  
**Warren, Flynn W.** see Stewart, James T., 2630  
**Warren, Joyce** see Steedman, Susan, 2611  
**Watson, Phillip** see DiPiro, Joseph T., 777  
**Weber, Jeffrey J.** Regional thrombolytic infusion for peripheral arterial occlusion: is urokinase really the drug of choice? 2414  
**Weeks, Angela** see Koch, Karen E., 1375  
**Weidie, Paul J.** see Bozek, Pamela S., 1151  
**Welage, Lynda S.** see Berardi, Rosemary R., 2289  
**Wellman, Gregory S.** see Sutter, Tricia L., 1924  
**Wells, Barbara G.** see Crismon, M. Lynn, 1594  
**White, C. Michael** Catecholamines and their blockade in congestive heart failure, 676  
**Williams, Hazel** see Mellenger, Michelle R., 171  
**Williams, Karl G.** Administrative liability of pharmacy managers (Management Consultation), 1874  
**Williams, Karl G.** Federal tax consequences of institutional pharmacy dispensing to outpatients (Management Consultation), 772  
**Winter, Michael E.** see Choy, Melissa, 2392  
**Wirsching, Rodney G.** see Griffith, Niesha L., 1127  
**Wirsching, Rodney G.** see also King, Julie L., 1389  
**Wittkowsky, Ann K.** see Mehlberg, Jennifer, 1033  
**Wolfe, Jonathan J.** see Johnson, Jill T., 1728  
**Wolfgang, Sally A.** see Kratzer, Anisa M., 1413  
**Wolin, Maurice J.** see Sundin, David J., 1520  
**Woller, Thomas W.** see Miller, Douglas E., 1620  
**Wood, Margaret** see Ralsch, Dennis W., 1274  
**Woodall, Sandra C.** In search of literature on cancer on the Internet (Current Literature), 2429  
**Woods, Anne** see Bell, Heather M., 2009  
**Woodward, Billy W.** The journey to professional excellence: a matter of priorities, 782  
**Wordell, Cindy J.** see Chase, Sandra L., 1382  
**Wu, Alan H. B.** see Mouser, Jay F., 1071  
**Wurster, Dale Eric** see Ketkar, Vaishali A., 466  
**X**  
**Xu, Quanyun A.** Stability of cisatracurium besylate in vials, syringes, and infusion admixtures, 1037  
**Y**  
**Yamaji, Akira** see Shibata, Nobuhito, 1598  
**Ycas, Joseph W.** see Mueller, Bradford J., 266  
**Yee, Helen S.** see Fong, Nancy T., 308  
**Yee, William P.** Abciximab vials as multidose containers (letter), 2026  
**Yee, William P.** Optimal weight base for a weight-based heparin dosing protocol, 159  
**Yiu, Irene M.** see Knoell, Daren L., 899  
**York, Lynn** see Al-Achi, Antoine, 1415  
**Young, W. Wayne** see Malone, Patrick M., 1146  
**Z**  
**Zacker, Christopher** Institutional and contingency approaches to the reprofessionalization of pharmacy, 1302  
**Zappala, Fern N.** FDA's Rx for keeping educational programs free of industry bias (Questions and Answers), 2472  
**Zgarlick, David P.** Motivations and practice-area preferences of pharmacists interested in pursuing a Pharm.D. degree through a nontraditional program, 1281  
**Zhang, Yan-Ping** see Xu, Quanyun A., 1037  
**Zhang, Yanping** Stability of acyclovir sodium 1, 7, and 10 mg/mL in 5% dextrose injection and 0.9% sodium chloride injection, 574  
**Zilz, David A.** Diversification continues to be key to success, 1699



